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Abstract 
Platelets are small fragments that are derived from megakaryocytes. They are released 
into the blood stream, where they prevent excessive blood loss at sites of tissue injury by 
sticking together and forming a haemostatic plug. However, excessive platelet clumping in 
diseased blood vessels can lead to blockages and cause thrombotic diseases such as heart 
attack and stroke In Australia, cardiovascular disease (CVD) and stroke are the two leading 
causes of death. In 2012, CVD accounted for 30% of all deaths and affected more than 3.72 
million Australians [1]. The cost to the Australian community for CVD-associated disability 
is approximately 7.8 billion dollars per year. In the Aboriginal and Torres Strait Island 
population, CVD is the most common cause of death [2-4]. 
CVD is the general term for a class of heart diseases involving heart and blood 
vessels. Whilst the term commonly refers to any form of disorder affecting the 
cardiovascular system, it is most typically linked to atherosclerosis. The mortality rates for 
CVD have increased in the past few years within high-income countries and it is now the 
leading cause of death in the Western world [5]. Thrombi are formed in response to damage 
to the endothelial lining of the blood vessels, which causes platelets to clump together and 
activate at the site of damage. In the pathological sequelae of atherosclerosis, rupture of 
collagen-rich plaques leads to in vivo platelet activation, adhesion and thrombus formation. 
In a physiological context, Ig-ITIM superfamily members negatively regulate the initial 
phase of contact-dependent events involving platelet-collagen GPVI interactions, thereby 
limiting the in vivo growth of thrombi. Few examples of naturally occurring inhibitors of 
platelet-collagen interactions have been described [6]. Prostacyclin and nitrous oxide (NO) 
are natural inhibitors released from the endothelium [7], while Ig-ITIM members appear to 
be the first identified natural inhibitors that serve an autoregulatory role when platelets come 
into contact with each other following exposure to collagen [8].  
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Platelet adhesion to the vascular endothelium is a crucial component of normal 
haemostasis and of pathological thrombus formation. Therefore, a full understanding of the 
regulation of in vivo platelet signalling pathways and thrombus formation will depend on 
elucidation of the nonredundant roles of Ig-ITIM superfamily members, including 
CEACAM2. These receptors appear to regulate specific intracellular effector pathways and 
to recognise distinct ligands where localisation may differ. They are also differentially 
expressed during activation of platelets.  
Carcinoembryonic antigen-related cell adhesion molecule-2 (CEACAM2) is a cell 
surface glycoprotein expressed on blood, epithelial and vascular cells. CEACAM2 
possesses adhesive and signalling properties mediated by immunoreceptor tyrosine-based 
inhibitory motifs. In this study, we demonstrate that CEACAM2 is expressed on the surface 
and in intracellular pools of platelets. Functional studies of platelets from Ceacam2
–/–
 
deficient mice (Cc2
–/–
) revealed that CEACAM2 serves to negatively regulate collagen 
GPVI-FcRγ–chain and the C-type lectin-like receptor 2 (CLEC-2) signalling. Cc2–/– 
platelets displayed enhanced GPVI and CLEC-2-selective ligands, collagen related peptide 
(CRP), collagen and rhodocytin (Rhod)-mediated platelet aggregation. They also exhibited 
increased adhesion on type I collagen, and hyper-responsive CRP and CLEC-2-induced 
alpha and dense granule release compared to wild-type platelets. Furthermore, using 
intravital microscopy to ferric chloride (FeCl3) injured mesenteric arterioles and laser 
induced injury of cremaster muscle arterioles, we herein show that thrombi formed in Cc2
–/– 
mice were larger and more stable than wild-type controls in vivo. Thus, CEACAM2 is a 
novel platelet immunoreceptor that acts as a negative regulator of platelet GPVI-collagen 
interactions and of ITAM receptor CLEC-2 pathways. 
Previous studies have implicated that the Ig-ITIM superfamily member, CEACAM1 
may regulate integrin function. As CEACAM2 is the twin of CEACAM1, it is possible that 
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CEACAM2 may also have a physiologic role in integrin IIb3-mediated platelet function. 
In this project, we investigated the functional importance of CEACAM2 in murine platelets. 
Using Ceacam2-deficient mice, we showed that they have prolonged tail bleeding times and 
volume of blood lost. Cc2
–/– 
platelets have moderate integrin IIb3 mediated functional 
defects with impaired kinetics of platelet spreading on fibrinogen and type I collagen and 
delayed kinetics in retraction of fibrin clots in vitro. This functional integrin IIb3 defect 
could not be attributed to altered integrin IIb3 expression. Cc2
–/– 
platelets displayed normal 
‘inside-out’ signalling properties as demonstrated by normal agonist-induced binding of 
soluble FITC-fibrinogen and JON/A antibody binding. This project provides direct evidence 
that CEACAM2 is essential for normal integrin IIb3-mediated platelet function and that 
disruption of mouse CEACAM2 induced a moderate integrin IIb3-mediated platelet 
functional defects. 
Based on these results, it appears likely that CEACAM2 functions in similar way to its 
closely related family member, CEACAM1. Therefore, CEACAM2 can be viewed as a 
novel platelet immunoreceptor that act as a negative regulator of platelet-collagen 
interactions and as a positive regulator of integrin IIb3-mediated platelet functions. 
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1.1 Platelet overview 
Platelets are small, disc-shaped cell fragments, derived from a precursor 
megakaryocyte that circulates in the blood system of mammals [9, 10]. They are required 
for clot formation, haemostasis and wound healing. Platelets are also involved in 
angiogenesis both in the embryo and the adult [9, 11]. Insufficiency of platelets, a condition 
known as thrombocytopenia can lead to excessive bleeding [10]. On the other hand, 
platelets are involved in diseases such as thrombophlebitis and atherosclerosis [12, 13]. 
Interestingly, the angiogenic properties of platelets, were found to promote metastatic 
diseases such as spreading of tumours. Anti-platelet therapies are used to prevent excessive 
clotting and myocardial infarction. 
Platelets were first described by Osler as disc-like objects that circulated singly in the 
blood but quickly aggregated when removed from circulation [14]. At the time Osler was 
not able to determine whether they were natural blood constituents, or contaminating 
organisms. Just a few years later, in 1881, Bizzozero reported some important facts about 
platelets including their importance to haemostasis and their aggregation in areas of 
damaged blood vessels [15, 16]. In addition, Bizzozero was probably the first to notice bone 
marrow-derived megakaryocytes, but did not connect them to platelets at the time [16]. 
However, about 20 years later, Wright showed the similar staining pattern between 
megakaryocytes and platelets [17]. Wright’s stain is one of the Romanowsky stains still 
used today for the identification of formed elements in the blood. 
Platelets are a rich source of growth factors used in wound healing that includes 
platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), insulin-
like growth factor 1 (IGF-1), epidermal growth factor (EGF) and vascular endothelial 
growth factor (VEGF). During the process of clot formation, platelets are shedding and 
these growth factors are released along with chemotactic signals to induce white blood cell 
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(WBC) migration to the wound site. Platelet enriched plasma has been used medically to 
speed the healing of ulcers and other wounds [18, 19]. 
1.1.1 Platelet formation  
The megakaryocytes (MKs), from which platelets are formed, are descended from 
multi-potent haematopoietic stem cells that give rise to all circulating blood cells [20]. MKs 
reside in the bone marrow and are the largest (50-100 μm) and also the rarest cell in the 
bone marrow accounting for approximately 0.01% of all cells [21]. Platelets are released 
from the MKs after a unique process called endomitosis; where the DNA is replicated many 
times without division [20]. This is followed by a rapid expansion in the amount of 
cytoplasm and the elaboration of a membrane demarcation system, as well as the synthesis 
of granules and proteins necessary for platelet function [22]. 
Platelets are produced from long cytoplasmic extensions called proplatelets. A 
detailed model of this process is provided by Italiano [22]. After endomitosis, during 
cytoplasmic expansion phase, the megakaryocyte synthesises platelet specific proteins and 
organelles. Microtubules are assembled at the centrosome, radiate out towards the periphery 
of the cell and then run in parallel with the cell membrane [20]. Before proplatelet formation 
initiates, the microtubules the cell surface. The microtubules help to form large pseudopods 
that elongate to become proplatelet processes. Organelles are moved along the microtubule 
tracks to the ends of the proplatelets where platelets are being assembled. Proplatelets 
become constricted in places, leading to a beaded appearance. Eventually, almost all of the 
megakaryocyte cytoplasm is converted into proplatelets [20]. These pinch off, and further 
subdivide to become individual platelets (Figure 1-1). 2000 to 5000 new platelets are 
produced per cell when the megakaryocyte cytoplasm is transformed into proplatelets [23]. 
About 10
11 
platelets are produced per day in the average human with circulating 
concentration of around 150-400x10
9
/litre [9, 20]. A reserve pool of platelets is stored in the 
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spleen-splenectomy was first proposed in 1916 as way of increasing circulating 
concentrations of platelets [24] and is still used to treat some cases of idiopathic 
thrombocytopenia purpura. 
 
   
Figure  1-1: Schematic diagram representing the process of platelet development. The burst-forming unit, 
BFU-Meg is the first cell specifically committed to megakaryocyte development. Thrombopoietin (Tpo) is the 
principle regulator of platelet production and affects all stages of development. Adapted from [22]. 
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1.1.2 Platelet production and apoptosis 
As mentioned, platelets bud off from cytoplasmic extensions called proplatelets [25]. 
The events leading up to platelet release in megakaryocyte, i.e cytoskeletal reorganisation, 
ruffling, and membrane condensation, resemble those of a cell undergoing apoptosis [22]. 
The remnant megakaryocyte does, in fact, undergo apoptosis, but not until after platelet 
release.  
1.1.3 The Process of Apoptosis and Platelet Assembly 
In megakaryocytes, the sequence of remodelling events behind platelet formation and 
release shares a number of functions associated with apoptotic programmed cell death. 
These areas of overlap include cytoskeletal rearrangement and disruption, and the 
condensation and ruffling of nuclear and plasma membranes. Naturally, these similarities 
suggest that apoptosis influences platelet biogenesis in the megakaryocyte progenitors. 
Apoptosis in degenerating megakaryocytes destroys the cell nuclei [26], and research has 
suggested that the process affects proplatelet formation and the final release of platelets into 
the bloodstream. Cell destruction is relatively well understood in the myeloid 
megakaryocytic cells [27], and there is a positive correlation between the action of apoptosis 
and cell maturation [28, 29]. In megakaryocytes, previous research identified a number of 
proapoptotic and antiapoptotic factors distributed according to the maturity of the cell [30]. 
Megakaryocytes in the early stages of maturation contain a number of apoptosis inhibitor 
proteins, including Bcl-2 and Bcl-xL, which restrict the formation of proplatelets [31, 32]. 
Furthermore, mature blood platelets lack Bcl-2, while aging megakaryocytes lack Bcl-xL 
[33], suggesting that apoptosis affects the platelet assembly and release processes in 
senescent megakaryocytes. Further research into the caspase proteins involved in the 
formation of proplatelets showed that two members of the family, caspase-3 and caspase-9, 
are particularly active in mature megakaryocytes, and that blocking these factors restricts 
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proplatelet development [31]. Similarly, the proapoptotic factor, nitric oxide (NO), is also 
found in megakaryocytes. In the genetically distinct cell line Meg-01, NO may influence the 
release of platelet-sized objects, acting in conjunction with a haematopoietic growth factor, 
thrombopoietin (TPO), to facilitate the expression and release of platelets [34, 35]. Finally, 
proapoptotic TGF-β1 and SMAD proteins are also present in megakaryocytes [36]. Further 
research investigated how these apoptotic factors interact during megakaryocyte and platelet 
maturation [37]. Caspase-3 and caspase-9 proteins are both active in terminally-
differentiated megakaryocytes, but only caspase-3 is found in platelets [37, 38]. Like 
caspase-9, caspase-12 is present in megakaryocytes but absent in platelets [39]. The 
changing location and activity of apoptotic factors in megakaryocytes and platelets 
according to maturation implies variation in the apoptosis mechanisms. During the 
proplatelet stage of biogenesis, apoptotic factors in younger platelets are modulated. 
1.1.4 Platelet anatomy 
Platelets are the smallest of circulating cell fragments; they are disc-shaped with a 
diameter of 2-5 µm, a thickness of 0.5 µm and a volume of only 6-10 femtoliters [9, 16, 40, 
41]. Despite their small size, platelets are quite complex. It consists of a plasma membrane, 
cytoskeletal elements, and a thick external glycocalyx (Figure 1-2). The Sol-Gel zone is the 
matrix of platelet cytoplasm, responsible for contraction and contains the open canalicular 
system (OCS), microtubules and microfilaments [42]. The organelle zone has platelet 
organelles, including mitochondria, lysosomes, alpha granules and glycogen granules, as 
well as stores of catecholamine, adenosine diphosphate (ADP), serotonin, calcium, platelet 
factor 4 (PF4), platelet mitogenic factor, fibrinogen, and β-thromboglobulin [43, 44]. 
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Figure  1-2: Diagrammatic structure of platelets showing different zones including the peripheral zone, 
the sol-gel zone, and the organelle zone. Platelet structure is depicting the presence of mitochondria, OCS, 
dense tubular system, microtubules, microfilaments, glycogen, membrane, glycocalyx and lysosome. Also 
shows the most important platelet granules, alpha and dense granules. Adapted from [45]. 
 
 
1.1.4.1 The Peripheral Zone 
 The peripheral zone is the outer layer of the disc-like platelets, and includes the 
plasma membrane, sub-membranous areas, and a thick glycoprotein layer called the 
glycocalyx. 
1.1.4.2 The Plasma Membrane 
The plasma membrane of the platelet is derived from the megakaryocyte and is not 
morphologically distinct from that of other cell types. However, the membrane contains 
functional features relevant to the role of platelets in initiating haemostasis. Platelets contain 
tissue factor within cholesterol-rich “islands” within the plasma membrane [40]. Tissue 
factor initiates clotting by serving as a co-factor for factor VIIa, which converts factor X to 
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Xa. The latter, in association with Va converts prothrombin to thrombin. This conversion 
requires an anionic phosphatidyl serine surface found on the unit membrane of platelets. 
The conversion of tissue factor to an active form seems to require the formation of 
microparticles on the surface of the membrane [46]. 
1.1.4.3 The Submembrane Area 
The submembrane area is a distinct zone from which platelet organelles are excluded. 
It is here that the cytoplasmic domains of transmembrane receptors interact. Some of these, 
including the cytoplasmic portions of GPIIb and GPIIIa, as well as filamin, an actin binding 
protein that also binds to the GPIb-IX-V complex, are associated with cytoskeletal elements 
like calmodulin, myosin, and actin filaments [40]. The submembrane area contains an 
extensive network of cytoplasmic filaments. 
1.1.4.4 The Glycocalyx 
The glycocalyx is not just a barrier but its dynamic structure is charged with sensing 
environmental changes that might require a haemostatic response and then initiating 
aggregation, which promotes thrombus formation. There are about 25,000 copies of GPIb-
IX-V complex and about copies of 80,000 integrin αIIbβ3 on the outside surface and in 
channels of the open OCS. Both types of receptor are mobile, which is important for their 
function in haemostasis [40]. Exposure of the subendothelium to the platelet because of a 
wound in the endothelial layer results in the immediate attachment (from nano to 
microseconds) of GPIb-IX-V receptor complex to the von Willebrand factor (vWF) that is 
attached to collagen. Collagen receptors, glycoprotein VI (GPVI) and the integrin α2β1 help 
make the attachment more stable. The binding of GPIb-IX-V to vWF causes actin filament 
and cytoskeletal rearrangements in newly attached platelets. 
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1.1.5 The sol-gel zone 
The cytoplasmic matrix is viscous network of fibrous material called the sol-gel zone, 
in which various organelles are embedded. The following subsections briefly describe the 
sol-gel zone contents. 
1.1.5.1 Microtubules and microfilaments 
Platelets contain rings of microtubules located deep in the submembrane region that 
help to maintain the shape of the resting platelet. When platelets are activated, the 
microtubules contract into tight rings around clusters of organelles. Surprisingly, the 
microtubule ring is not actually a network, but a single microtubule that coils on itself many 
times [40]. Disappearance of the microtubule ring due to low temperatures [47] or treatment 
with microtubule dissociating drugs, like colchicine [48], result in the loss of the typical 
discoid shape of the platelet. 
In the resting platelet, about 30-40% of actin molecules are assembled into filaments, 
portions of which are in the sol-gel zone, making up the matrix that surrounds the 
organelles. In activated platelets, actin in association with myosin makes up contractile 
filaments which pull on the microtubule ring and drive alpha granules and dense bodies 
together in the platelet centre. Strong contractions result in the secretion of granule and 
dense body contents to the outside via the OCS. 
1.1.5.2 Glycogen 
Glycogen particles are randomly distributed in the sol-gel zone, sometimes encircled 
by membranes. White [49] has referred to these membrane-bound glycogen particles as 
glycosomes, a particular organelle involved in glycogen metabolism. Biochemical evidence 
suggests that platelets can synthesise glycogen given a primer and can also perform 
glycogenolysis. Some glycogen particles seem to be associated with the OCS. 
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1.1.6 Organelle zone 
The organelle zone contains three types of secretory granules: alpha granules, dense 
bodies and lysosomes (Table 1). Alpha granules and dense bodies secrete their products 
after platelet activation by calcium dependent exocytosis. Also present are small 
mitochondria which provide for the energy needs of the platelet. There are also glycosomes, 
tubular inclusions as well as multivesicular bodies derived from the Golgi apparatus of the 
megakaryocyte.   
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Table 1-1. The contents of organelles of platelets [44]. 
Granules  Contents of Granule 
 
 
1. Dense granules  
Secretion of ions 
Guanine: GTP, GDP.  
Nucleotides: Adenine: ATP, GTP, ADP, GDP 
Serotonin (Transmitters), Histamine, Bivalent cations, Amines. 
 
2. Alpha-granules  
 
Adhesion molecules: P-selectin (CD62P), Glycoprotein IIb/IIIa 
(GPIIb/IIIa, integrin αIIbβ3, CD41/CD61), Platelet endothelial cell 
adhesion molecule-1 (PECAM-1/CD31), vWF, Thrombospondin-1 
(TSP1), Vitronectin, Fibronectin.  
 
Mitogenic factors; TGF-ß, PDGF,  
 
Protease inhibitors; Plasminogen activator inhibitor-1 (PAI-1), 
Tissue factor pathway inhibitor (TFPI), C1 inhibitor. 
 
Coagulation factors: Fibrinogen, Kininogen, Factors V, VII, XI, 
XIII.  
 
3. Lysosomes  
 
Glycosidases, Proteases. Cationic proteins. Digestive enzymes. 
Acid hydrolases, cathepsins D, LAMP-1, LAMP-2 and WAMP-1. 
4. Glycosomes 
Glycogen. 
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1.1.6.1 Alpha Granules 
Alpha granules are the most numerous of the secretory granules, with about 40 to 80 
granules present per platelet, depending on the site of the platelets. The granules are usually 
oval-shaped and 200-500 nm in diameter. They are more electron dense in the centre than in 
the periphery. They contain vWF that is generally contained in tube-like inclusions. Alpha 
granules also contain a bewildering variety of molecules within them, including adhesion 
factors, chemokines, molecules in the coagulation and fibrinolytic pathways, an array of 
growth factors, some immunologic molecules including IgG, and others that are not platelet 
specific, including albumin and histidine-rich glycoprotein [50]. The large number of 
proteins found in alpha granules lead to speculation that there may be more than one type of 
alpha granule [51], but so far the alpha granules have resisted functional subdivision. 
However, there are a so-called giant granules are present some times in normal individuals 
and can arise by fusion during long term storage of platelets in vitro. Giant alpha granules 
are also characteristic of several disease states of platelets [40, 52, 53]. Using electron 
tomography to create three-dimensional maps, van Nispen tot Pannerden and colleagues 
recognised four alpha granule types based on morphological criteria: 1) spherical granules 
containing 12-nm vWF tubules, 2) subtypes containing many luminal vesicles, 3) 50 nm-
wide tubular organelles and 4) a population with 18.4-nm crystalline cross-striations [54]. 
Clathrin coated areas were noted both on spherical and tubular granules. 
1.1.6.2 Dense granules 
Dense granules are so named because of an electron dense, nearly opaque spherical 
centre, which is clearly separated from the surrounding membrane. There are about ten-fold 
fewer dense bodies relative to alpha granules. Some dense bodies have granule-like particles 
in the space between the central opacity and membrane and some have filamentous 
structures radiating from the central core [40]. Though usually ovoid or spherical, some 
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dense bodies have long tail-like extensions. The electron density of dense bodies is probably 
due to calcium complexed with pyrophosphate and serotonin. Relative to the alpha granules, 
they contain fewer proteins and more small molecule secretion products (Table 1). Dense 
bodies are slightly acidic and contain some membrane proteins usually associated with 
lysosomes, such as LAMP-2 and LAMP-3, but not LAMP-1 [55, 56]. 
1.1.6.3 Lysosomes 
Lysosomes are formed early in megakaryocyte development, but platelets have a 
small number of lysosomes, 1-3 per platelet. These lysosomes contain acid hydrolases, 
cathepsin D and, LAMP-1, LAMP-2, WAMP-1 and stain for acid phosphatase. The 
functional significance of lysosomes in platelets is unclear. Levin (2007) made the point that 
some of the nucleated thrombocytes in non-mammalian species have a phagocytic role, so 
perhaps it is not surprising to find lysosomes in platelets. Lysosomes can expel their 
contents when platelets are stimulated in vitro, but it is not clear that this is physiologically 
relevant. White (2007) suggested that lysosomes in platelets are essentially vestigial. 
However, defective platelet lysosomes (as well as defective dense bodies) are associated 
with Hermansky–Pudlak syndrome, a genetic bleeding disorder [57]. 
1.1.6.4 Mitochondria 
Platelets have a few mitochondria that are relatively small with uncomplicated 
structures. Drugs that block anaerobic glycolysis do not lead to a significant drop in ATP 
concentrations, therefore it is believed that mitochondria supply most of the energy 
requirements of the platelet [40]. Jobe and colleagues demonstrated that formation of the 
mitochondrial permeability transition pore (MPTP), a feature associated with apoptosis in 
nucleated cells, regulates early platelet activation events, including phosphatidylserine 
externalisation, membrane vesiculation and procoagulant activity [58]. 
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1.1.6.5 Membrane Systems 
Platelets have very complicated membrane systems for such small cells, including the 
surface connected OCS, the dense tubular system, and membrane complexes as well as 
occasional appearances of the Golgi apparatus. 
1.1.6.6 Golgi Apparatus 
In the megakaryocyte, the Golgi apparatus consists of the typical flattened membranes 
or saccules that function in the development of dense bodies, alpha granules, and lysosomes.  
However, Golgi complexes have almost disappeared by the time that proplatelets develop.  
Membranes of the Golgi apparatus are undetectable in most platelets, but can be found in 
0.2 to 1%  by thin section analysis [40]. Most likely, these are adventitious remnants rather 
than functional organelles. However, Golgi zones are common in patients with certain 
platelet hypogranular syndromes, in particular white platelet syndrome [59]. 
1.1.6.7 The Surface Connected OCS 
The OCS is a serpentine collection of membranes that is open to the surface of the 
platelets. It is essentially long invaginations of the plasma membrane that anastomose and 
form a labyrinthine system within the cell. As these are open to the surrounding plasma, 
they greatly increase the surface area of the platelet, allowing signalling molecules access to 
the interior of the cell. The OCS may be the route by which plasma proteins such as 
fibrinogen are taken up by the platelet and then are transferred to the alpha granules, which 
as mentioned previously, contain proteins of non-platelet origin. The passageways of the 
OCS are also the means by which platelet stores are secreted during platelet activation. The 
OCS also serves as the source of surface membrane when a platelet binds to a damaged 
blood vessel. The platelet can increase its surface area to four fold after adhesion to the 
vascular surface by evaginating the OCS.  Membranes of the OCS are also used to surround 
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bacteria taken up by platelets [40].  Finally, the OCS seems to be the source of membrane 
for the long tethers that form during platelet adhesion [54]. 
1.1.6.8 Dense tubular systems 
The dense tubular system (DTS) originates from the rough endoplasmic reticulum of 
the megakaryocyte but functions as smooth endoplasmic reticulum within the platelet [40]. 
It consists of thin elongated membranes which contain calcium binding sites and enzymes 
for prostaglandin synthesis. It does not communicate with the open canilicular system, but 
some channels appear to associate with the microtubule ring surrounding the inner platelet. 
Much like the sarcoplasmic reticulum in muscle, the dense tubular system stores calcium 
and releases it upon platelet activation [60]. Within seconds of the platelets contact with 
thrombin, the DTS rounds up into vesicular form. This morphological change appears to be 
associated with discharge of calcium which facilitates exocytosis of granule contents. 
1.1.6.9 Membrane complexes 
Although the DTS and OCS do not seem to be physically communicating [54], they 
are physically associated with each other, similar to the arrangement between sarcoplasmic 
reticulum and T-tubules in the muscles. Small channels of the DTS are interspersed between 
open canaliculi. Freeze fracture studies reveal a very intimate relationship between the two.   
1.2 Platelet physiology 
The principal role of platelets in the body is to maintain haemostasis by controlling 
bleeding through thrombus, or clot formation at the site of damaged blood vessels 
endothelium. 
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1.2.1 Platelet function in haemostasis 
Under normal circumstances, platelets circulate independently in the blood. Aged or 
damaged platelets are removed by phagocytosis in the spleen and also by Kupffer cells, 
specialised resident macrophages in the liver.  Platelets help maintain haemostasis by 
initiating and participating in thrombus (clot) formation to control bleeding. Thrombi are 
formed in response to damage to the endothelial lining of the blood vessels, which causes 
platelets to clump together and activate at the site of damage. Under normal conditions, the 
endothelial cells inhibit activation of platelets by the production of proactive NO, 
prostaglandin and ADPase, which break down adenosine diphosphate, a platelet activator. 
The endothelial cells also produce vWF, which aids the platelet adhesion to collagen within 
the extracellular matrix.   
When an injury occurs to the endothelial cell layer, which may be the result of 
exogenous trauma, or due to the insult of ageing, the collagen in the extracellular matrix, 
along with vWF and tissue factor (factor III) are exposed to the blood. When the platelets 
contact any of protein, they are activated and clumped together. Platelets can also be 
activated by thrombin in combination with tissue factor. Platelets have within them 
granulated stores of vWF and tissue factor, which are excreted and thus have positive 
feedback effect on clotting activity as the platelets are activated. Activated platelets release 
a number of other active molecules including PF4, the growth factors TGF beta and PDGF, 
the matrix protein fibronectin, and the clotting proteins beta thromboglobulin, fibrinogen, 
and coagulation factors V and XIII. Activation of platelets also initiates the arachidonic acid 
pathway to convert prostaglandin H2 to thromboxane A2 (TXA2), which further facilitates 
platelet aggregation. 
In platelet aggregation, the platelets use the proteins fibrinogen, fibronectin, 
vitronectin, thrombospondin and vWF as connecting bridges. Important aggregation 
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receptors include integrin αIIbβ3 (GPIIb/IIIa), the GPIb-IX-V complex, integrin α2β1 and 
GPVI. The two latter are specific for collagen [61]. 
Aggregation of the platelets and their adhesion to damaged surfaces of the blood 
vessel act together to form the platelet aggregate. The contractile myosin and actin filaments 
in platelets are stimulated to contract during formation of the thrombus, retracting the clot 
(Figure 1-3). Clots consist not only of platelets, but most importantly fibrin, as well as other 
blood cell types which are caught in the nest of fibrin fibres (Figure 1-4). Blood fibrinogen 
is a soluble plasma glycoprotein that is converted to fibrin by the serine protease thombin. 
Fibrin is then cross-linked by activated clotting factor XIII to form a stable clot (Figure 1-5). 
Haemostasis is important but only a temporary solution. Active wound repair is needed. As 
previously mentioned, platelets secrete growth factors that stimulate the invasion of 
fibroblasts and the repair of connective tissue. 
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Figure  1-3: Adhesion and activation mechanisms supporting the haemostatic and prothrombotic 
function of platelets. Platelet adhesion mediated through GPIb coupling. This binding process induces 
differential expression and thus the formation of complex. GPIb interacts with the A1 domain of vWF and 
mediates platelet tethering, allowing further interaction between GPVI and collagen. This process switches the 
integrin αIIbβ3 from low-affinity to high-affinity binding state leading to fibrinogen binding and platelet-
platelet aggregation. Then the activation process leads to activation of GPCRs, and secretion of ADP and 
TXA2, which bind to their ligands, the P2Y12 and TP receptors, respectively. Thrombus formation is also 
triggered by tissue factor (TF), which plays a crucial role in platelet activation by binding to the platelet 
protease activated receptors (PAR-1 and PAR-4). Adapted from [62]. 
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Figure  1-4: Clot formation. Colorised electron micrograph. Red blood cells = red. Leuckocytes= green.  
Platelets = grey.  Fibrin=brown. The Fibrin mesh of Clot. Colourised electron micrograph of fibrin clot 
enclosing platelets, red blood cells and fibrin fibers. Red blood cells = red. Fibrin fibers = light green. 
aggregation = purple. Adapted from [63]. 
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1.2.2 Platelet activation 
When the endothelial layer is injured, as when blood vessel is cut or damaged, vWF 
and collagen become available to platelets which then adhere to the site of injury, are 
activated and begin to clump. Platelets can also be activated by thrombin, the formation of 
which is aided by tissue factor from the subendothelium. 
Activated platelets change shape, developing pseudopods, and stretch to cover the 
damaged endothelium. The contents of alpha granules and dense bodies are secreted through 
the OCS into the plasma. Dense bodies secrete ADP, serotonin, and calcium. ADP further 
stimulates aggregation [64, 65]. Likewise, serotonin weakly accelerates platelet aggregation 
separately but also potentiates the response to ADP [66] and increases overall procoagulant 
activity. Calcium helps in aggregation as well by enabling binding of glycoprotein receptors 
to various agents. Alpha granules secrete, among other proteins, the fibrous adhesion 
proteins fibrinogen, vWF, fibronectin and thrombospondin which serve as connecting 
agents in further aggregation. Integrin αIIbβ3 on the platelet surface is a calcium-dependent 
receptor for fibrinogen, vWF, fibronectin, and thrombospondin, as well as vitronectin. The 
GPIb-V-IX complex also binds vWF, GPVI and GPIa binds collagen, locking the platelets 
to damaged endothelium. The activated, aggregated platelets form a plug in the wound site 
to stem the flow of blood.  
Platelet activation through ADP also initiates the arachidonic acid pathway, leading to 
the synthesis of TXA2, which provides a positive feedback mechanism to yield more platelet 
aggregation [67, 68]. This pathway is dependent upon phosphoinositol 3-kinase. A complex 
series of events involving tissue factor (the extrinsic pathway) or other various clotting 
factors (the intrinsic pathway) result in prothrombin being converted to thrombin (Figure 1-
5) [69]. The latter cleaves fibrinogen to make fibrin, which polymerises into long strand. 
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Fibrin strands are cross-linked by factor XIII to form a stable network that strengthens the 
platelet plug [70-72]. 
 
 
 
Figure  1-5: Blood coagulation cascade. The coagulation cascade is initiated via intrinsic pathway at the site 
of blood vessel damage by activating factor XII or via extrinsic pathway at the site of trauma when tissue 
factor is exposed. Adapted from [69-73].   
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1.2.3 Endogenous mechanisms of inhibition of platelet function 
As long as the endothelium remains healthy and undamaged, platelets circulate in a 
largely resting and quiescent state. Dangerous arterial thrombi can occasionally occur when 
atherosclerotic plaques form at lipid rich sites in otherwise healthy blood vessels [74]. There 
is homeostatic balance between prothrombotic and anti-thrombotic mediators within the 
blood. 
The main endogenous inhibitors of platelet function, all produced by endothelial cells 
include NO, endothelial ADPase (also called ectonucleotidase CD39) and the eicosanoid 
prostacyclin [74, 75]. Endothelial nitric oxide synthase (eNOS), located in the plasma 
membrane of endothelial cells, generates NO, a gaseous locally-active hormone. NO 
passively diffuses across the platelet plasma membrane where it stimulates soluble guanylyl 
cyclase (sGC) [74, 76]. This enzyme catalyses the formation of cyclic GMP which in turn 
inhibits platelet adhesion, activation and aggregation [76]. NO also causes smooth muscles 
surrounding the blood vessel to relax, leading to dilation of the vessels. NO is also produced 
by the platelet itself shortly after activation [77]. This inhibits further platelet recruitment 
into aggregates, unless the stimulus is sufficiently strong. 
In animal models of atherosclerosis, treatment with L-arginine, which is an eNOS 
substrate, inhibits atherosclerotic lesions [78]. An L-arginine supplement given to human 
subjects inhibits ADP-dependent aggregation of platelets. NO effects are concentration 
dependent, under normal circumstances, NO is produced in the nanomolar range, which is 
sufficient to prevent platelet adhesion. Excessive NO, in the micromolar range, can lead to 
vascular injury. 
Prostacyclin is an arachidonic acid derivative that inhibits platelet aggregation, 
platelet activation and vasoconstriction. Prostacyclin synthase, the last enzyme in the 
prostacyclin pathway is found in the endoplasmic reticulum of endothelial cells and smooth 
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muscle cells, but is not present in platelets. Prostacyclin’s effects on platelets and smooth 
muscle cells are mediated by prostacyclin receptor. It is a G-protein coupled membrane 
receptor of the prostanoid family (see section 1.5.1.3). Insufficient or poorly regulated 
prostacyclin concentrations have been implicated in a wide variety of cardiovascular 
conditions including hypertension, stroke, atherosclerosis and myocardial infarction [79]. 
Endothelial CD39 is one of a family of Ecto-nucleoside triphosphate 
diphosphohydrolases that hydrolyse the terminal phosphates in nucleotide di- and 
triphosphates [80, 81]. It is an integral cell membrane protein with its active site on the 
external side. Thus, it can hydrolyse ADP and ATP that is in the blood plasma. These 
nucleotides act as signalling molecules as well as potential energy sources for chemical 
reactions. Excess ADP in the plasma, released from platelets or from damaged vascular 
tissue can have prothrombotic effects, through ADP receptors on platelets. The activity of 
endothelial CD39 inhibits the critical platelet recruitment phase [82]. 
1.2.4 Pharmaceutical inhibitors of platelet activation 
When endogenous inhibitors of thrombus formation are insufficient, people are prone 
to dangerous clot formation that can cause cerebrovascular accidents (stroke) or induce 
myocardial infarction by blocking coronary arteries. There are three classes of drugs that 
have been used to protect patients from overactive platelets: nonsteroidal anti-inflammatory 
drugs (particularly aspirin); thienopyridines; and GPIIb/IIIa inhibitors [83].  
The production of TXA2 is inhibited by aspirin and other cyclooxygenase inhibitors 
[83]. TXA2 is produced by activated platelets and functions as a positive feedback agent, 
increasing the activation of platelets. Aspirin treatment has been demonstrated to have 
significantly reduced heart disease by inhibiting thrombus formation in patients with 
atherosclerosis [83, 84]. 
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Thienopyridines, such as Ticlopidine and Clopidogrel block the P2Y12 receptor on 
platelets, which is the receptor for ADP [82, 83] (see section 1.5.1.2). Clopidogrel is usually 
favoured, because Ticlopidine treatment has the side-effect of thrombocytopenia. These 
drugs are prescribed for people with atherosclerosis, post myocardial infraction, and those 
who have just undergone coronary angioplasty. 
GPIIb/IIIa (integrin αIIbβ3) inhibitors prevent the cross-linking of platelets through the 
binding of the glycoproteins to fibronectin, vWF, vitronectin and other large proteins [83]. 
Inhibitors in clinical use include Abciximab (a monoclonal antibody), Eptifibatide (isolated 
from snake venom) and Tirofiban [85]. 
1.3 Integrins 
Integrins mediate attachment of cells to surfaces, extracellular matrix or other cells. 
They are receptors involved in cell signalling in the sense that they can help inform the cell 
about ligands, matrix proteins and conditions on the exterior of the cell by ‘outside-in’ 
signalling [86]. Integrins are also be involved with ‘inside-out’ signalling-influencing the 
outside environment on the basis of biochemical changes within the cell [86, 87].   
Integrins link the cell surface to extracellular matrix proteins, such as fibronectin, 
collagen and laminin. Thus, they may help to regulate cell shape, cell movement and even 
the cell cycle [87]. Integrins work alongside other cell adhesion molecules as well as 
members of immunoglobulin superfamily to mediate intercellular communication and cell 
to basement membrane interactions. Integrins are heterodimers consisting of an α and a β 
subunits. In mammals, there are eighteen known α chains and only eight β chains. The 
subunits can be mixed and matched depending on a cell’s requirements so that there are 24 
distinct integrins in mammals [87]. Both subunits span the plasma membrane and both have 
tails that extend into the cytoplasm. The various subunits vary in size from 90-160 
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kilodaltons. Several α subunits contain the αA domain near the N-terminal which is similar 
to the A1 domain in vWF that mediates binding to collagen proteins. The A1 domain may 
contain divalent cation binding sites that are occupied when integrin is interacting with 
arginine-glycine-aspartic acid (RGD) sites on matrix proteins.  
The major integrins of interest in platelet biology are αIIbβ3, αvβ3, α2β1 and α5β1. 
Integrin αIIbβ3 will be described in some detail and other integrins will be described briefly. 
1.3.1 β3 Family of integrins 
There are two β3 integrins, so named because they share the same beta subunit. 
Integrin αIIbβ3 and αvβ3, are both expressed on platelets. Their alpha subunits share 36% 
sequence homology. Knockout experiments in mice show the importance of these integrins 
to platelet function. In the absence of β3 gene there is essentially no platelet aggregation 
with resultant haemorrhagic effects [87]. 
1.3.1.1 Integrin αIIbβ3 
Integrin αIIbβ3 is the main platelet integrin, with about 80,000 copies per platelet. It is 
the crucial receptor required in physiological processes such as clot retraction, platelet 
spreading, cytoskeletal reorganisation, irreversible platelet adhesion, platelet aggregation 
and thrombus stability [88]. Platelet aggregation is mediated by integrin αIIbβ3 which is also 
known as GPIIb-IIIa. This protein is normally expressed only on megakaryocytes and 
platelets. On the latter, it is the major integral protein of plasma membrane and is also 
expressed on the membranes of alpha granules.  
This receptor goes from low-affinity resting state to an active state wherein it has 
high-affinity for extracellular ligands vWF and fibrinogen [89, 90], which cross-link 
platelets together.  It also is able to bind thrombospondin, vitronectin, plasminogen and 
fibronectin [90]. The binding of most proteins by integrin αIIbβ3 is via the RGD recognition 
26 
 
sequence. However fibrinogen contains RGD, a different amino acid sequence in its 
recognition of integrin for fibrinogen, K-Q-A-G-D-V [91-93].  
The various domains of the alpha and beta chains are depicted in Figure 1-6 and 1-7 
[89]. The A domain of the beta chain is the one principally involved in the binding of RGD 
sequences. The A domain also has three metal binding sites called MIDAS, ADMIDAS and 
LIMBS (for ligand-induced metal binding site) [94, 95]. The beta subunit has four EGF 
domains so named because of their resemblance to Epidermal Growth Factor. The propeller 
domain in the alpha chain, which interacts with the A domain of the beta chain, has a series 
of seven amino-acid repeats (the ‘blades’) that are involved in binding divalent cations. The 
calf and thigh domains of integrin αIIb are primarily in the form of beta pleated sheets [96] 
and both have similar, immunoglobulin-like, β-sandwich folds [97]. Both subunits have tail 
domains that extend into cytoplasm and interact with a multitude of intracellular proteins. 
There is small acidic region between the thigh and first calf domain called genu (latin for 
knee) which binds to calcium. Another genu exists in the beta subunit involving the hybrid, 
PSI and EGF domains [96]. 
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Figure ‎1-6: Depiction of Structure of integrin αIIbβ3 complex. This cartoon showing the αIIb (green) domains 
and β3 (blue) subunits in an extended conformation Adapted from [89]. 
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The presence of the genu in both subunits allows a conformational shift to occur from 
bent to an extended state in a calcium-dependent manner [98]. When the receptor binds to 
the ligand, the protein changes to an extended form. Crystal structure of the pure receptor 
shows the bent state. The activation of integrin αIIbβ3 is termed ‘inside-out’ signalling, 
because the events that regulate it are intracellular in nature but result in changes that occur 
on the extracellular surface. During ‘inside-out’ signalling, changes in conformation of the 
extracellular domains increase the affinity for its ligand. The same integrin also participates 
in ‘outside-in’ signalling, where external events lead to widespread biochemical events 
within the cell [99]. This type of signalling happens after the ligand is bound. In this case, 
changes in conformation of the cytoplasmic tails create interaction sites for cytoskeletal 
proteins as well as protein kinases. Inside-out signalling is mediated through the GPVI and 
the GPIb-IX-V complexes and G-Protein coupled receptors (GPCRs)  (Figure 1-7) [89]. 
Binding of polymeric collagen, exposed during vascular injury to the GPVI complex causes 
clustering of GPVI receptor (see section 1.6.1) and its associated Fc receptor gamma subunit 
which ultimately results in the activation of phospholipase C. That enzyme catalyses the 
formation of inositol 1,4,5 trisphosphate (IP3) and diacylglycerol. IP3 mobilises Ca
2+
, 
whereas diacylglycerol activates protein kinase C, which phosphorylates a number of 
different intracellular proteins. Both events appear to be involved in activation of the 
integrin. Binding of vWF to the GPIb-IX-V complex initiates a similar set of events.   
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Figure  1-7: Inside-out and ‘outside-in’ integrin αIIbβ3 signalling events mediated by GPCRs, GPVI and 
GPIb-IX-V. This carton explains different platelet signalling pathways. Firstly, ‘inside-out’ integrin αIIbβ3 
signalling is initiated via one of the GPCRs, collagen receptors, integrin α2β1 and GPVI which all converge via 
release of PIP2 from the membrane and lead to mobilisation of calcium. ‘Inside-out’ integrin αIIbβ3 signalling 
brings about a separation of the transmembrane domains of the two subunits of integrin αIIbβ3. This separation 
is thought to allow the tail units to interact with specific cellular proteins involved in ‘outside-in’ signalling 
shown here as phosphorylated Src. 
 
 
Ultimately, the cytoplasmic tails of the integrin subunit are bound by one or more 
proteins, resulting in an “unclasping” of the tail region and a conformational shift which 
results in an increase in affinity of the extracellular domains for RGD and other ligands. The 
exact sequence of events is not known with precision. The integrin tails interact with 20 or 
more different cytoplasmic proteins. The best candidate for the activating protein is the head 
domain of Talin [89, 100]. Talin is an abundant cytoplasmic protein that mediates the 
interaction of integrins (β3 cytoplasmic tail) with actin microfilaments of the cytoskeleton.   
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Platelet aggregation occurs in two phases, first reversible aggregation that depends on 
inside-out signals, and then irreversible aggregation that occurs in response to outside-in 
signalling [101]. Inside-out signalling brings about separation of the trans-membrane 
domains of the two subunits. This separation is thought to allow the tail units to interact 
with specific cellular proteins involved in outside-in signalling. On larger scale, a factor that 
seems to be involved is clustering of the integrin in membrane brought about by cross-
linking of their extracellular domains through their ligands proteins such as fibrinogen. 
Artificial cross-linking of the dimers using chemicals is sufficient to bring about the 
activation of two protein kinases associated with outside-in signalling, c-Src and Syk [102]. 
Binding of fibrinogen to integrin αIIbβ3 causes protein tyrosine phosphatase (PTP-1B) 
to associate with a complex between the integrin, c-Src, and c-Src kinase (CSK). The latter 
is a protein kinase that phosphorylates c-Src to keep it in a normally inactive state. Upon the 
association of PTP-1B, CSK dissociates from the complex, and c-Src is dephosphorylated 
and becomes active. c-Src is a tyrosine kinase with a multitude of substrates that are 
involved in downstream signalling associated with other kinases including Syk, Tec tyrosine 
kinases, integrin linked kinase, protein kinase C, and phosphatidylinositol 3-kinase [101]. 
The kinase cascade results in many of the effects associated with irreversible platelet 
aggregation and activation. 
Glanzmann's thrombasthenia (GT) is a disease of platelets in which integrin αIIbβ3 is 
either absent from the platelets or defective [103, 104]. In many cases, expression of the 
protein is normal but its binding properties are compromised (Type II GT). The condition 
can be inherited or acquired through autoimmune responses. Platelet numbers and 
morphology are normal but integrin αIIbβ3 cross-linking of platelets by fibrinogen does not 
occur, and bleeding times are quite prolonged [103, 105]. Nose bleeds, heavy menstrual 
flow, and excessive post-operative bleeding are common symptoms [105]. GT, along with 
31 
 
mouse knockout experiments, demonstrates the key role for integrin αIIbβ3 in platelet 
activation and aggregation [106]. 
Through its role in cross-linking platelets through fibrinogen and other ligand 
proteins, integrin αIIbβ3 plays a direct role in initial platelet aggregation. The bidirectional 
signalling and the resulting kinase cascade mediates many of the activities leading to 
irreversible platelet aggregation, thrombus formation and clot retraction. 
1.3.1.2 Integrin αvβ3 
The integrin αvβ3 has two subunits, alpha v and beta 3. It serves as receptor for 
vitronectin on platelets and is also found on endothelial cells, monocytes, macrophages, 
dendritic cells, chondrocytes and fibroblasts. This integrin is involved in the binding of 
platelets to endothelial cells during inflammatory processes. It is also known to play a role 
in angiogenesis and tumour metastasis which may be related to its presence on platelets, as 
these are a source of tumour growth factors and angiogenic factors. αvβ3, however, is likely 
to exert only a minor influence as there only about 50 copies of the protein on the platelet 
surface as compared to about 50,000-80,000 copies for integrin αIIbβ3 [107]. 
1.3.2 Integrin α2β1  
The integrin α2β1, also known as GPIa-IIa on platelets or VLA-2 on lymphocytes, is 
present on a wide variety of cells. Its ligands include collagen and the laminin family of 
proteins, but it does not appear to function as a laminin receptor on platelets. Per platelet, 
there are around 2000-4000 copies of integrin α2β1. 
The alpha subunit has the typical seven amino acid repeats in the propeller domain. 
This domain can also interact with three to four Ca
2+
 ions. The structure of integrin α2β1 is 
shown in Figures 1-8 and 1-9. There is an I domain sandwiched between the second and 
third repeats that binds to the GFOGER amino acid sequence on collagen or collagen related 
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peptide (CRP) [108]. Currently, it is believed that this integrin increases its affinity for the 
collagen ligand after the platelet is activated by interaction between collagen and the platelet 
GPVI. This interaction alone is insufficient to activate the platelet under high shear 
conditions. Another platelet glycoprotein (GPIb), and the presence of vWF in plasma are 
necessary for this to occur. 
Integrins are responsible for firm adhesion of the activated platelet to the 
subendothelium. Since Glanzmann’s thrombasthenia platelets still adhere, even though they 
lack integrin αIIbβ3, it is likely that integrin α2β1 interaction is sufficient for adherence albeit 
not for creation of an effective plug. 
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Figure  1-8: Integrin alpha2-beta1/collagen complex containing Gly-Phe-Hyp-Gly-Glu-Arg motif. Protein 
chains are coloured from the N-terminal to the C-terminal using a rainbow (spectral) colour gradient. Adapted 
from [109, 110].  
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Figure  1-9: Functional and structural mode of integrin α2β1 activation. Activation of integrin α2β1 
necessitates the involvement of α2β1 propeller, Beta-1 I-like domain and other alpha-2 domains. All these 
differential activation reactions occur with the binding of collagen and actin with the integrin. Adapted from 
[111]. 
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1.3.3 Other Integrin family members 
The integrin α5β1 is present on many cell types including platelets. Its function in 
platelets is not well defined but its general role is to bind the extracellular matrix protein 
fibronectin as well as some proteinases. The integrin may have a role in stabilising adhesion 
of the platelets to injury sites on the vasculature. 
The integrin α6β1 is also present on many cell types including platelets. Its general role 
is binding to the laminin family and other extracellular matrix proteins. It may also have a 
role in stabilising platelet adhesion to sites of injury. 
The β2 family of integrins consists of αLβ2 and αMβ2. The former is present on 
activated but not resting platelets, whereas the latter has yet to be detected. The usual 
ligands for αLβ2, which is also expressed in T-lymphocytes, are cell adhesion molecules 
ICAM1 and ICAM2. The former is expressed on endothelial cells. Gene knockout studies 
have discovered that platelets in mice without the β2 gene have much shorter half-lives and 
that caspase activities (which are frequently associated with apoptosis) were elevated [112]. 
1.4 Leucine rich repeat family 
A leucine rich repeat (LRR) is fairly common protein motif called the α/β horseshoe 
fold that is present in many proteins but is not necessarily related in function. Within 
platelets, leucine rich repeats are found in two important receptors, the GPIb-IX-V complex 
(also known as CD42) and the Toll-like receptors.  
1.4.1 GPIb-IX-V complex 
The GPIb-IX-V is non-covalent multimeric complex composed of GPIbα, GPIbβ, 
GPIX and GPV subunits. It serves as receptor for vWF, thrombospondin I and P-selectin, 
which is found both on activated platelets and on endothelial cells [113]. It also interacts 
with α-thrombin, factors XI and XII, and kininogen, all of which are involved in coagulant 
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activity. There are about 50,000 copies of the GPIb-IX-V complex found on an average 
sized platelet. This complex is essential for platelet adhesion under conditions of high shear. 
Bernard-Soulier syndrome, or haemorrhagiparous thrombocytic dystrophy, is a 
genetic bleeding disorder caused by absence of the GPIb-IX-V complex or a defect in its 
activity. It is characterised by the inability of platelets to bind to or aggregate at sites of 
vascular injury. It is one of the giant platelet syndromes; the normal attachment of GPIb-IX-
V to the cytoskeleton through filamen help to regulate the size of the platelet [113]. 
Immune thrombocytopenic purpura is sometimes caused by autoantibodies to GPIb-
IX-V or integrin αIIbβ3. The structure of GPIb-IX-V (hereinafter called ‘the complex’) is 
shown in Figure 1-10. All four subunits are transmembrane membrane proteins with tails 
protruding into the cytoplasm. Leucine rich repeats are found in three of four subunits with 
the exception being GPIbβ which is linked by disulphide bonds to GPIbα. GPIbα has an 
unusual region of sulphated tyrosines adjacent to a long section with associated sialomucin. 
Most of the ligand binding sites are located in the N-terminal loop of the GPIbα with the 
notable exception of collagen, which binds to GPV. Calmodulin associates with the 
cytoplasmic tails of GPIbβ and GPV which may help regulate surface expression of the 
complex. Filamin binds to the cytoplasmic tail of GPIbα, linking it to the cytoskeleton. 
The GPIb-IX-V complex acts as an ‘outside-in’ signalling receptor to activate the 
platelet integrins αIIbβ3 and α2β1, which in turn mediate stable platelet adhesion, aggregation 
and clot retraction. The mechanisms by which this signalling works have not yet been 
completely clarified but they involve both G-proteins coupled and tyrosine kinases. Key 
elements include c-Src, which is a tyrosine kinase, phospholipase γ2 (PLCγ2) which raises 
Ca
2+
 in the cytosol by generating IP3; and PI-3 kinase, which generates signals that activate 
integrin αIIbβ3. Extracellular signal regulated kinase 1/2 (Erk-1/2) and Syk kinase also 
appear to be involved. 
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Figure  1-10: Structure of GPIb-IX-V. Panel (A) shows the leucine-rich repeats, the sulphated tyrosine 
residues and the sialomucin regions. Protein binding sites are indicated in panel (B). The C-terminal region of 
GB1bα alpha region interacts with filamin. The GPV and GPIb beta chain carboxy-terminals interact with 
calmodulin. Adapted from [113]. 
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1.4.2 Toll-like receptors 
This class of receptors are the proteins, which play a crucial role in the innate immune 
system. These single, membrane-spanning and non-catalytic receptors identify the 
structurally conserved molecules obtained from microbes. The Toll-like receptors have two 
sections of 9-11 leucine rich domains connected by a linker region, transmembrane domain, 
glycosylated double loop domain and a cytoplasmic Toll/Interleukin-1 signalling domain. A 
small molecule, MD-2 associates with the extracellular terminus. Toll-like receptors interact 
with lipopolysaccharides and some endotoxins. Experiments in mice have suggested a role 
for Toll-like receptor-4 in that treatment with lipopolysaccharide caused platelets to adhere 
more tightly to fibrinogen whereas mice which genetically lacked the receptors did not show 
the same response [114].  
1.5 Seven transmembrane receptor family 
The seven transmembrane domain receptors are mostly GPCRs, and are widely used 
mechanisms in eukaryocytes to sense the presence of extracellular ligands, such as 
hormones or neurotransmitters or significant extracellular peptide. These receptors activate 
intracellular signalling modalities such as the cAMP system or the phosphatidylinositol 
signal transduction pathway, leading frequently to complex cellular responses. They are 
tightly linked to cellular metabolism and can have very general effects. Therefore, if several 
GPCRs act through cAMP, they are generally affecting the same cytosolic pool of cAMP 
and therefore are likely to have similar effects, regardless of the initial stimulus. Additive 
results may occur when more than one type of stimulus is used. 
There are generally seven transmembrane domains with three intracellular and three 
extracellular loops in these long proteins (Figure 1-11). There is also long cytoplasmic tail 
which may interact with protein kinase C, protein kinase A or GPCR kinase. GPCRs are 
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generally highly conserved. Of the 367 human and 392 mouse GPCRs studied by Vesalius 
and colleagues, 343 were common to both species [115]. 
 
 
 
Figure  1-11: Structure of generic GPCR. IL=intracellular loop. EL=extracellular loop. Filled black 
squares=N-acetyl glucosamine. Unfilled circles=mannose. N=Asparagine. X=any amino acid. C=cysteine. 
E/D=glutamate or aspartate. Y=Tyrosine. R/K=arginine or lysine. G alpha=alpha subunit of G protein. G 
beta/gamma=subunits of heterodimeric G protein. PKC=Protein Kinase C. PKA= Protein kinase A. 
GRK=GPCR kinase. Adapted from [116]. 
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1.5.1 GPCRs expressed in platelets 
In the platelet, there are various GPCRs, including thrombin receptors, ADP receptors, 
the prostacyclin receptor, the thromboxane receptor, receptors for the neurotransmitters 
serotonin, dopamine and epinephrine, vasopressin receptor, an adenosine receptor, and 
possibly chemokine receptors. These are considered in more detail below. 
1.5.1.1 Thrombin receptors 
Thrombin receptors are called protease activated receptors (PARs) because they are 
activated by specific cleavage of the N-terminal domain (Figure 1-12). This results in new 
N-terminus which by rearrangement of the protein acts as a tethered ligand [109, 117]. This 
is an unusual situation for a GPCR; whereas most of these receptors can be turned on and 
off depending on the concentrations of their respective ligands, thrombin receptors can only 
be activated once. In terms of platelets, this is no particular disadvantage given their short 
lifespan, and the fact platelets themselves are single-use mechanisms for generating 
thrombi. However, PARs are not just restricted to platelets, though expression of PAR 
mRNA is mainly found in cells involved in the vasculature, including endothelial cells and 
smooth muscle cells.  
 There are four PARs, numbered 1-4. PAR-2 is not a thrombin receptor since it is 
activated by trypsin and related proteases. PAR-1 seems to be important in human platelets 
which have 2500 copies per platelet, with about two thirds present on the plasma membrane. 
PAR-1 signalling however is apparently insignificant in mouse platelets. The lack of PAR-1 
gene in mice caused 50% embryonic lethality but the survivors had no haemorrhagic 
diseases and their platelets could be activated normally [118]. Humans and mice both have 
signalling systems that utilise two PARs. In humans, the pair is PAR-1 and PAR-4 but in 
mice it appears to be PAR-3 and PAR-4 [117].  Mouse platelets express PAR-3, but in 
human platelets the expression is insignificant [117]. In the absence of PAR-3, PAR-4 is 
41 
 
sensitive to thrombin at high (30 nM) levels but not low (1 nM) levels. On the other hand, 
PAR-3 by itself does not activate platelets in response to thrombin, even when 
overexpressed. PAR-3 appears to act as a co-factor to PAR-4, increasing its sensitivity to 
thrombin [119]. Mouse PAR-4 is required for platelet thrombus propagation but not 
juxtamural thrombus formation or fibrin generation [120]. Although platelets isolated from 
PAR-4-deficient mice are not responsive to thrombin, they can be activated by other 
agonists. Also, there is no evidence that the mice bleed spontaneously indicating that 
thrombus propagation is not required for haemostasis in the absence of injury [121]. 
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Figure  1-12: Structure of G-Protein coupled receptors. GPCRs display a common structure consisting of 
seven transmembrane domains with three intracellular and three extracellular loops in these long proteins. 
GPCRs also contain a long cytoplasmic tail which may interact with protein kinase C, protein kinase A or 
GPCR kinase. GPCRs are generally highly conserved. Of the 367 human and 392 mouse GPCRs studied by 
Vassilatis and colleagues, 343 were found to be common to both species [115]. This figure illustrates the 
GPCRs signalling pathways via Gα protein. Adapted from [122]. 
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1.5.1.2 ADP receptors 
ADP was the first known small molecule platelet agonist. ADP and other nucleotides 
may be released from damaged cells or may be secreted from intact cells or activated 
platelets. There are two platelet ADP receptors of the seven transmembrane family P2Y1 
and P2Y12 (Figure 1-13) [64, 83, 123]. They are part of a family of 14 such receptors that 
have been cloned, although not all members of the family are known to respond to 
nucleotides. ADP is a platelet aggregating agent, it can trigger reversible aggregation and 
shape change, whereas secondary aggregation and secretory activities are dependent upon 
TXA2. 
P2Y1 is expressed on platelets as well as most other human tissues. It is present on the 
plasma membrane but also in membranes of the OCS and those of the alpha granules. In the 
presence of P2Y12 antagonists, ADP induced transient aggregation and shape change, 
suggesting that these can be mediated by the P2Y1 receptor alone [83]. Similar results were 
achieved for platelets from mice engineered to lack the gene for P2Y12 and from humans 
who were congenitally deficient in P2Y12 [64]. 
Activation of platelet P2Y1 by ADP leads to activation of phospholipase C mediated 
by a specific G protein, Gq [83, 123]. The resultant increase in cytosolic calcium is 
mediated by IP3. Some of the calcium is released from intracellular stores, though some may 
also influx from the extracellular medium. Platelets from mice lacking the Gq gene do not 
undergo shape change in response to ADP [83, 124] but still undergo partial aggregation. 
P2Y12 expression is restricted to platelets, vascular smooth muscle cells and to some 
regions of the brain. It has the structure of classic GPCR sequence. It is stimulated by ADP 
and its analogues whereas ATP is an antagonist [123]. P2Y12 has the major responsibility 
for platelet aggregation. It is coupled to adenyl cyclase inhibition through the G protein 
subtype Gαi2 [64]. Adenyl cyclase inhibition does not directly cause activation of integrin 
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αIIbβ3 and platelet aggregation but does counteract inhibitory prostaglandins, which works 
through increasing cAMP. P2Y12 amplifies intracellular calcium mobilisation induced 
through the P2Y1 receptor and the secretion of dense granules stimulated by TXA2 or 
thrombin [83]. The details of P2Y1 receptor signal transduction have yet to be totally 
elucidated but it appears to involve the phosphoinosotide 3-phosphate activation of Rap1-B 
and phosphorylation of serine/threonine protein kinase B/Akt. Metabolites of the 
antithrombotic thienopyridine drugs ticlopidine and clopidogrel are antagonists of P2Y12 
[125].  
 
           
Figure  1-13: Different subtypes of ADP receptors. P2Y1 and P2Y12 are GPCRs. There are two main ADP 
receptors. The P2Y12 receptor leads to inhibition of adenylyl cyclase (AC) and a decrease in cyclic AMP 
(cAMP), resulting in platelet secretion of thrombotic mediators and in platelet aggregation. The P2Y1 receptor 
leads to improved calcium influx (Ca
2+
), resulting in platelet shape change. Adinosine-3-phosphate-5phosphate 
(A3P5P) and Cangrelor (formerly AR-C9931MX) are two specific P2Y1 and P2Y12 antagonists, respectively. 
Adapted from [83]. 
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1.5.1.3 Prostaglandin family receptors 
There are ten known prostaglandin receptors, all are GPCRs of the seven 
transmembrane family. Five have been detected on platelets: receptors for TXA2, PGI2 
(prostacyclin) PGD2, PGE1 and PGE2. TXA2 and prostacyclin are important physiological 
regulators of platelet function. 
Thromboxane A2 receptor: TXA2 is a short-lived autocrine factor that amplifies 
aggregation and activation of platelets after they have been stimulated by agonists such as 
thrombin or ADP. It also functions as a vasoconstrictor and mitogenic agent, hastening the 
proliferation of cells involved in vascular repair [126]. Signals initiated at the TXA2 receptor 
in response to binding facilitate integrin αIIbβ3 activation and subsequent secretion of dense 
granule contents. There are two forms of TXA2 receptors on platelets, TPα and TPβ, which 
appear to arise in humans from differential splicing of a single gene [68]. Both mRNA 
transcripts are present in platelets. There is some evidence that TPβ heterodimerise with 
other GCPRs such as the prostacyclin receptor which may have functional significance 
[127]. In mice, most of the known TXA2 functions also seem to be mediated through a 
single gene, the deletion of which results in a mild bleeding disorder [128]. The mouse gene 
seems to be organised similarly to the human gene with the entire coding region in exons 
two and three [128, 129]. 
The activated TPα in platelets couples through the G proteins Gq and G12/13 [109] and 
possibly Gi [68]. The former stimulates protein phospholipase C-β which acts to raise 
intracellular calcium as well as activating protein kinase C signalling pathways. G12/13 
indirectly regulates the phosphorylation of myosin light chain through the Rho kinase. Both 
forms of TP appear to be coupled to adenyl cyclase, however TPα activates adenyl cyclase, 
whereas TPβ inhibits it. An Arg60 to Leu mutation in TPα in human patients leads to a 
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bleeding disorder [68]. This mutation decreases phospholipase C activation but does not 
affect adenyl cyclase inhibition. 
Prostacyclin receptor: Prostacyclin (PGI2), a prostaglandin secreted by endothelial 
cells, inhibits platelet aggregation through the PGI2 receptor. This receptor called the IP 
receptor [74], activates adenyl cyclase through the G protein protein Gαs resulting in an 
increase in cyclic AMP [75]. The C-terminal portion of the IP receptor is substituted with a 
C-15 farnesyl isoprenoid chain at Cys383. The isoprenoid substitution is not required for 
prostacyclin binding but is necessary for efficient coupling to both adenyl cyclase and 
phospholipase C activation [126]. 
PGD2 receptor: Prostaglandin D2 has an anti-aggregatory activity on platelets through 
its receptor, of which there about 200 copies per average human platelet. There are a 
decreased number of these receptors in patients with type IIa hyperlipoproteinemia which 
may account for the thrombotic disorders that occur in such people [130].  
PGE1 and PGE2 receptor: PGE1 induces cAMP accumulation in platelets through the 
IP receptor. PGE2 is a bimodal regulator of platelet aggregation: at high concentration it is 
an inhibitor but at low concentrations it potentiates the response of platelets to collagen or 
ADP. There are two receptors for PGE2, called EP3 and EP4 in the mouse. EP3 inhibits 
adenyl cyclase whereas EP4 does the opposite [131]. EP3 is also a receptor for PGE1 but 
EP4 is not. IP is not receptor for PGE2. 
1.5.2 Chemokine receptors 
Platelets are the source for several chemokines including PF4, β thromboglobulin, 
epithelial/neutrophil activation peptide 78 (ENA-78) and the regulated upon activation, 
normal T-cell expressed and secreted (RANTES) chemokine. Platelets also have chemokine 
receptors including CCR1, CCR3, CCR4, CX3CR1, and CXCR4 [109, 132]. The latter is 
47 
 
the receptor for stromal cell factor 1 and for TARC (thymus and activation related 
chemokine). CXCR4 is also found on megakaryocytes and may have a role in their 
maturation [22]. CCR3 and CCR4 are receptors for RANTES which is released during 
platelet activation and so is likely to be involved in autocrine feedback regulation. CCR4 is 
also a receptor for some megakaryocyte produced cytokines and TARC which is also found 
in alpha granules. CX3CR1 is the receptor for fractalkine, known to be involved in 
atherosclerosis [133]. 
1.5.3 Other seven transmembrane receptors 
There are a number of other GPCR with seven transmembrane regions expressed in 
platelets. These include the vasopressin receptor, the adenosine receptor, a β2-adrenergic 
receptor, the serotonin receptor,  and D5 and D6 receptors for dopamine [109]. Vasopressin 
(anti-diuretic hormone) is a platelet agonist in the presence of adenosine, as the two 
receptors act in a synergistic manner. Serotonin is a major component of dense granules, so 
the presence of the receptor is another example of platelet autocrine regulation; serotonin 
functions as an agonist. The actions of dopamine on platelet function are still unclear. 
1.6 ITAM-coupled receptors in platelets 
The consensus immune receptor tyrosine based activation motif (ITAM) is 
YxxI/Lx(6–12)YxxI/L whereas the consensus immunoreceptor tyrosine based inhibitory 
motif (ITIM) is S/I/V/LxYxxI/V/L with 25-30 amino acid spacing between tyrosine residues 
[134]. In both cases, the tyrosines are phosphorylated by Src family kinases after ligand 
recognition and receptor clustering. However, in some cases ITAMs can mediate inhibitory 
signals and ITIMs can mediate positive signals [134]. 
As previously discussed, both the GPVI-associated FcRγ, the FcγRIIa and CLEC-2 
(sections 1.6.1, 1.6.2 and 1.6.3) are ITAM coupled immunoreceptors that upon 
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phosphorylation leads to platelet activation events. Both have dual consensus ITAM 
sequences in their cytoplasmic regions and are also associated with calmodulin. Curiously, 
activation through either ITAM leads to the proteolytic cleavage and shedding of both [135] 
though the intramembranous region of FcγRIIa is protected. 
The immunoglobulin (Ig) superfamily is a group of proteins that are structurally 
related as they all contain a specific region called the ‘immunoglobulin domain’. The 
superfamily includes both soluble and membrane proteins, many of which are involved in 
recognition phenomena. The superfamily includes proteins of the immune system including 
antibodies, membrane proteins involved in antigen presentation and co-receptors, as well as 
some cell adhesion molecules, cytokine receptors, growth factor receptors and even the 
large intracellular muscle protein titin. The immunoglobulin superfamily is probably the 
largest family of proteins known with 700 plus members. 
Among the members of the immunoglobulin superfamily found in platelets are GPVI, 
PECAM-1, the carcinoembryonic antigens CEACAM1 and CEACAM2, G6B, signal 
regulatory protein α (SIRPα) and the ITAM and ITIM coupled receptors. The 
carcinoembryonic antigens are discussed in a separate section (see section 1.8); the 
remainder is discussed below. 
1.6.1 GPVI 
GPVI is a platelet membrane receptor for collagen. It is 58 kilodalton glycoprotein 
that functions primarily as a signalling molecule through the FcRγ chain. Ablation of the 
FcRγ gene results in loss of GPVI from the platelets probably because FcRγ acts as a 
chaperone and required to trafficking GPVI to surface membrane [3]. The collagen binding 
domain resides in two immunoglobulin (Ig) C2 loops at the end of a long mucin-like stalk 
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(Figure 1-14). The cytoplasmic tail contains binding sites for calmodulin and The Src family 
of tyrosine kinases. The extreme C terminal end is absent in the mouse. 
Of the macromolecules in the exposed extracellular matrix, collagen is the most 
thrombogenic; binding leads first to adhesion of platelets followed by the secretion of alpha 
and dense granule contents then platelet aggregation. This leads to further autocrine 
stimulation of thrombus formation. 
 
 
 
Figure  1-14: Structure of GPVI. Immunoglobulin domains, glycosylation sites, the mucin-rich stalk and the 
juxtamembrane region are shown. The proline rich region binds the src homology domains of Fyn and Lyn. A 
basic region in the C-terminal region binds to calmodulin and interacts with FcR γ-chain. Adapted from [136]. 
 
 
Collagen binds not only to GPVI but also to integrin α2β1 (Figure 1-15), but there are 
CRPs that bind only to GPVI [136], therefore the contribution by each to thrombus 
formation can be experimentally separated. The snake venom toxin convulxin is also very 
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powerful activator of signalling processes through GPVI. Since it is tetrameric, the toxin is 
able to cross-link the GPVI receptor, which presumably collagen does as well, since it 
presents multiple binding sites in its highly repetitive structure. These agents have allowed 
the dissection of activation through GPVI from that of other receptors. Also, collagen-
induced thrombus formation under shear conditions is deficient in platelets lacking GPVI 
[137]. 
Cross-linking of GPVI receptors leads to the phosphorylation of the ITAM of FcRγ by 
Src-like kinases Fyn and Lyn (Figure 1-15). The kinases are bound to the proline rich 
cytoplasmic region of GPVI. Syk kinase binds to the phosphorylated ITAM portion of 
FcRγ, leading to Src kinase mediated and autophosphorylation of Syk. Syk initiates a series 
of down-stream events which include the formation of a Linker of Activation T cells (LAT) 
signalosome and activation of PLCγ2. PLCγ2 is also activated by integrin α2β1 and GPIb-
IX-V but signalling through GPVI is considerably more powerful. Src kinase inhibitors 
completely inhibit aggregation and limit adhesion on collagen/vWF surfaces under 
conditions of high shear. Similar results are obtained in platelets deficient in PLCγ2 [136, 
138]. 
Some idea of the complexity of signalling processes is given by Figure 1-15. 
However, it is probably even more complicated. For instance, GPIb-IX-V and GPVI are 
physically and functionally connected. Note the presence of Btk/Tec (Bruton’s tyrosine 
kinase) in the signalosome adjacent to PLCγ2. Btk and other kinases of Tec family are non-
receptor tyrosine kinases which frequently are involved in PLC activation and calcium 
mobilisation. An inhibitor of Btk was shown to prevent collagen-induced thromboembolism 
in an experimental mouse model [139]. 
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Figure  1-15: Signalling through GPVI and the LAT signalosome. Collagen interacts directly with 
GPVI/FcR γ-chain and integrin α2β1. Also collagen interacts indirectly to GPIb-IX-V complex via the A1 
domain of vWF. The ITAM regions of the latter interact with Src homology regions after phosphorylation and 
lead to platelet thrombus formation. Adapted from [136]. 
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1.6.2 FcγRIIa- A second platelet ITAM receptor 
Another member of the immunoglobulin superfamily found in human platelets but not 
mouse is FcγRIIa [140]. It has molecular weight of 42 kilodaltons and contains two C-2 
type Ig loops, similarly to GPVI. On its cytoplasmic tail it has two ITAMs. FcγRIIa is 
complexed with GPIb-IX-V and can be activated on the surface by vWF or from within by 
G-protein-coupled receptors. 
FcγRIIa is involved in immunological defences to a variety of pathogens; it is present 
on macrophages and neutrophils. By binding to antibody complexes, it may promote 
interaction between platelet and pathogens. Its presence on platelets is problematic however, 
since clustering of the protein is induced by many antibodies in immune disorders. Similarly 
to GPVI, clustering of FcγRIIa activates platelets. This is particularly difficult in heparin 
induced thrombocytopenia wherein antibodies to complexes of heparin with PF4 activate 
platelets through FcγRIIa, leading to deficiency of platelets and thrombus formation [141]. 
1.6.3 The C-type lectin CLEC-2 in platelets 
Exploring how C-type lectin 2 (CLEC-2) activates platelets through a signalling 
process that uses the single YxxL sequence, down to the molecular level, is crucial for 
further understanding its role in platelet function. As a result, this section will explore the 
historical research describing CLEC-2, which led to the modern understanding of how this 
receptor is an important mediator of the platelet activation process. This will include a 
description of the structure of CLEC-2 and their signalling pathways. 
CLEC-2 was the subject of research by Suzuki-Inoue et al. when researching 
rhodocytin (aggretin), a toxin found in snake venom [142]. The group observed that 
CLEC-2 acted as a rhodocytin receptor in platelets. Subsequent assays conducted by 
Chaipan et al. and Kerrigan et al. showed that CLEC-2 belongs to the V (non-classical) C-
type lectin receptor group [143, 144]. High levels of the receptor are expressed in human 
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and mouse platelets and low levels are found in mouse neutrophils and sinusoidal 
endothelial cells in the liver of rats. However, the two research programs found no 
evidence that CLEC-2 was expressed in human neutrophils. This research followed 
studies by Colonna et al. which highlighted the presence of CLEC-2-derived mRNA in a 
range of blood cell types, including dendritic cells, granulocytes, and monocytes [145]. 
However, they found no evidence of CLEC-2 protein in these cells. Previously, Weis et al. 
and Drickamer groups had proposed a likely structure for CLEC-2, suggesting that it 
included a single transmembrane section connected to a stalk region, alongside an N-
terminal domain embedded in the cytoplasmic tail [146, 147]. The two research groups 
also discovered a C-type lectin-like domain (CTLD), specifically a C-terminal 
carbohydrate-like recognition domain (CRD). Through a process of elimination, the two 
research groups deduced that ligands must bind to the receptor site through a protein-
based interaction, because the CTLD possessed none of the residues that are essential for 
the binding of carbohydrates. Following this line of reasoning, it is therefore possible to 
suggest that rhodocytin also uses this binding mechanism to bind, because it contains no 
glycosylated groups. 
CLEC-2 contains only one signalling motif, a single YxxL motif incorporated in the 
cytoplasmic tail alongside a triple amino acid group (Figure 1-16). This singular motif 
separates CLEC-2 from similar proteins containing ITAM, because other members of this 
family incorporate a double YxxL sequence separated by between six and twelve amino 
acids. Although the receptor protein families containing ITIM and immunoreceptor 
tyrosine-based switch motif (ITSM) also incorporate a single YxxL group, it is 
structurally and, therefore, functionally different to the YxxL group found in CLEC-2. 
The CLEC-2 YxxL structure does not include the conserved amino acid sequence located 
before the YxxL motif. For the ITIM and ITSM receptor proteins, these YxxL motifs 
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perform an essential function in regulating the inhibition of ITAM. They achieve this by 
interacting with the SHP-1/SHP-2 tyrosine phosphatases or SHIP-1/SHIP-2 inositol 
phosphatases that form part of the SH2 domain. 
 
 
              
 
Figure  1-16: The CLEC-2 structure and signalling pathways. CLEC-2 signalling pathway is mediated after 
rhodocytin stimulation via atypical ITAMs leads to Syk activation and resulting in platelet activation. Red 
colour (ITAMs domains), Green colour (SH2 domains), Pink colour (Tyrosine kinase, Syk) and Blue colour 
(CLEC-2 structure). Adapted from [148]. 
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1.6.3.1 Rhodocytin 
To study the molecular basis of how haemotoxins promote clotting, Huang et al. and 
Shin and Morita purified venom extracted from the Malayan Pit Viper (Calloselasma 
rhodostoma) [149, 150]. The results showed that the major active toxin was rhodocytin, a C-
type lectin [149, 150] which caused platelet activation and aggregation. Blocking of integrin 
α2β1 by antibody inhibited the powerful aggregating action [149, 151]. Subsequently, Eble et 
al. argued that integrin α2β1 could not be the mechanism behind clotting, because rhodocytin 
showed no affinity for recombinant integrin α2β1 [152]. Conversely, simultaneous research 
by Clemetson suggested that integrin α2β1 and GPIbα antibodies could restrict rhodocytin-
induced platelet activation [153]. This contradicted research conducted by Shin and Morita, 
which suggested that cleaving GPIbα had no effect on rhodocytin-initiated platelet 
activation [150]. Bergmeier et al. added further complexity by showing that integrin α2β1, 
GPIbα, and GPVI, a collagen receptor, were not necessary components of platelet activation 
in the presence of rhodocytin [154]. Their research involved depleting the GPIbα group of 
mice through the action of O-sialoglycoprotein endopeptidase, and the GPVI group via 
JAQ1, a GPVI monoclonal antibody, leaving no active integrin α2β1 complex [154]. Thus, 
Bergmeier et al. proposed that the process by which rhodocytin stimulates powerful 
activation of platelets does not require integrin α2β1, GPIbα, or GPVI [154]. 
To further explore the processes underpinning rhodocytin-induced platelet activation, 
Suzuki-Inoue et al. used rhodocytin affinity chromatography and mass spectrometry as part 
of a proteomic approach [142], showing that CLEC-2 was crucial. Research using activation 
with NFAT as a reporter construct to study expression in DT40 cells derived from chickens 
further supported this [142]. Finally, this line of research showed that the engagement of 
CLEC-2 was the only process needed to initiate human platelet activation by rhodocytin. 
This was achieved by showing that a polyclonal antibody to CLEC-2 instigated human 
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platelet activation without FcγRIIa, a platelet low-affinity IgG Fc receptor [142]. Fuller 
(2006) showed that integrin α2β1 was not involved in the rhodocytin-CLEC-2 binding 
process, by showing that azide-free preparations of integrin α2β1-blocking antibodies did not 
inhibit the action of rhodocytin on platelet activation. In conclusion, this part of research 
shows that the CLEC-2 receptor is responsible for facilitating platelet aggregation in the 
presence of rhodocytin. 
1.6.3.2 The CLEC-2 signalling pathway 
The CLEC-2 receptor was identified through cloning processes using a bio-informatic 
screen to look for receptors with a similar structure to C-type lectin [145]. Its exact function 
and ligands remained largely unknown until research showed that it was a signalling 
receptor located on the platelet surface, with the ability to instigate platelet aggregation 
[142]. Structural assay techniques were used to study the composition of CLEC-2, finding 
that the lectin-like receptor contained a YxxL motif in its cytoplasmic tail. The results also 
suggested that this motif was very similar to the YxxL-(X)10-12-YxxL found in ITAM, 
with one difference: CLEC-2 contains a single rather than a tandem motif. To make a 
distinction between the two motif types, CLEC-2’s single motif arrangement is referred to 
as a half- or hemi-motif, in common with other similar receptors. It is known that the ITAM 
signalling motif, which is found in T-cell receptors as well as in the GPVI/FcRγ-chain 
complex collagen receptor in platelets, plays a highly significant role in immune responses. 
Investigation of the GPVI/FcRγ-chain’s role in signalling events shows that GPVI cross-
linking within the FcRγ-chain cytoplasmic domain induces tyrosine phosphorylation of the 
ITAM receptor through the action of Fyn and Lyn, members of the Src kinase family. At the 
next stage of the signalling cascade, the phosphorylated ITAM undergoes binding with the 
SH2 tandem domain, which initiates downstream signalling events that induce tyrosine 
phosphorylation of a number of Syk substrates, including the adaptor proteins LAT, SLP-
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76, and Vav1/3. A number of effecter enzymes, including Bruton's Tyrosine Kinase (Btk); 
PI3-kinase; the Rho family members Rac and Cdc42; and PLCγ2, are also activated [155]. 
Suzuki-Inoue’s research group investigated the rhodocytin signalling process, 
showing that the toxin prompts the single YxxL motif to undergo phosphorylation and, via a 
downstream cascade, bind with the Syk tandem SH2 domains. Crucially, the hemi-ITAM 
must be present for CLEC-2 signal transduction to occur [142, 156]. Further studies 
revealed the process by which the CLEC-2 domain’s single YxxL motif binds with the SH2 
domains of Syk. Research studies led by Watson and O’Callaghan suggested that CLEC-2 
has a dimeric form in inactivated platelets, with a 2:1 stoichiometric binding ratio between 
the tandem SH2 domains of Syk and the phosphorylated domains of two CLEC-2 molecules 
[155, 157]. 
Studies using immunoprecipitation further revealed the potential processes behind 
the interaction of CLEC-2 and Syk tyrosine kinase. Firstly, phosphorylated CLEC-2 
peptides could bind and precipitate Syk from mouse platelets and, in turn, CLEC-2 
precipitation from platelets treated with rhodocytin is facilitated by the tandem SH2 
domains of Syk tyrosine kinase [142]. Secondly, a number of point mutations that inhibit 
phosphotyrosine binding in the Syk N- and C-terminal SH2 domains blocked CLEC-2-
induced signalling processes in transfected DT40 cells [156]. Added to this, Suzuki-Inoue 
et al. showed that the presence of both the Syk N- and the C- terminal SH2 domains is 
essential for an interaction to occur, because neither domain on its own was able to 
instigate the precipitation of CLEC-2 from platelets treated with rhodocytin [142]. Taken 
together, these research studies show that Syk tyrosine kinase regulation of CLEC-2 uses a 
unique process, with a pair of phosphorylated CLEC-2 receptors cross-linked across the 
N- and C-terminal SH2 domains. 
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Overall, the downstream elements of the CLEC-2 signalling pathway closely 
resemble the GPVI process, instigating the tyrosine phosphorylation of LAT, SLP-76, and 
Vav1/3, and the activation of Btk and PLCγ2 effector enzymes [142, 156]. Syk and 
PLCγ2 knockout murine platelets showed no response at all, even at extreme 
concentrations of rhodocytin, reinforcing the idea that Syk and PLCγ2 are crucial 
components of signal transduction mediated by CLEC-2. Conversely, murine platelets 
lacking LAT or SLP-76 adaptor proteins, or Vav1/3, a guanine nucleotide exchange 
factor, showed no reaction at low concentrations of rhodocytin but limited reaction at 
higher concentrations. Therefore, they have an essential compensatory function during 
CLEC-2 signalling [142]. Adaptor proteins are essential to the YxxL motif-containing 
receptor signalling process, because they create a protein framework around which PLCγ2 
interacts with the platelet membrane. Many adaptor proteins, including the membrane 
adaptor LAT and the cytosolic adaptors SLP-76 and Gads, are present in platelets. The 
adaptor proteins LAT or SLP-76 play some role in the CLEC-2 signalling process, and 
GPVI-based signalling is inhibited if these proteins are deficient. However, the effect of 
SLP-76 is subtly different: mice with the SLP-76 protein knocked out have an inhibited 
GPVI signalling process, while CLEC-2 signalling is only partially inhibited, suggesting 
that the CLEC-2 complex has the ability to use other adaptor proteins to retain some 
functionality [142, 156]. Research also showed that Gads in platelets interacts with SLP-
76 and tyrosine phosphorylated LAT, so must play a major role in recruiting PLCγ2 to the 
platelet membrane surface by creating links with the SLP-76 and LAT functional groups. 
In Gads-deficient mice, platelet activation in the presence of relatively low concentrations 
of CLEC-2 or GPVI is only slightly retarded, and full activation occurs in the presence of 
high concentrations of these agonists. This implies that Gads has a relatively minor role in 
the CLEC-2 and GPVI signalling pathways, and supports the existence of platelet 
activation processes independent of Gads further down involving LAT adaptor molecule 
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1.6.3.3 Endogenous CLEC-2 ligands 
In a landmark study investigating how platelets interacted and bound with human 
immunodeficiency virus type 1 (HIV-1) particles, Chaipan et al. suggested that CLEC-2 
possessed an endogenous ligand. The study showed that platelets had the ability to bind 
with HIV-1 particles, internalising them via a process using CLEC-2 and DC-SIGN 
receptors [143]. DC-SIGN was the main driver of this process, by binding with mannose 
sugar complexes within the HIV-1 viral envelope protein, Env [158]. However, the 
presence or absence of Env protein made little difference to CLEC-2 binding, indicating 
that the receptor used a protein derived from the host cell used by the virus during 
replication. If CLEC-2 and DC-SIGN were blocked, platelet binding to the viral particles 
was significantly inhibited, indicating that the proteins interacted and promoted the 
propagation of the HIV-1 virus throughout the infected host [143]. 
Suzuki-Inoue et al. building upon their affinity purification research that identified 
CLEC-2, showed that podoplanin was a CLEC-2 ligand [159]. Many types of tumour cells 
preferentially express podoplanin on their leading, invasive edge, and this ligand can play 
a role in platelet aggregation [160]. In turn, this tumour-cell induced platelet activation 
may prompt cancer metastasis through the release of metalloproteinases and growth 
factors, ultimately leading to tumour cell invasion and growth [161, 162]. Indeed, this 
tumour cell-induced activation resembles some of the features of the platelet activation 
process in the presence of rhodocytin, with a distinct, recognisable delay [163, 164]. This 
lag phase prompted Suzuki-Inoue et al. to hypothesise that CLEC-2 was the receptor 
responsible for mediating platelet activation in tumour cells through the action of 
podoplanin. 
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1.7 ITIM-coupled receptors in platelets 
Probably the most important ITIM-bearing receptor in platelets is PECAM-1 which 
inhibits platelet responses to collagen binding. Phosphorylation of the ITIM regions result in 
the binding of protein-tyrosine phosphatase SHP-2 and with a lower affinity the related 
phosphatase SHP-1 (Figure 1-15). Both phosphatases have Src homology 2 (SH2) domains 
that bind to phosphorylated tyrosine ITIM Y663 and Y686 motif [165]. Also recruited is 
PP2A, which also contains the SH2 domain, which is an inhibitor of p38 MAP kinase. 
Phosphorylation of SHP-1 and 2 introduces docking sites for Grb2 which connects the 
complex to signalling processes through integrin αIIbβ3. 
1.7.1 PECAM-1  
PECAM-1 was first recognised as the leukocyte differentiation antigen CD31 present 
on platelets, monocytes and granulocytes [166]. Various investigators working on 
endothelial cells described this protein known as glycoprotein (GP) IIa, GPIIa’, 
ENDOCAM, or the hec7 antigen that was particularly concentrated at cell/cell junctions. 
Cloning of the cDNA for the protein showed that it was of immunoglobulin superfamily and 
homologous to other cell adhesion molecules [167]. So the protein was renamed once again 
as the platelet/endothelial cell adhesion molecule-1 or PECAM-1. Among other activities, 
PECAM-1 interacts with neutrophil membrane glycoproteins to promote neutrophil 
transmigration through the endothelial layer [168, 169]. 
PECAM-1 is 130 kilodalton transmembrane glycoprotein with six type C2 Ig-
Domains (6 Ig) [166, 170, 171]. Two ITIMs are in the cytoplasmic tail of the protein [166]. 
Both ITIMs become tyrosine phosphorylated after integrin αIIbβ3-mediated platelet 
aggregation and recruit the SH2 domain containing protein-tyrosine phosphatases, SHP-1 
and SHP-2. 
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The cytoplasmic tail can be variously sized depending on differential splicing of exons 
10-16 yielding isoforms of PECAM-1 that may have functionally different properties. The 
expression of PECAM-1 on the platelet surface varies between individuals from 5000 to 
8800 copies per platelet [74, 172]. There are several allelic variations of PECAM-1 that 
have been described [173] some of which may be implicated in cardiovascular disease. 
Despite the fact that PECAM-1 can interact with PECAM-1 molecules on other cells, 
it is not involved directly in platelet aggregation. However, engagement of Ig-Domain 6 of 
PECAM-1 using anti-PECAM-1 antibodies augmented platelet activation [174]. Despite its 
homology and activity in other cell types as a cellular adhesion molecule, its role in platelets 
is mostly related to signal transduction. It serves as a bidirectional signalling device.  
Dephosphorylation of Syk and Btk kinases by SHP-1 leads to a decrease in their 
activity [175]. In turn, the decrease in kinase activity inhibits tyrosine phosphorylation of 
PLC, and hence a decrease in its activity, thus lowering the concentration of inositol (1,4,5) 
triphosphate and diacylglycerol (DAG). In principle, this could account for some of the 
inhibitory properties of signalling through PECAM-1. In fact, mutation of tyrosine to 
phenylalanine resides at ITIM sites prevents recruitment of SHP-2 by PECAM-1 [134, 176, 
177]. 
PECAM-1 is a positive modulator of adhesion strengthening mediated by integrin 
αIIbβ3. It is a negative regulator of collagen and immune complex receptors that have ITAM-
1 sequences like FcRγ which is complexed to GPVI. PECAM-1 deficient mice form larger 
thrombi that are more stable than wild-type mice (Figure 1-17), confirming an inhibitory 
role for PECAM-1 in vivo [178]. 
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Figure  1-17: Difference in thrombus formation in PECAM-1+/+ mice versus PECAM-1–/– mice by 
intravital microscopy (IVM). (A) Shows the Control and (B) The thrombus formation in cremaster muscle 
arteriole by using nitrogen dye laser. PECAM-1
-/-
 mice were labelled with CD41 Ab (Fab fragment). After 
three minutes, thrombus formation was studied using bright field and florescence microscopy. The yellow 
arrows show the direction of blood flow while blue arrows specifically show the laser-induced damage 
position. The red blot indicates the size of the clot. Adapted from [178]. 
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1.7.2 Other ITIM receptors 
Another ITIM coupled receptor found in platelets is G6B, which contains single Ig 
domain and two ITIMs in its cytoplasmic tail [179]. Like PECAM-1, phosphorylation of the 
ITIMs produces sites for SHP-1 and SHP-2 binding. Cross-linking of G6B with antibodies 
causes an inhibition of platelet aggregation in response to such agonists as ADP and 
collagen-related peptides. This inhibition does not require calcium. Inhibition of signalling 
through CLEC-2 or GPVI seems to be independent of SHP-1 and SHP-2 and may involve 
inhibition of signalling through Src and Syk kinases [180]. 
Also found on platelets is another ITIM bearing immunoreceptor, TREM-like 
transcript 1 (TLT-1) [181]. TLT-1 also contains a proline rich region. TREM stands for 
triggering receptors expressed on myeloid cells and represents a family of at least five 
members. TLT-1 is found only on megakaryocyte and platelet alpha granules but relocates 
to the platelet surface upon stimulation with agonists [182]. The TLT-1 cytoplasmic tail 
binds to ezrin/moesin/radixin family of proteins which suggest that it maybe involved in 
linking to fibrinogen [183]. Unlike the other ITIM containing proteins, TLT-1 is involved in 
promoting platelet activation rather than inhibiting it. TLT-1 deficient mice have an 
extended bleeding time and develop inflammatory lesions and haemorrhage [183]. 
1.8 Carcinoembryonic antigen related cell adhesion molecule family 
The original carcinoembryonic antigen (CEA) is a cell adhesion molecule expressed 
during embryogenesis but not normally found in adults [184]. Its presence in tumours of 
various types made it a valuable tumour marker. CEA-related molecules make up a family 
of at least 29 members, which are in turn a subset of the immunoglobulin superfamily (see 
section 1.6.1, 1.6.2 and 1.7.1). 
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Carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) contains 4 
Ig-Domains, a transmembrane domain followed by a long (ITIM-containing) or short 
cytoplasmic domain (ITIM-less). CEACAM1 (also known as biliary glycoprotein and 
CD66a) was discovered first as a protein receptor of the hepatitis virus in the bile ducts 
within the liver [185]. CEACAM1 displays broad expression that is conserved in human and 
rodents and has since been recognised as a cell adhesion protein expressed on the surface of 
granulocytes, leukocytes, monocytes, dendritic cells, endothelial cells and in some epithelia 
[186].  
CEACAMs preferentially form homodimers, i.e.: CEACAM1 binds itself 
(homophilic-homophilic interaction involving Ig-Domain 1), or heterodimers with CEA and 
CEACAM6. CEACAMl is a member of the Ig-ITIM superfamily that is a cousin of 
PECAM-1. These two receptors share similarities in structure and function in many 
biological systems, particularly in their ability to act as inhibitory co-receptors to modulate 
ITAM-associated signalling pathways. 
In mice, there are two CEACAM genes designated as CEACAM1 and CEACAM2 
[185]. While CEACAM2 is restricted to the mouse, functions of CEACAM2 in the mouse 
are taken over by CEACAM1 in humans based upon evolutionary conservations. 
CEACAM1 and CEACAM2 share some similarities in structure, but differ in the number of 
extracellular Ig-Domains (CEACAM1 contains 4 Ig-Domains while CEACAM2 contains 2 
Ig-Domains, Figure 1-18) and in the ligand binding properties of their distal variable N-
terminal Ig-Domain. CEACAM1 N-terminal variable Ig-Domain 1 mediates homophilic 
binding while CEACAM2 does not [186]. At this stage the only ligand identified for 
CEACAM2 is the murine coronavirus mouse hepatitis virus spike glycoprotein(s). Both 
CEACAM1 and CEACAM2 contain transmembrane receptors and contain identical ITIMs 
in their cytoplasmic domains.  
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Figure  1-18: Immunoglobulin superfamily receptors and Lectin- like receptors. This figure shows 
comparison of the structures of PECAM-1, CEACAM1, and CEACAM2. CEACAM1 and CEACAM2 
structures vary considerably at the N-terminus. The structures above represent the most common forms, 
although differential splicing leads to a number of isoforms. CEACAM1 and CEACAM2 have identical 
transmembrane and cytoplasmic regions including the ITIM. The cytoplasmic domain is only ten amino acids. 
Purple colour (Ig domains), Green colour (ITIM domains), Red colour (ITSM domains) and Orang colour 
(Lectin domains). 
 
 
 
The role of CEACAM2 protein in platelet function is not clearly defined. Based upon 
previous studies, CEACAM1 is expressed on the surface of murine and human platelets and 
expression is upregulated by platelet activation. CEACAM1 is expressed modestly on the 
surface of resting platelets [187] but has prominent intracellular expression profile 
suggesting that like TLT-1 it is compartmentalised until platelet activation events occur. The 
fact that CEACAM2 has different ligand properties than CEACAM1 would suggest unique 
biological roles as the avidity of ligand interactions (activation versus clustering) appears 
fundamental to drive cell signalling responses (Figure 1-19). In preliminary studies, 
CEACAM2 appear to function in a similar way as CEACAM1 at least in the context of 
insulin metabolism [188]. 
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Figure  1-19: Model of the expected role of CEACAM2 in GPVI signalling pathway via LAT 
signalosome. The ITAM regions of the latter interact with Src homology regions after phosphorylation. ITIM 
residues of CEACAM2 interact with SH2 domains of SHP-1 resulting in a conformational change where the 
catalytic domain opens up. This event allows the catalytic domain to do dephosphorylation of ITAM signalling 
elements to downregulate the ITAM pathway components. Adapted from [136]. 
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CEACAM1 is expressed on the surface of mouse and human platelets and inhibits 
platelet-collagen interactions as well as thrombus growth [187]. CEACAM1 is capable of 
homophilic reactions, which are critically dependent on amino acid residues 43 and 44 [189, 
190]. Three C2 and one N-terminal V-type Ig domains are contained within the extracellular 
portion of CEACAM1 (Figure 1-18). The CEACAM1 gene contains a functional promoter 
and nine exons [191]. During mRNA processing, exon 7 is alternatively spliced which 
results in the expression of two isoforms, the short isoform (CEACAM1-4S) lacking 61 of 
the 71 amino acids of intracellular domain and the long isoform (CEACAM1-4L) which 
includes serine (Ser503) and tyrosine (Tyr488) phosphorylation sites [192]. The short 
isoform lacks the intracellular phosphorylation sites of 4L isoform [192]. CEACAM1 
mediates various functions, including cell adhesion [193] and tumor suppression [194], and 
acts as a 12 mediator of angiogenesis [195] and T-lymphocyte signalling [196]. 
Platelets from mice lacking the CEACAM1 gene displayed enhanced reactivity to 
collagen and CRP and larger thrombus growth both in vitro and in vivo. The Ceacam1-
deficient mice were more susceptible to collagen induced thromboembolism than wild-type 
mice [187].  
The human CEACAM1 gene has two homologues in mice, termed CEACAM1 and 
CEACAM2, whereas only one is found in the rat [197]. The differences in the coding region 
between the CEACAM1 and CEACAM2 are mainly found in exon 2. As in the human, the 
mouse CEACAM1 gene is expressed abundantly in the liver, spleen, small intestine and 
prostate.  In contrast, CEACAM2 is only found in the kidney, testis and to smaller extent in 
the spleen [188] (which is a repository for platelets). The differences in expression indicate 
that the two related proteins are not functionally redundant. Though the presence of 
CEACAM1 has been demonstrated in platelets [187], there appears to be no published data 
on the expression of CEACAM2 in platelets. 
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Interestingly, CEACAM1 is substrate of the insulin tyrosine kinase [198]. Deletion of 
CEACAM1 gene in mice results in insulin resistance, dyslipidemia and fatty liver due to 
elevated tryglyceride and cholesterol levels. CEACAM1 deficient mice are being 
investigated as model of metabolic syndrome and type II diabetes. It should be noted, 
however that deletion of CEACAM1 is not lethal nor does it appear to cause obvious 
developmental defects. 
Like PECAM-1, phosphorylation of the ITIM of CEACAM1 is known to result in the 
recruitment of SHP-1, at least in T-cells [199]. Like PECAM-1, CEACAM1 contains ITIM 
sequences that when phosphorylated inhibit Src family kinases, probably through interaction 
with Src homology (SH) domains [200]. Platelets express at least six Src family kinases 
including Lyn, Fyn, Fgr, Src, and Yes. As previously discussed, Fyn and Lyn are known to 
be involved in platelet activation through the GPVI collagen receptor (see section 1.6.1) and 
Fyn and Src are involved in ‘outside in’ signalling through integrin αIIbβ3 (see section 
1.3.1.1). Lyn is also implicated in vWF signalling through the GPIb-IX-V receptor. It seems 
likely that PECAM-1 and CEACAM1 and possibly CEACAM2 and other ITIM bearing 
inhibitors such as G6b achieve inhibition by down-regulating the activity of Src family 
kinases in the absence of strong signalling through collagen or vWF binding. 
1.9 Mechanism of stable thrombus formation in mice 
Mechanisms of platelet activation and aggregation are thought to have some 
similarities in mammals with minor differences in receptor repertoires. The small 
differences with respect to human platelets (containing 3 ITAM containing receptors) and 
mouse platelets (lacking FcγRIIa, while containing two ITAM receptors which are 
GPVI/FcR γ-chain and CLEC-2) need to be understood when exploring the formation of a 
thrombus [119]. The shorter GPVI cytoplasmic tail in mice, fall under the heading of 
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variations on a theme, rather than fundamental differences. Nevertheless, the following 
describes the situation in mice, in which researchers have the advantage of clean genetic 
techniques. First, it should be made clear that thrombus formation is not the only function of 
platelets. They are known to interact with and engulf pathogens. Animals or humans with 
thrombocytopenia have spontaneous bleeding events in the absence of obvious injury. Thus, 
platelets are involved in haemostasis on a non-emergency basis. Small vascular leaks that 
occur in the normal course of physiology do not require large clots. Platelets also appear to 
be actively involved in the both adult and embryonic regulation of angiogenesis [201-204]. 
In vivo mouse model of platelet thrombus formation have shown that this is a dynamic 
highly complex multi-step process. These studies include platelet activation, involvement of 
vWF, collagen, fibrinogen and fibronectin, various platelet aggregation accumulations, 
intracellular calcium mobilisation, and release of secondary wave mediators, ADP, and 
TXA2. Thrombus formation initially involves platelet translocation and adhesion via platelet 
adhesive receptor–ligand interactions to exposed extracellular matrix (ECM) components; 
platelet accrual occurs, this may be followed by fragments of thrombus breaking off and 
embolising downstream [205-208]. Finally, a thrombus will grow and eventually occlude 
the vessel. Several factors influence thrombus stability, including platelet adhesive protein-
ligand interactions, outside-in signalling events of integrins, particularly integrin αIIbβ3, 
stable platelet adhesion, signalling molecules involving Src family kinases and secondary 
wave mediators, ADP, TXA2 and their receptors P2Y12 and TP [209]. Numerous studies 
confirm the role of other platelet receptors on the stability of thrombus formation in vivo, 
including CD40L, Gas6, semaphorin 4D and contact-dependent signalling events [210-212]. 
Mechanisms of stable thrombus formation are explained in Figure 1-20. 
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Figure  1-20: Mechanisms of stable thrombus formation in mice. Transmission electron microscope image 
of activated platelets. Mechanisms involved in formation of stable thrombus include recruitment of new 
platelets, adhesion, adhesion strengthening, recruitment of TF-bearing microparticles, aggregation, 
stabilisation of aggregation, and growth of aggregate. Adapted from [211]. 
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1.10 Aims of the thesis 
The main aim of the project is to investigate the different roles of the novel platelet 
immunoreceptor ‘CEACAM2’ in contact-dependent events that modulate platelet function 
in vitro and on thrombus formation in vivo. 
 To determine the functional role of CEACAM2 in GPVI contact-dependent platelet 
activation (Chapter 3).  
 To define if CEACAM2 negatively regulates platelet function via CLEC-2 mediated 
mechanisms (Chapter 4). 
 To investigate the contribution of CEACAM2 in contact-dependent platelet adhesion 
under in vitro flow conditions using type I collagen as the ECM. Furthermore, to 
investigate the contribution of CEACAM2 in contact-dependent platelet adhesion 
under in vivo flow conditions. Three different mouse models of ferric chloride 
(FeCl3)-induced vascular injury of mesenteric arterioles, laser induced injury of 
cremaster muscle arterioles and FeCl3-induced injury upon GPVI depletion were 
used in CEACAM2 knockout (Cc2
–/–
) compared to wild-type mice (Chapter 5). 
 To determine the role of CEACAM2 in ‘outside-in’ integrin αIIbβ3-mediated 
signalling pathways (Chapter 6).  
  
72 
 
 
 
 
 
 
 
 
2 Chapter Two: General materials and methods 
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2.1 Materials 
2.1.1 Antibodies and chemicals  
Rabbit anti-mouse CEACAM2 was provided by Professor Sonia Najjar (Toledo, OH). 
Rabbit anti-mouse CEACAM1 was provided by Dr. Nicole Beauchemin (Goodman Cancer 
Research Centre, McGill University, Montreal, Canada). PECAM-1 antibody (Anti-mouse, 
390) was provided by Dr Steve Albelda (University of Pennsylvania, Philadelphia, PA). The 
specific anti-rabbit fluorescein isothiocyanate (FITC) and rabbit anti-mouse phycoerythrin 
(PE) were purchased from Dako (Botany, Australia). Antiphosphotyrosine- horseradish 
peroxidase (HRP)-conjugated, RC20, anti-mouse CD3e, rat anti-mouse CD44, anti-mouse 
integrin β3 (CD61), FITC-conjugated anti-mouse CD62P antibodies and FITC-Annexin V 
were obtained from BD Biosciences Pharmingen (Franklin Lakes, NJ). Antiphosphotyrosine 
HRP-conjugated, 4G10 antibody was purchased from Millipore (Billerica, MA). Anti-
mouse GPVI [3], anti-mouse integrin α2β1 (CD49b) [213], anti-mouse GPIbα-IX-V complex 
(CD42b) [2], anti-mouse GPVI (JAQ1) [137], anti-mouse CD9 and PE conjugated JON/A 
monoclonal antibodies were purchased from Emfret Analytics (Würzburg, Germany). Anti-
phospho-Src-(Tyr416) and anti-Src-(36D10) antibodies were purchased from Cell 
Signalling Technology (Danves, MA). Anti-PLCγ2 (sc-407), Syk (c-20; sc-929), GAPDH 
(6C5; sc-32233) and Erk-2 antibodies were purchased from Santa Cruz Biotechnology 
(Dallas, TX).  
Protease activated receptor-4 (PAR-4) agonist peptide (H-Ala-Tyr-Pro-Gly-Lys-Phe-
NH2; AYPGKF-NH2) was purchased from GL Biochem Ltd. (Shanghai, China). Platelet 
agonists Adenosine diphosphate (ADP) and acid-soluble collagen were obtained from 
Chrono-Log Co. (Havertown, PA). Collagen-related peptide (CRP) was purchased from Dr. 
Richard W. Farndale (University of Cambridge, Cambridge, United Kingdom). Type I 
collagen fibrils were obtained from Nycomed (Linz, Austria). Rhodocytin (Rhod) agonist 
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was kindly provided by Professor Bernhard Nieswandt (University Clinic of Wuerzburg and 
Rudolf Virchow Centre, Germany). Thrombin, calcium ionophore (CI-A23187), Phorbol 
12-myristate 13-acetate (PMA), epinephrine (Epi), sodium chloride (NaCl), dimethyl 
sulfoxide (DMSO), calcium chloride (CaCl2), prostaglandin E1 (PGE1), bovine serum 
albumin (BSA) were purchased from Sigma Aldrich (St Louis, MO). Potassium chloride 
(KCL), MgCl2-6H2O, NaHCO3, sodium citrate, glucose, HEPES, sodium dodecyl sulphate 
(SDS), polyacrylamide gel electrophoresis (PAGE), Tween 20, quinacrine,  2-
Mercaptoethanol, paraformaldehyde, Osmium tetroxide (OsO4), glutaraldehyde, ethanol, 
acetone, iron (III) Chloride (FeCl3) were purchased from Sigma Aldrich (St Louis, MO). 
PCR primers (107 [sense], 123 [anti-sense], SNeo9 [sense], Aneo8 [antisense]) and RED 
Extract-N-Amp were purchased from Sigma Aldrich (St Louis, MO). Enhanced 
chemiluminescence (ECL) system, protein G sepharose 4 fast flow and hyperfilm ECL were 
supplied from GE Healthcare Life Science (NSW, Australia). Polyvinylidene difluoride 
(PVDF) membrane and prestained SDS-PAGE standards (low range) were purchased from 
Bio-Rad laboratories (NSW, Australia). Fura-2-pentaacetyxymethylester (FURA-2/AM) 
was obtained from Molecular Probes (Eugene, OR).  
2.1.2  Mice 
The generation of Cc2
–/–
 mice and breeding onto C57BL/6 background for 10 
generations has been described [188].
 
Wild-type C57BL/6 mice were purchased from ARC 
animal facility (Perth, WA, Australia). Age- and sex-matched wild-type and Cc2
–/–
 
littermates were housed at RMIT University animal facility. All procedures were approved 
by the RMIT University animal ethics committee #0918 and #1239. The genotyping of Cc2
–
/–
 mice was confirmed by polymerase chain reaction (PCR) analysis of tail genomic DNA. 
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2.2 Methods 
2.2.1 Genotyping 
2.2.1.1 Purification of mouse tail genomic DNA 
Using the DNeasy Protocol for Rodent tails to extract and separate genomic 
Deoxyribonucleic acid (DNA) samples for genotyping, tail clips of 3-weeks-old mouse tail 
tissue were assayed using DNeasy
®
 blood and tissue kit handbook (Qiagen Pty.Ltd, Clifton 
Hill, Victoria). 
2.2.1.2 PCR protocol 
Standard Polymerase Chain Reaction (PCR) methodology was used to determine the 
CEACAM2 genotype and generated a number of primer sets used to facilitate genotyping of 
the DNA: primer 1) - 107 (sense) 5´ GCC CTT CTC TGG GAG GAG AAT CAA T 3´, 
primer 2) 123 (anti-sense) 5´ GCC TTC AGC AGC GTG GAG TGG A 3´, primer 3) SNeo9 
(sense) 5´ GGA TCG GCC ATT GAA GAA GAT 3´, primer 4) Aneo8 (antisense) 5´ CGC 
CAA GCT CTT CAG CAA TAT 3´. 
Following the PCR Genotyping Protocol, the -107 primer, situated in exon 2, is the 
promoter sequence for CEACAM2 and 123, and is exclusive to CEACAM2. To disrupt the 
functionality of the gene, SNeo9 and ANeo8 were delivered via a neomycin cassette for 
making CEACAM2 knockout. Using the protocol, it was predicted that ~1050 bp and ~750 
bp of PCR products would be generated for CEACAM2 wild-type (WT) and knockout (KO) 
mice respectively. 
PCR master mix including 1.0 µL of Milli-Q H2O, 1.0 µL of 20 µM-107 [0.4 µM], 1.0 
µL of 20 µM-123 [0.4 µM] and 5.0 µL of RED Extract-N-Amp was prepared to detect 
CEACAM2, wild-type allele. Moreover, to detect CEACAM2 knockout allele, another PCR 
master mix including 1.0 µL Milli-Q H2O, 1.0 µL 20 µM-ANeo8 [0.4 µM], 1.0 µL 20 µM-
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SNeo9 [0.4 µM] and 5.0 µL RED Extract-N-Amp-PCR was prepared. 3.0 µL of wild-type 
or Cc2
–/–
 Qiagen purified genomic DNA was added to 8.0 µL of PCR master mix for each 
sample including control. Purified DNA mixture was amplified under the following cycling 
condition using Bio-Rad C1000™ thermal cycler PCR machine protocol (Pittsburgh, PA). 
The PCR conditions were based on the following cycles:  94°C for 15 minutes 
(Denaturation), (94°C for 30 seconds denaturation, 62°C for 30 seconds annealing, 72°C for 
3 minutes extension) x 2 cycles, (94°C for 30 seconds denaturation, 55°C for 30 seconds 
annealing, 72°C for 3 minutes extension) x 40 cycles, 10 minutes in 72°C. Following these 
cycles, samples were kept at 4°C.  
2.2.1.3 Agarose gel electrophoresis 
The next stage of genotyping involved using gel electrophoresis to separate the PCR 
products. The assay used 2% (w/v) agarose gel as the medium and, for post-electrophoresis 
staining of the nucleic acid fragments, containing 1x Sybr Green, a sensitive, stable, and 
safe dye, was added. The first stage involved immersing the 2% (w/v) agarose gel in 1 × 
Tris-Acetic acid-EDTA buffer pH 8.5 (TAE), before loading the gel with 10 µl of each PCR 
product. To stain the DNA bands after electrophoresis, 4 µl of 2 log ladder of standard DNA 
marker was loaded onto the agarose gel. Electrophoresis, using a 120V power source, was 
run for 35 minutes, and the Bio-Rad Molecular Imager Gel Doc XR+ System facilitated 
DNA imaging. For each PCR assay, a number of DNA and non-DNA controls were 
assessed, to help confirm each genotype, and Milli-Q H2O, highlighted any potential 
contamination of the PCR reagents with DNA. The known DNA controls included 
CEACAM2
+/+
 (WT), CEACAM2
+/–
 (Heterozygous), and CEACAM2
–/–
 (KO), alongside 
three WT and three KO unknown DNA controls. 
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2.2.2 Blood collection and platelet preparation 
Blood was drawn from anaesthetised wild-type and Cc2
–/–
 mice by inhalation of 2% 
(v/v) isoflurane followed by cardiac puncture, using a 1-ml syringe with a 26-gauge needle.  
The blood was transferred to a microfuge tube containing 100 µl 3.2% (w/v) tri-sodium 
citrate and 50 ng/mL PGE1 [8]. The top layer, platelet rich plasma (PRP) was isolated by 
centrifuging blood samples at 115 g for 8 minutes at room temperature without brake.  
Washed platelets were generated by re-spinning PRP down in the presence of 50 
ng/mL PGE1 at 640 g for 10 minutes without brake, then resuspending the platelet pellet 
gently in 500 µL Ringer-citrate-dextrose, RCD (108 mM NaCl, 38 mM KCl, 1.7 mM 
NaHCO3, 21.2 mM sodium citrate, 27.8 mM glucose, and 1.1 mM MgCl2.6H2O, pH 6.5). 
Washed platelets were then prepared for platelet count. 
Platelet poor plasma (PPP) was obtained by centrifugation of the remaining blood 
after PRP collection at 800 g for 10 minutes at room temperature without brake. The top 
layer of the blood samples was separated and pooled into a separate tube as PPP. 
2.2.3  Measurement of platelet aggregation 
Platelet function was evaluated by turbidimetric aggregometry. Turbidimetric 
aggregation measures the increase in light transmission as platelets come out of suspension 
to form aggregates, in response to stimulation with a chemical agonist using a 4-channel 
light transmission aggregometer (Chrono-log, Havertown, PA).  The data were recorded 
using AGGRO/LINK (8) software (Chrono-Log Co, Havertown, PA). 
2.2.3.1 Murine PRP aggregation 
Platelet aggregation responses were measured on a 4-channel light transmission 
aggregometer using PRP as previously described [214, 215].
 
Wild-type and Cc2
–/–
 platelets 
were normalised to 100x10
9
/L in RCD buffer pH 7.4 by using a Cell-DYN Emerald 
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analyser (Abbott, Lake Forest, IL). The platelets were pre-incubated with 100 µg/mL 
fibrinogen and 1 mM CaCl2 in a final volume of 250 µL for 5 minutes at 37
o
C and then 
stirred constantly (1000 rpm) for 1 minute at 37
o
C prior to addition of agonists. The platelet 
aggregation baseline was set using mouse PPP diluted 1:2 in RCD buffer pH 7.4. Platelet 
aggregation was initiated by addition of agonist including 125-500 µM PAR-4 agonist 
peptide (AYPGKF-NH2), 2.5-10 µM ADP, 1.25-5 µg/mL CI-A23187, 1.25-5 µg/mL 
Collagen, and 0.625-2.5 µg/mL cross-linked CRP. For experiments related to CLEC-2 
signalling, 0.12-0.48 µg/mL Rhodocytin (Rhod) was used to initiate platelet aggregation. 
The platelet aggregation response was monitored for 10 minutes. 
2.2.3.2 Murine washed platelet aggregation 
Platelet aggregation responses were measured on a 4-channel light transmission 
aggregometer using washed platelets as described in section 2.2.3.1. The only exception was 
that the platelet aggregation baseline was set using RCD buffer pH 6.5 instead of mouse 
PPP. Platelet aggregation was initiated by addition of agonist including 0.25-1 U/mL 
thrombin, 250-500 µM PAR-4 agonist peptide, and 5-10 µg/mL CRP. 
2.2.4 Haematological parameters 
Blood was collected from anaesthetised wild-type and Cc2
–/–
 mice as described in 
section 2.2.2. Most of the haematopoietic cells were analysed from murine whole blood by 
using Cell-DYN Emerald analyser. In addition, neutrophils, lymphocytes and monocytes 
were quantified by a manual WBC differential count. 
2.2.5 Static platelet adhesion assay 
A time-course of normal static platelet adhesion assay was performed with 12 mm 
circular glass coverslips (Crown Scientific, Moorebank, New South Wales) placed into 4x24 
well plates, with one plate used for each time point of 15 min, 30 min, 45 min and 60 min. 
The 12 mm circular glass coverslips were coated with ECM, 50 µg/mL type I collagen or 
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fibrinogen at 100 µg/mL for 2 hours at room temperature. After 2 hours incubation, plate 
wells were washed with RCD at pH 6.5 by using a vacuum pump to aspirate fluid. Plate 
coverslips were blocked with 10% (w/v) normal human serum supplemented with 50 µg/ml 
phenyl methyl sulphonyl fluoride (PMSF) for 60 minutes at room temperature, then washed 
with RCD pH 7.4 prior to the addition of platelets. 
Washed platelets were normalised to 100x10
9
/L by using RCD pH 6.5, and CaCl2 was 
added to platelet suspension to a final concentration of 1 mM. Platelets were added to plate 
wells containing coverslips and incubated together in a humidified chamber to adhere with 
ECMs for 15 min, 30 min, 45 min and 60 minutes at 37°C. The 24-well plates containing 
washed platelets were removed from the incubator after appropriate times, and then 
unbound platelets were washed gently with RCD pH 6.5. The adherent platelets were fixed 
with 3.7% (w/v) paraformaldehyde for 30 minutes at room temperature, and then fixed 
platelets washed with RCD pH 7.4. 
The adherent platelets on coverslips were prepared on 76x26 mm glass microscope 
slides with a frosted end and 22x40 mm coverslips, then mounted by Vectashield 
(Australian Laboratory Service, Melbourne, Victoria) and sealed with nail polish. The 
adherent wild-type and Cc2
–/–
 platelets were analysed at different time points using a Zeiss 
Axiovert microscope (Carl Zeiss, Gottingen, Germany) captured with an Axiocam MRm 
camera and analysed with Axiovision Rel 4.6 software and differential interference contrast 
microscopy at 63x magnification (DIC under oil). Finally, the number of adherent platelets 
per high-powered field were quantified for both wild-type and Cc2
–/–
 platelets [214]. 
2.2.6 Platelet spreading studies 
The 12 mm circular glass coverslips were placed in 24-well plates and coated with 50 
µg/mL type I collagen or fibrinogen at 100 µg/mL, then blocked with 10% (w/v) normal 
human serum. Platelet preparation was carried out as described in section 2.2.5. 
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Intravital Microscopy - 100x10
9
/L washed platelets were allowed to adhere in the 
absence or presence of several agonists such as 0.5 mM PAR-4 agonist peptide, 20 µM 
ADP and 100 nM PMA, and then mixed gently. The washed platelets with appropriate 
agonist were then added to suitable ECMs. In addition, washed platelets without agonist 
were added to RCD pH 7.4 as a negative control. Adherent platelets were incubated in a 
humidified chamber to adhere with ECMs for 60 minutes at 37°C. Non-adherent platelets 
were washed away, and the coverslips and glass microscope slides were prepared as 
previously described in section 2.2.5. Finally, images of wild-type and Cc2
–/–
 spread 
platelets were captured, saved and then the surface area of spread platelets was measured in 
µm
2
 using a Zeiss Axio Image M1 motorised microscope on 63x oil DIC magnification (see 
section 2.2.5). 
Scanning Electron Microscope (SEM) studies - Adherent platelets were fixed 
overnight (O/N) on a rotating wheel in 0.1M phosphate buffer pH 7.2 (11.5 mL of 0.2M 
NaH2PO4 H2O [27.6 g/L] plus 38.5 mL of 0.2M Na2HPO4 [anhydrous; 28.4 g/L]) containing 
1% (w/v) paraformaldehyde and 1.5% (v/v) glutaraldehyde, then samples were rinsed 5 
times for 4 hours in 0.175M phosphate buffer (19.25 mL of 0.2M NaH2PO4 H2O plus 68.25 
mL of 0.2M Na2HPO4 anhydrous; pH 7.2). Samples were post fixed for 1h with 0.175M 
phosphate buffer pH 7.2 containing 1% (v/v) OsO4, and then rinsed in Milli-Q water three 
times for 10 minutes on a rotating wheel. 12 mm coverslips were taken out into 12 mm 
coverslips holder, and then samples were dehydrated in a series of ethanol 50, 70, 90, 95, 
2x100% for 10 minutes each, 50/50 ethanol/acetone and 100% acetone for 10 minutes. The 
samples were loaded onto an automated critical point drying machine (CPD) using Leica 
EM CPD300 (Leica Microsystems, NSW, Australia). The samples were prepared for SEM 
imaging and coated with gold sputter using Emscope SC500 Sputter Coaters (Quorum 
Technologies, East Sussex, United Kingdom). SEM high resolution images were captured 
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using a JCM-6000 Benchtop-SEM at 10kV (JEOL, NeoScope, Portsmouth, NH) equipped 
with digital camera, high and low vacuum mode. Finally, the number of filopodia per 
platelet was counted in 3 different categories (0, 1-3 and ˃3) and analysed on SEM images 
from random fields involving the percentage of 100 platelets counted. 
2.2.7 Mouse tail bleeding assay 
Wild-type and Cc2
–/–
 mice were sex and age-matched (6-8 weeks). Mice were 
anesthetised by Isotec 3 machine using 2% (v/v) isoflurane and 2 litres/min of oxygen (O2). 
Once anesthetised, mice were laid in lateral recumbency on a firm surface and under 
gravity. The tail was laid horizontally with the tip over the edge. Tails were transected at 2 
mm diameter of tail tip with a sharp scalpel blade. A stopwatch was started immediately 
upon transection and blood drops were collected into an Eppendorf tube containing 100 µL 
of 3.2% (w/v) tri-sodium citrate. The tail bleeding time was recorded from until there was 
no more blood drops or for 15 minutes, whichever occurred first. When no blood was 
observed within 60 seconds of cessation, bleeding time was considered stopped. Volume of 
blood loss was recorded for each genotype [216]. 
2.2.8 Clot retraction assessment 
PRP was derived from wild-type and Cc2
–/–
 mice, then normalised to 100x10
9
/L in 
RCD buffer pH 7.4.  1 mL of platelet suspensions were prepared and corrected with PPP to 
the final volume 250 µL. Platelet mixtures were placed in siliconised glass tubes containing 
6 µL of mouse erythrocytes to give colour contrast. Platelet clots were initiated by the 
addition of thrombin to the final concentration of 2.5 U/mL, then they were mixed gently. 
The reaction was allowed to proceed for 10 hours at 37 °C with a toothpick present. 
Photographic images of the clot retraction were recorded following appropriate time points 
(0-10 hours). At appropriate time points (0-24 hours), the blood clot was removed using the 
toothpick and the remaining serum volume was measured per percentage or µL [217, 218]. 
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2.2.9 Flow cytometric immunophenotyping 
2.2.9.1 Analysis of CEACAM2 and other platelet glycoprotein expression on mouse 
platelets 
Surface and total expression of CEACAM2 in wild-type and Cc2
–/–
 platelets was 
performed using washed platelets as previously described [99]. For surface expression, 50 
µL of washed platelets (100x10
9
/L) were pre-incubated for 1 hour at room temperature with 
a primary antibody such as anti-rabbit CEACAM1 antibody, 2457 (1/500), anti-rabbit 
CEACAM2 antibody, 2052 (1/100), anti-mouse PECAM-1 (10 µg/mL), pre-immune rabbit 
serum (1/100), anti-mouse GPVI (10 µg/mL) and anti-mouse CD9 (10 µg/mL). The 
platelet-antibody complex was washed with 0.2% (w/v) BSA-RCD pH 6.5, followed by 
FITC-conjugated anti-rat (1/200) or PE-conjugated anti-rat (1/100) or Streptavidin-PE 
(1/200) for 45 minutes at room temperature.  For direct antibody conjugation, platelets were 
pre-incubated with anti-mouse integrin β3, CD61 (10 µg/mL), anti-mouse integrin α2β1, 
CD49b (15 µg/mL), anti-mouse GPIbα/IX/V, CD42b (10 µg/mL), and anti-mouse CD44 
(10 µg/mL) for 45 minutes at room temperature. 
To determine the total protein expression, platelets were pre-incubated with 0.1% 
(w/v) saponin in RCD buffer pH 6.5 and appropriate antibody for 1 hour at room 
temperature. The platelets were diluted by addition of 300 µL RCD buffer pH 7.4. 10,000 
individual platelets were analysed on a FACS Canto II flow cytometer (BD Biosciences, 
San Jose, CA) and Weasel software Version 3.0.2 (Walter and Eliza Hall Institute of 
Medical Research, Victoria, Australia). The template was formatted for a platelet-specific 
FITC/PE protocol with forward scatter (FSC), side scatter (SSC), and fluorescent parameters 
in log scale. The main platelet population was selected prior to the acquisition of data. 
Changes to the surface expression of CEACAM1 and CEACAM2 was also measured 
on wild-type and Cc2
–/–
 platelets upon addition of several agonists such as 0.125-1.0 U/mL 
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thrombin, 100-300 µM PAR-4 agonist peptide and 1.0-4.0 µg/mL CRP. After addition of 
agonists, platelets were pre-incubated with either anti-rabbit CEACAM1, 2457 (1/500) or 
anti-rabbit CEACAM2 antibodies, 2052 (1/100) followed by PE conjugated anti-rat (1/200). 
The platelets were diluted by addition of 300 µL RCD buffer pH 7.4. 10,000 individual 
platelets were analysed on a FACS Canto II flow cytometer and Weasel software Version 
3.0.2. 
2.2.9.2 Analysis of alpha granule release (FITC-P-selectin)  
Washed mouse platelets (100x10
9
/L; 50 µL) were activated with several agonists 
including 0.1-0.2 U/mL thrombin, 100-300 µM PAR-4 agonist peptide and 0.5-2.0 µg/mL 
CRP or CLEC-2 selective agonist, Rhod at 0.6-1.2 µg/mL for 15 minutes at 37°C. The 
activated platelets were fixed with 1% (w/v) paraformaldehyde for 10 minutes at room 
temperature, and then terminated with RCD pH 6.5. Fixed platelets were then pre-incubated 
with 10 µg/mL P-selectin antibody (FITC-CD62P) for 30 minutes at room temperature, then 
washed with 0.2% (w/v) BSA-RCD pH 6.5, then spun at 640 g for 10 minutes without 
brake. The platelets were diluted by addition of 300 µL RCD buffer pH 6.5. Alpha granule 
exocytosis was identified using platelet population characteristic forward and side laser 
scatter and examined for expression of FITC-CD62P. 10,000 individual platelets were 
analysed on a FACS Canto II flow cytometer and Weasel software Version 3.0.2 [219]. 
2.2.9.3 Analysis of dense granule release using quinacrine uptake  
Washed mouse platelets (100x10
9
/L; 50 µL) were pre-stained with 100 µM of 500 µM 
quinacrine dye for 30 minutes at 37°C. Stained platelets were then terminated with 0.2% 
(w/v) BSA-RCD pH 6.5, and then spun at 640 g for 10 minutes without brake. The platelets 
were activated with several agonists including 0.125-1.0 U/mL thrombin, 100-300 µM 
PAR-4 agonist peptide and 0.25-4.0 µg/mL CRP or 0.4-1.2 µg/mL Rhod of CLEC-2 
selective agonist, for 10 minutes at 37°C. The platelets were diluted by addition of 300 µL 
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RCD buffer pH 7.4. Dense granule exocytosis was recorded as the percentage decrease in 
quinacrine fluorescence intensity compared to resting platelets. 10,000 individual platelets 
were analysed on a FACS Canto II flow cytometer and Weasel software Version 3.0.2. 
2.2.9.4 Analysis of soluble FITC-fibrinogen and JON/A-PE binding 
FITC-conjugated fibrinogen was prepared by conjugating 20 mg human fibrinogen to 
FITC (Sigma Chemical, St Louis, MO) in 0.15 M carbonate buffer pH 9.0 for 1 hour at 
room temperature. The FITC-labelled fibrinogen was purified using a PD10 column 
(Amersham Pharmacia, Piscataway, NJ), and then the column was eluted with 15 mL (15 x 
1 mL) of PBS and 1 ml fractions were collected [8, 220]. 
Measurement of FITC-labelled fibrinogen and PE-conjugated JON/A mAb binding to 
platelets via GPIIb/IIIa (integrin αIIbβ3) was performed. Washed mouse platelets (50 µL 
containing 100x10
9
/L in RCD pH 6.5) were pre-incubated with FITC-labelled fibrinogen at 
1.2 µg/mL or PE-conjugated JON/A mAb (1:50 dilution) in the presence or absence of 
agonists. Platelets were activated with agonists including 0.125-1.0 U/mL thrombin, 100-
300 µM PAR-4 agonist peptide, 10 µM ADP, mixture of 10 µM ADP plus 20 µM Epi, 20 
µM PMA and 0.25-4.0 µg/mL CRP for 1 hour at 37°C in a dark room. Washing steps were 
performed using RCD pH 6.5 containing 0.2% (w/v) BSA after each step. The platelets 
were fixed with 1% (w/v) paraformaldehyde for 10 minutes at room temperature. They were 
then diluted by addition of 300 µL RCD buffer pH 6.5 and 10,000 individual platelets were 
analysed as described in section 2.2.9.1. 
2.2.9.5 Phosphatidylserine exposure 
PRP and washed platelets were generated as described in section 2.2.2. PRP was pre-
incubated with 1 mM acetylsalicylic acid for 45 minutes at 37°C. Washed platelets were 
isolated and the pellet was gently resuspended in 500 µL Tyrode’s buffer (10 mM HEPES, 
pH 6.5, containing 138 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 3 mM NaH2PO4, 5 mM 
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glucose) containing 0.1 U/mL apyrase. 100x10
9
/L washed platelets were pre-incubated with 
2.5 mM CaCl2 and 2 µL of FITC-labelled Annexin V, followed by agonist stimulation, 
0.125-0.5 U/mL thrombin, 100-300 µM PAR-4 agonist peptide and 1-4.0 µg/mL CRP for 
45 minutes at 37°C. The labelled platelets were then terminated with 0.2% (w/v) BSA-
Tyrode’s buffer pH 6.5, and then spun at 640 g for 10 minutes without brake. The platelets 
were diluted by addition of 300 µL Tyrode’s buffer and 10,000 individual platelets were 
analysed on a FACS Canto II flow cytometer and Weasel software Version 3.0.2. 
2.2.10 Western blot 
Washed platelets from wild-type and Cc2
–/–
 mice were stimulated with 10 µg/mL of 
CRP versus resting at different time points (0, 15-30 seconds, 1-3 minutes) to measure 
global tyrosine phosphorylation (pTyr). Reactions were terminated with an equal volume of 
Triton lysis buffer (15 mM HEPES, pH 7.4, containing 145 mM NaCl, 0.1 mM MgCl2, 10 
mM EGTA, 2 mM sodium orthovanadate, 0.2 mM leupeptin, 1 mM phenylmethylsulfonyl 
fluoride and 1% [v/v] Triton X-100) as previously described [8, 219]. Platelet lysates were 
mixed for 1 hour at 4°C on a rotator, and then centrifuged at 15,000 g for 15 minutes at 4°C. 
After platelet lysate separation, Triton-soluble supernatants were isolated, and retained 
protein concentration determined by Bio-Rad protein assay (section 2.2.12). 30 µg of 
protein was eluted with 30 µL of SDS reducing buffer for 10 minutes at 100°C, then eluted 
proteins were loaded onto a 10% SDS-PAGE. Proteins were transferred to PVDF membrane 
by Western blotting. PVDF membranes were blocked with blocking buffer (1 M Tris-HCl, 
pH 7.4, containing 3% [w/v] BSA and 0.05% [v/v] Tween 20) for 2 hours at room 
temperature. PVDF membranes were soaked in HRP-conjugated RC20 (1/5000; 0.25µg/µL) 
or 4G10 (1/20,000) antibodies for 2 hours at room temperature, and then washed three times 
with Tris-buffered saline  (TBS; 20 mM Tris, pH 7.4, containing 150 mM NaCl and 0.05% 
[v/v] Tween 20) for 10 minutes. This blot was stripped with stripping buffer (62.5 mM Tris-
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HCl, pH 6.7, containing 100 mM 2-Mercaptoethanol and 2% (v/v) SDS) and re-probed 
using anti-Erk-1/2 Ab for detection of Erk-1 and 2 antigens as aprotein loading control. 
Membranes were then developed with the ECL detection system.  
To determine the GPVI depletion in mice, blood samples were collected through 
cardiac puncture from wild-type and Cc2
–/–
 mice as described in section 2.2.2, 5 days after 
treatment with either 100 μg of anti-mouse GPVI (JAQ1) antibody or 100 μg isotype 
control. Washed platelets were generated as described in section 2.2.2. A platelet count was 
performed using Cell-DYN Emerald analyser to standardise platelet counts required for 
Western blotting. 100 μL of washed platelets (100x109/L) were mixed with an equal volume 
of 1% (v/v) Triton lysis buffer and incubated for 1 hour at 4°C on a rotator. Platelet lysates 
were generated as described in section 2.2.10. Equal amounts of protein (100 µg) were 
loaded on 10% SDS PAGE gel, transferred to a PVDF membrane, probed with 
immunoblotting: rabbit polyclonal anti-human GPVI (5 µg/mL) and HRP conjugated anti-
rabbit antibodies (1/10,000) and visualised using the ECL development kit as described in 
section 2.2.10. 
2.2.11 Immunoprecipitation and immunoblotting 
For immunoprecipitation, the only differences from the method described for western 
blot were that the platelets were stimulated with 10 µg/mL of CRP, a GPVI selective agonist 
or with 1.2 µg/mL Rhod, a CLEC-2 selective agonist versus resting (0 and 90 seconds). 
Triton-soluble supernatants were prepared as described above and precleared twice with 50 
µL of 50% (v/v) Cyanogen bromide (CNBr) activated sepharose beads followed by mixing 
for 15 minutes at 4°C, then centrifuged at 4000 g for 5 minutes at 4°C. After centrifugation, 
Triton-soluble supernatants were pre-incubated with either 1 µg of anti-PLCγ2, anti-Src-
(36D10) or Syk (c-20) antibodies overnight at 4°C followed by the addition of 50 µL of 
50% (w/v) protein G-sepharose beads for 1 hour at 4°C. Protein-antibody complexes were 
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then washed 5 times with immunoprecipitation buffer (50 mM Tris-HCl, pH 7.4, containing 
150 mM NaCl and 1% [v/v] Triton X-100) followed by centrifuged at 4000 g for 5 minutes 
at room temperature. The protein-antibody complexes were eluted with 30 µL of SDS 
reducing buffer for 10 minutes at 100°C, then eluted proteins were loaded and separated on 
10% SDS-PAGE. Protein transfer and membrane blocking were described as above. 
Membranes were coated with 4G10 (1/20,000) or anti-phospho-Src-(Tyr416; 1/2,000) 
antibodies for 2 hours at room temperature, and then washed three times with TBS for 10 
minutes. A protein loading control blot was stripped and re-probed using anti-PLCγ2 
(1/5,000), anti-Src-(36D10; 1/2,000), Syk (c-20; 1/2,000), then incubated with anti-rabbit 
HRP-conjugated secondary antibody diluted in TBS at 1/20,000. Membranes were washed 
with TBS and developed by ECL [215, 219]. 
2.2.12 Bio-Rad protein assay 
The Bio-Rad protein assay was performed to estimate the protein concentration in the 
platelet lysate as described [221].  800 µL of different dilutions of samples (1/80, 1/160 and 
1/320) and BSA standard (1.25, 2.5, 5 and 10 µg/mL) or blank sample (water only) were 
prepared in Milli-Q water. 200 µL of Bio-Rad dye was added to protein, BSA standard and 
blank samples, followed by mixing and 5 minutes incubation at room temperature. The 
absorbance maximum for an acidic solution is determined when Bio-Rad dye binds to the 
protein and this binding leads to a shift in the wavelength from 465 to 595 nm.  Protein 
concentration of BSA standard and samples was determined by measuring the fluorescence 
intensity at the wavelength 595 nm using a spectrophotometer analyser (Perkin Elmer, 
Waltham, MA). A standard curve was created by plotting OD 595 nm versus known 
amounts of BSA protein standard values, and then the protein concentration of the 
appropriate sample was calculated based on the X factor and dilution. To adjust the final 
concentration, the unknown sample concentration was calculated by multiplying the X 
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factor with dilution. The mean of protein concentrations was calculated and expressed as 
µg/mL to determine the appropriate protein concentration for each sample. 
2.2.13 Analysis of murine platelet adhesion and thrombus formation under in vitro 
flow 
Mouse blood was drawn as previously mentioned in section 2.2.2. A three channel µ-
slide III
0.1 
with dimensions (0.1 x 1.0 x 45 mm, H x W x L), (Microslides, ibidi, Martinsried, 
Germany) was pre-coated with 500 µg/mL type I fibrillar collagen (Nycomed, Linz, 
Austria) for 1 hour at 37
o
C, followed by washing with RCD pH 7.4 for 1 minute. 
Anticoagulated whole blood from wild-type and Cc2
–/–
 mice was normalised to 300x10
9
/L 
platelets then pre-incubated with 0.05% (w/v) rhodamine 6G dye for 30 minutes at 37
o
C. 
Labelled blood was perfused through the collagen-coated µ-slide III
0.1
 at a shear wall flow 
rate of 1800 seconds
-1
 for 6 minutes. Nonadherent cells were washed at the same shear wall 
flow rate with RCD buffer pH 7.4. Thrombi were recorded in real-time for 6 minutes and 
imaged using Z-stack analysis and deconvolution of 3D reconstructions using a Zeiss 
Axiovert microscope equipped with an Axiocam MRm camera (Carl Zeiss, Thornwood, 
NY). Thrombus volume was calculated from the thrombus area (µm
2
) multiplied by the 
thrombus height (µm) for wild-type and Cc2
–/–
 thrombi at various time points.  
2.2.14 FeCl3-induced vascular injury of mesenteric arterioles in vivo 
FeCl3-induced vascular injury of mesenteric arterioles was performed according to 
the method described [187, 222]. Wild-type and Cc2
–/–
 mice (4-6 weeks old) were 
anaesthetised with Ketamine (20 μl/g) /xylazine (1 μl/g) through intraperitoneal injection, to 
facilitate manipulation of the animal. The limbs were secured using masking tape and the 
teeth were tied to straighten the neck. An incision was then made between the clavicle and 
the neck, to expose the jugular vein. Two (10S) black threads were placed around the 
jugular vein, and a hole was created for cannula insertion at 15°C parallel to the vein to 
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deliver the rhodamine 6G dye or top up anaesthetic. The mesenteric arterioles were then 
located and visualised using a Zeiss Axiovert microscope equipped with an Axiocam MRm 
camera (Carl Zeiss). The diameter of arterioles (80-100 μm) was measured with the 
Axiovision Rel 4.6 program. A 1mm×4mm whatman filter paper strip was soaked in freshly 
prepared 7.5% (w/v) FeCl3 solution for ~ 3 seconds, and then placed on the vessel at the 
required site for 4 minutes. The filter strip was then removed, and the injury site was flushed 
with some saline. The vessels were then checked and the injured area was located by phase 
contrast microscopy using the Axiovert microscope to detect the FeCl3 deposits indicating 
oxidative damage. 75 μl of rhodamine 6G dye (0.05% w/v) was infused directly into the 
cannula, visualised by the brightness of the vein under the Axiovert microscope, then 
rhodamine fluorescent channel (at position 5) and Z-stack images were captured (90-120 
slices). Real time thrombus growth was monitored on the rhodamine channel and Z-stack 
images were recorded over 10 minutes of 2-minute cycles. 
2.2.15 Laser-induced injury of cremaster muscle arterioles in vivo 
Laser-induced injury of cremaster muscle arterioles was performed according to the 
method described [222, 223]. The mice were prepared for the procedure as described in 
section (2.2.14). The mice were then transferred to the cremaster examination board and a 
small incision was made at the tip of the scrotum to loosen the membrane using a blunt 
forceps. A 10S thread was used to tie one testicle and the cremaster muscle located at the 
bottom of the testicle was located and removed. To avoid dryness of the muscle a few drops 
of superfusion buffer (saline) were added. A small hole was made at the tip using a 
cauteriser, and a fine forceps was placed into the hole. Another hole was made at the centre 
of the muscle. The cauda epididymis was held and the membrane between the muscle and 
the testis was hydrated using superfusion buffer (saline). The testis was then pushed back 
into the body. The right and left edges of the muscle were then held and tied using a 6S 
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thread that was later secured on the board using yellow waterproof tape. The cremaster 
arteriole was located under long-distance lens 20x, under bright field (TL shutter open, 
position 1, filter H) and viewed through a Zeiss Axiovert microscope equipped with an 
Axiocam MRm camera and Axiovision Rel4.6 software. The potential cremaster muscle 
arteries of diameter (30-40 μm) were measured using a gauge on the monitor of an intravital 
microscope.  
Endothelial injury was induced in the cremaster muscle artery by the Micropoint Laser 
System, manufactured by Photonics Instruments (Photonic instrument, St. Charles, IL), with 
the resulting images displayed by Axiovision microscope technology. To create an injury at 
a specific parafocal location on the vessel wall, the laser was switched to laser channel 
(position 6) and concentrated through the objective lens of the microscope [224], with one 
or two pulses used to create an injury of sufficient size and severity with maximum of 10 
pulses. To avoid any interference caused by previous thrombi developed in the subject mice, 
additional injuries were induced upstream. No noticeable trends related to size or formation 
characteristics were apparent across this sequence of multiple thrombi created in individual 
mice. Following laser injury, 100 μL of 0.05% (w/v) rhodamine 6G dye was infused and 
visualised by the brightness of the vein under the microscope, and rhodamine channel 
(position 5) and Z-stack images were captured (80-100 slices). Thrombus formation was 
monitored on rhodamine channel and Z-stack images for the vessel were captured. Real-
time recording was determined over 10 minutes of 2-minute cycles. 
2.2.16 Quantification of platelet thrombus parameters 
Thrombus formation parameters were calculated according to the method described 
[187, 222]. Z-stack images were deconvolved and thrombus formation parameters of 
thrombus area (µm
2
), thrombus height (µm), vessel length (µm), vessel diameter (µm), 
thrombus volume (µm
3
), vessel volume, percentage of vessel occlusion and stability score 
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were determined using Axiovision Rel4.6 software. Thrombus area was calculated by 
drawing around selected thrombi using scaling outline in µm
2
, and thrombus height and 
their length were also measured in µm. Thrombus volume was derived by multiplying 
thrombus area with thrombus height of the platelet clot. Vessel volume was calculated by 
the formula: [Vessel volume = π x (vessel diameter/2)2 x vessel length]; Percentage (%) of 
vessel occlusion was calculated by the formula: [% of vessel occlusion = Thrombus 
volume/vessel volume x 100%]. 
To determine the thrombus formation characterisation, a specific formula for each 
parameter was used as follows:  
I. Thrombus volume = Thrombus area x Thrombus height. 
II. Vessel volume = π x (vessel diameter/2)2 x vessel length. 
III. Percentage (%) of vessel occlusion = Thrombus volume / vessel volume x 100%. 
IV. Average for % vessel occlusion = (% Vessel occlusion at 6-8 min + % Vessel 
occlusion at 8-10 min) / 2. 
V. Stability score = Average of the % vessel occlusion. 
a) 0-10% is stability score equal to 1 
b) 11-20% is stability score equal to 2 
c) 21-30% is stability score equal to 3 
d) 31-40% is stability score equal to 4 
e) 41-50% is stability score equal to 5 
f) 51-60% is stability score equal to 6 
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g) 61-70% is stability score equal to 7 
h) 71-80% is stability score equal to 8 
i) 81-90% is stability score equal to 9 
j) 91-100% is stability score equal to 10, (complete vessel occlusion). 
 
For time-lapse analysis, the number of emboli (<20 m) was calculated over 2 
minutes starting from the time of first thrombus. Size of embolus (<20 m) was calculated 
by the length of each embolus just before it broke away from the vessel wall over 2 minutes 
starting from the time of first thrombus. Time to vessel occlusion was calculated as the time 
from the initial recording until blood had stopped flowing through the vessel. Data were 
plotted using GraphPad Prism software program version 6 (GraphPad, San Diego, CA). 
2.2.17 Statistical analysis  
Statistical analysis was carried out using GraphPad Prism software program version 6 
(GraphPad, San Diego, CA). All data sets are expressed as mean ± standard error of mean 
(SEM). Statistical significance was determined using unpaired Student’s t test or two-way 
analysis of variance (ANOVA). Data were checked for normal distribution
 
using the 
Shapiro-Wilk normality test. P-value <0.05 was considered significant. To correct multiple 
comparisons for type I error, the Bonferroni post-test was performed. 
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3 Chapter Three: In vitro characterisation of CEACAM2 
regulation of collagen GPVI/FcR gamma chain signalling 
pathway in platelets 
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3.1 Introduction 
As one of the most important constituents of vessel wall, collagen contributes to 
platelet activation and adhesion in response to vascular damage. Platelets and collagen can 
interact directly via direct platelet collagen receptors expressed on the membrane surface. 
Alternatively, the interaction can be indirect, when immobilised vWF binds to one or both 
of the platelet receptors GPIb-V-IX and activated integrin αIIbβ3 [225]. Research has 
identified a number of collagen receptors expressed in platelets, with GPVI [226] and 
integrin α2β1 the two most important [227]. The former is essential to platelets adhering to 
fibrillar collagen, whereas the latter is not essential, as shown by research using β1 integrin-
null platelets [228]. 
In platelets and megakaryocytes, the GPVI-FcRγ-chain complex is the most important 
collagen signalling receptor expressed on the surface [229, 230]. GPVI induces 
phosphorylation of a tandem YxxL sequence on the Fc receptor (FcR)–γ–chain, as part of a 
Src-dependent process involving the ITAM. In turn, the tyrosine kinase, Syk, is recruited 
and activated via its tandem SH2 domains, inducing a signalling cascade that creates a 
linker for T cell-dependent signalosome activation. In turn, this mediates PLCγ-2 activation, 
increasing the concentration of intracellular Ca
2+
 and activating
 
protein kinase C, with 
increased platelet aggregation [231, 232].  
Many negative regulatory mechanisms downregulate in vivo platelet-collagen 
interactions. Major regulators include nitric oxide and prostacyclin [74], released by the 
endothelium, and members of the immunoglobulin Ig-ITIM superfamily, contained within 
platelets. The latter group includes PECAM-1, and CEACAM1, which auto-regulate platelet 
interactions in the presence of collagen [219, 233-235]. Collagen plays a role in platelet 
adhesion and thrombus development, especially with GPVI/FcRγ–chain signalling. Thus, 
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natural inhibitors of the auto-regulatory mechanisms moderating signalling processes 
between the GPVI/FcRγ–chain and collagen must be present in platelets [224].  
The ITIM-bearing receptor regulation of ITAM in leukocytes is well understood. 
However, less is known about regulation in platelets where Ig-ITIM–bearing receptors bind 
with multiple phosphatase types, including SH2-domain containing tyrosine phosphatase-1 
and -2 (SHP-1, SHP-2), and SH2-domain containing inositol polyphosphate 5’-phosphatase 
(SHIP) [236]. Current theories suggest that Ig-ITIM bearing receptors undergo differential 
interaction with the distinct phosphatase groups, in a manner depending on cell conditions 
and activation status [237, 238]. 
Regulation of these complex inhibitory mechanisms is difficult to dissect because, 
under certain conditions, inhibitory ITAM signalling is mediated by ITAM-bearing 
receptors, via the FcRγ–chain or DAP12 adaptor [239, 240]. Switching between ITAM 
signalling activation and inhibition is governed by the strength of ligand binding to the 
receptor. Low-avidity ligand interactions may influence regulation of inhibitory signalling 
by phosphatases. Conversely, higher-avidity ligand cross linkages may activate ITAM-
mediated signalling responses. Hence, understanding the complex relationship between 
activation and inhibition in platelets is crucial [239, 240]. 
Several studies imply that Ig-ITIM superfamily members in platelets regulate platelet-
collagen interactions [8, 187]. Human and murine platelets do not contain the prototypic 
inhibitory Ig-ITIM superfamily member FcγRIIb, but instead, PECAM-1 and CEACAM1 
are Ig-ITIM-superfamily members that are able to negatively regulate interactions [187, 
219, 233]. Other Ig-ITIM superfamily members, including triggering receptors expressed on 
myeloid cells (TREM), transcript-1 (TLT-1), and G6B, are critical for modulating platelet 
function [179, 182]. Much remains to be investigated in order to assess the contribution of 
Ig-ITIM superfamily to platelet thrombus formation. 
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CEACAM2 (previously known as Bgp2) is a type I-transmembrane receptor from the 
CEACAM superfamily of genes that is expressed in several cell types, including intestinal 
tissue crypt epithelia, kidney cells, testis and several nuclei in the brain, including the 
ventromedial hypothalamus [188, 241, 242]. CEACAM1 and CEACAM2 proteins, are 
encoded by different genes containing 9 exons each [197], but share a similar overall 
structure in particular with respect to Ig-Domains in the extracellular segment and an almost 
identical ITIM-containing cytoplasmic tail. However, the two proteins differ by two 
important features. Firstly, CEACAM1 predominantly possesses four extracellular Ig-
Domains (CEACAM1-4L), in contrast to CEACAM2 that has two extracellular Ig-Domains 
(N terminal, A2 domain) resulting from alternative splicing of exons 3 and 4 (CEACAM2-
2L) [242].  This leads to a differential degree of glycosylation with CEACAM2 containing 5 
out of the 16 N-linked glycans in CEACAM1. Secondly, the two receptors display 
differential ligand binding properties of the distal variable N-terminal Ig-Domain that 
promotes homophilic binding in CEACAM1, but not CEACAM2 [186]. The only ligand 
thus far identified for CEACAM2 is the murine coronavirus mouse hepatitis virus spike 
glycoprotein (s) [185]. In addition, CEACAM2 proteins utilise two ITIMs identical to 
CEACAM1 to recruit SHP-1, and to a lesser degree, SHP-2 protein-tyrosine phosphatase 
[243, 244]. With SHP-1 playing an important role in platelet activation by the collagen 
receptor GPVI [245], it is likely that SHP recruitment to the ITIM domains of CEACAM1 
contributes to the regulatory role of CEACAM1 in platelet-collagen interactions [187]. 
The potential involvement of CEACAM2 in regulating platelet-collagen interactions 
is unknown. Thus, the aim of this chapter was to investigate whether CEACAM2 regulates 
platelet-collagen interactions in vitro. 
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3.2 Results 
3.2.1 Genotyping of wild-type and CEACAM2 knockout mice 
Before performing the functional studies, Northern blot and RT-PCR analysis 
methodologies allowed verification of the age/sex-matched wild-type and homozygous 
CEACAM2 knockout mice genotypes [188]. Following the technique developed by 
Professor Sonia Najjar’s laboratory at Toledo University, USA, a number of primer 
combinations were used (Figure 3-1). Primer -107 (sense) acted as the forward primer for 
the wild-type allele, because it binds with exon 2 found in the murine CEACAM2 gene. For 
the CEACAM2 encoding genes, primer 123 (anti-sense) acted as a reverse primer because it 
binds with 3’-end of the encoding genes. These particular primers exclusively amplify the 
murine CEACAM2 wild-type allele, creating a 1050 bp fragment. Conversely, these primers 
cannot amplify the deleted CEACAM2 gene in the same way because the neomycin cassette 
replaces the CEACAM2 coding region through homologous recombination. Moving to the 
allele Knockout (KO) group, forward primer SNeo9 (sense), which binds with the neomycin 
cassette, was used. For the reverse primer, ANeo8 (anti-sense) was used, because it binds 
with 3´-end of the neomycin cassette. These particular primers amplify only the knockout 
allele and deliver a 750 bp fragment: they cannot amplify the wild-type CEACAM2 gene in 
the same way due to homologous recombination of the CEACAM2 coding region [188]. 
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Figure  3-1: CEACAM2 primers map design to identify the wild-type and CEACAM2 knockout mice. 
CEACAM2 is located on chromosome 7 and found in exon 2. Specific sense and antisense primers are used 
for CEACAM2-wild-type (-107 and 123) and CEACAM2 knockout (-SNeo9 and ANeo9; respectively) genes. 
Adapted from [186]. CEACAM2 knockout gene was generated by replacing exon 1, including the translation 
initiation site in the Ceacam2 gene with a gene encoding neomycin resistance. More details were provided in 
Chapter 2, section 2.2.1.2. 
 
 
To image and examine the DNA fragments resulting from electrophoresis of the PCR 
products, Sybr safe DNA stain was added to 2% (w/v) agarose gel. Each PCR run included 
a number of DNA controls: known Cc2
+/+ 
(Wild-type), Cc2
+/–
 (Heterozygous), and Cc2
–/–
 
(KO), alongside 3 unknown Cc2
+/+ 
and 3 unknown Cc2
–/–
 DNA types. To eliminate any 
DNA recombination of PCR reagents and primers, Milli-Q H2O acted as the non-DNA 
control. Wild-type and Cc2
–/–
 mice generate different PCR products after amplification, 
namely 1050 bp and 750 bp fragments respectively. In these images, the DNA marker is in 
Lane 1, the Cc2
+/+
, Cc2
+/–
, and Cc2
–/– 
DNA controls are in Lanes 2-4, and Milli-Q H2O is in 
Lane 5. In Figure 3-2A, Lanes 6, 7, and 8 display amplified DNA products as 1050 bp 
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fragments that are specific to wild-type mice following electrophoresis with 123 and -107 
primers. The lack of banding in the final three lanes (9-11) shows that these lanes belonged 
to the Cc2
–/–
 mice and were not amplified by the wild-type mouse specific primers. 
Conversely, in Figure 3-2B, bands in Lanes 9-11 show the presence of 750 bp PCR 
fragments that are specific to Cc2
–/–
 mice. Lanes 6–8 show no amplification, so the genomic 
DNAs extracted from these mice suggested that they belonged to the C57BL/6 and 
CEACAM2 KO groups. 
           
Figure  3-2: PCR CEACAM2 genotype for mouse tail DNA. (A) Wild-type mice displayed amplified DNA 
products as 1050 bp fragments in lane 6-8). (B) Cc2
–/–
 showed the presence of 750 bp PCR fragments. Lane 1 
(2-Log ladder DNA marker), lane 2 (Wild-type DNA), lane 3 (Heterozygous Cc2 
+/–
 DNA), lane 4 (Cc2
–/–
 
DNA), lane 5 (Milli-Q H2O), lane 6-8 (wild-type DNA) and lanes 9-11 (Cc2
–/–
 DNA). 
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3.2.2 Cc2–/– mice have normal haematological parameters 
To determine whether CEACAM2 deletion affects production of haematopoietic cells 
such as platelets, a comparison of wild-type and Cc2
–/–
 mice of the same sex and age was 
performed. All haematological parameters including WBC count, red blood cell (RBC) 
count, haemoglobin (Hb), packed cell volume (PCV), mean cell volume (MCV), mean cell 
haemoglobin (MCH), mean cell haemoglobin concentration (MCHC), red cell distribution 
width (RDW), neutrophils, lymphocytes and monocytes and platelet count (PLT) were 
determined. As Table 3-1 reveals, all haematological parameters including platelet count 
were normal in Cc2
–/–
 compared to wild-type mice. The assays were run in triplicates, and 
the data shown are representative of 6 independent experiments, presented as mean 
fluorescence intensity (MFI) ± SEM (P> 0.05 is non-significant for all haematological 
parameters), using statistics Student t-test. 
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Table 3-1: Haematological parameters of wild-type and Cc2
–/–
 mice. Results are 
expressed as MFI ± SEM. (P> 0.05 is non-significant for all haematologic parameters), 
using statistics Student t- test.  
 
Haematological parameter Wild-type 
(n = 6) 
Cc2
–/–
  
(n = 6) 
WBC, ×10
9
/L 6.20 ± 1.03 5.25 ± 0.66 
RBC, ×10
12
/L 9.07 ± 0.22 8.89 ± 0.46 
HGB, g/L 132.33 ± 3.08 129.33 ± 6.90 
PCV, L/L 0.43 ± 0.01 0.42 ± 0.02 
MCV, fl 48.33 ± 0.55 48.00 ± 0.85 
MCH, pg 14.61 ± 0.24 14.56 ± 0.23 
MCHC, ×10
3
 g/L 302.00 ± 3.40 303.83 ± 3.21 
RDW, % 13.25 ± 0.18 13.58 ± 0.19 
PLT, ×10
9
/L 726.66 ± 23.10 741.00 ± 9.80 
WBC/Neut/, % 8.58 ± 1.72 7.41 ± 1.50 
WBC/Lymph, % 88.91 ± 2.34 90.00 ± 2.27 
WBC/Mono, % 2.50 ± 0.65 3.08 ± 1.26 
WBC/Neut, ×10
9
/L 0.55 ± 0.17 0.37 ±  0.07 
WBC/Lymph, ×10
9
/L 5.47 ± 0.88 4.74 ± 0.65 
WBC/Mono, ×10
9
/L 0.17 ± 0.06 0.16 ± 0.07 
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3.2.3 CEACAM2 is expressed on the surface and in intracellular pools of murine and 
human platelets 
Next, we aimed to investigate whether CEACAM2 is expressed on the cell surface 
and in intracellular pools of resting murine platelets. To determine whether surface 
expression of CEACAM2 is increased after granule release, we examined the binding of a 
specific anti–mouse CEACAM2 polyclonal antibody to resting and agonist stimulated wild-
type mouse platelets, detected by flow cytometry. As shown in Figure 3-3A, resting 
platelets incubated with the anti-mouse CEACAM2 antibody had a two-fold increase in 
surface expression compared to normal rabbit pre-immune serum (21.56 ± 1.754 vs 9.854 ± 
1.597, respectively; **P<0.01; n=5). This finding indicates the presence of CEACAM2 on 
the surface of mouse platelets. In addition, characterisation of the total distribution of 
CEACAM2 in mouse platelets was determined by permeabilisation of the platelet 
membrane with saponin. Saponin-treated platelets incubated with anti-CEACAM2 antibody 
had a 2.5-fold higher MFI than those incubated with normal rabbit pre-immune serum 
(83.66 ± 8.935 vs 33.08 ± 6.756, respectively; **P<0.01; n=5; Figure 3-3A). This finding 
points to an additional intracellular CEACAM2 pool in mouse platelets. CEACAM2 is 
predominantly expressed in platelets as the commonly found CEACAM2-2L (CC2-2L) 
form of ~ 52 kDa (Figure 3-3B). CC2-2L of CEACAM2 contains 2 Ig-Domains (N 
terminal, A2 domain), a transmembrane domain and long ITIM-containing cytoplasmic 
domain. As shown in Figure 3-3B, there is no detectable protein expression in the platelet 
lysates from Cc2
–/–
 mice, but significant expression in the wild-type mouse platelet lysate. 
Equivalence in protein loading was determined by stripping and reprobing the blot with 
anti-GAPDH. Cell surface expression of CEACAM2 was increased in a dose-responsive 
manner upon agonist stimulation with thrombin (0.12-1 U/mL), PAR-4 agonist peptide 
(100-300 µM) and CRP (1-4 µg/mL) compared to resting platelets (***P<0.001; n=4; 
Figure 3-3C). In Cc2
–/–
 platelets, the expression of several platelet glycoproteins, including 
103 
 
GPVI, PECAM-1, CEACAM1, integrin α2β1, integrin αIIbβ3, GPIb-IX-V complex, CD44 
and CD9 was similar to wild-type platelets (Figure 3-4A-B). In contrast, CEACAM2 was 
expressed in wild-type platelets but absent in Cc2
–/– 
platelets (Figure 3-4A). Consistently, 
up-regulation of CEACAM1 surface expression was similar in wild-type versus Cc2
–/–
 
platelets upon a dose-responsive manner of agonist stimulation with thrombin (0.12-1 
U/mL), PAR-4 agonist peptide (100-300 µM) and CRP (1-4 µg/mL)  (Figure 3-2C). These 
data show that CEACAM2 protein is localised to both the surface and intracellular pools in 
resting mouse platelets. 
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Figure ‎3-3: CEACAM2 is expressed on the surface and in intracellular pools in murine platelets. (A) 
Flow cytometric analysis of CEACAM2 surface and total expression on resting murine platelets. Platelets 
were stained with a polyclonal anti-murine CEACAM2 2052 antibody followed by a secondary PE conjugated 
anti-rabbit antibody. Normal rabbit serum was included as a negative control. For total expression, platelets 
were resuspended in 0.1% (w/v) saponin, and then washed with a combination of 0.1% (w/v) saponin and 
0.2% (w/v) Bovine serum Albumin (BSA). Data were collected by a live platelet gate based on forward versus 
side scatter profiles on a FACS Canto II flow cytometer. Results are cumulative data derived from four 
independent experiments and represented as MFI ± SEM (**P<0.01; n=4). (B) Platelet lysates from wild type 
and Cc2
–/–
 mice were analysed by 10% SDS-PAGE and Western blotting using 1:2000 of rabbit anti–mouse 
CEACAM2 polyclonal antibody (2052) (upper panel), followed by reprobing with GAPDH antibody to 
control for protein loading (bottom panel). A ~52 kDa band representing CEACAM2 and another one (band 
X) at ~95kDa representing an unidentified protein were detected. (C) CEACAM2 surface expression was 
increased upon agonist stimulation of wild-type murine platelets using thrombin (0.125-1.0 U/mL), PAR-4 
agonist peptide (100-300 µM) and collagen related peptide (CRP; 1.0-4.0 µg/mL) over a dose-dependent range 
(**P<0.01 and ***P<0.001; n=4). CEACAM2 surface expression was determined as described in panel A. 
105 
 
 
 
Figure ‎3-4: Immunoglobulin immunoreceptors expression in murine platelets. (A) Flow cytometric 
analysis of PECAM-1, CEACAM1 and CEACAM2 expression on resting wild-type versus Cc2
–/–
 platelets. 
Wild-type and Cc2
–/–
 platelets were stained with a monoclonal anti-murine PECAM-1 antibody, polyclonal 
anti-murine CEACAM1 2457 antibody or polyclonal anti-murine CEACAM2 2052 antibody followed by a 
secondary PE conjugated anti-rat or anti-rabbit antibody. Normal rabbit serum (NRS) and isotype control 
antibody CD3 were included as negative controls. Data were collected by a live platelet gate based on forward 
versus side scatter profiles on a FACS Canto II flow cytometer. Results are cumulative data derived from four 
independent experiments and represented as MFI ± SEM (**P<0.01; n=4). (B) Cell surface expression of 
platelet glycoproteins was monitored by flow cytometry using specific monoclonal antibodies for wild-type 
and Cc2
–/–
 platelets. MFI was reported with a standard error of mean for at least four independent experiments 
and no significant difference was demonstrated. (C) Total expression of platelet glycoproteins on resting wild-
type and Cc2
–/–
 murine platelets was determined and antibodies concentrations were described in Methodology 
section. (D) Cell surface expression of CEACAM1 upon agonist stimulation of wild-type versus Cc2
–/–
 murine 
platelets was determined as described in Figure 3-3, panel B. 
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3.2.4 Cc2–/– platelet response to GPVI-selective agonists 
To determine whether CEACAM2 negatively regulates ITAM-bearing, collagen–
GPVI–mediated platelet responses, platelet aggregation responses were evaluated using 
wild-type versus Cc2
–/– 
mice platelets. PRP were stimulated using a range of G-protein-
coupled agonists, PAR-4 agonist peptide (125–500 µM; Figure 3-3Aa–c), ADP (2.5–10 
µM; Figure 3-5Ad–f) and CI-A23187 (1.25–5.0 µg/mL; Figure 3-5Ag–i), with acid-soluble 
type I collagen (1.25–5 µg/mL; Figure 3-6Aa–c) and the GPVI collagen receptor selective 
agonist, CRP (0.625–2.5 µg/mL; Figure 3-6Ad–f). In addition, washed platelets were 
stimulated using thrombin (0.5-1 U/mL; Figure 3-7Aa–b), PAR-4 agonist peptide (250–500 
µM; Figure 3-7Ac–d) and CRP (5–10 µg/mL; Figure 3-7Ae–f). As shown in Figures 3-5 
and 3-7A-B, similar platelet aggregation profiles were observed in wild-type and Cc2
–/– 
platelets treated with thrombin, PAR-4 agonist peptide, ADP and CI. However, in response 
to collagen and CRP agonist (Figure 3-6A-B), enhanced platelet aggregation responses were 
observed in Cc2
–/– 
platelets, particularly at subthreshold doses compared to wild-type 
platelets. These data suggest that lack of CEACAM2 leads to hyper-responsive tyrosine-
kinase dependent signalling pathway in platelets upon collagen and CRP stimulation. 
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Figure ‎3-5: Cc2–/– platelets are normal after stimulation with GPCRs and calcium ion channel agonists. 
(A-B) Aggregation responses of PRP (platelet count adjusted to 100x10
9
/L) for wild-type (+/+) and Cc2
–/–
 
mice were determined following stimulation with the following agonists: (a-c) PAR-4 agonist peptide (125-
500 µM), (d-f) ADP (2.5-10 µM), (g-i) calcium ionophore (1.25-5 µg/mL). Note that Cc2
–/–
 are comparable to 
wild-type platelets. These data are representative of at least four independent experiments (P>0.05; n=4). 
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Figure ‎3-6: Cc2–/– platelets are hyper-responsive to stimulation with type I collagen and GPVI selective 
agonist, CRP. (A-B) Aggregation responses of PRP (100x10
9
/L) for wild-type (+/+) and Cc2
–/–
 mice were 
determined following stimulation with the following agonists: (a-c) type I collagen (1.25-5 µg/mL) and (d-f) 
CRP (0.625-2.5 µg/mL). Note that Cc2
–/–
 platelets are hyper-responsive to stimulation by type I collagen and 
GPVI-selective agonist, CRP. These data are representative of at least four independent experiments (*P<0.05 
and **P<0.01; n=4). 
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Figure ‎3-7: Cc2–/– washed platelets are hyper-responsive to stimulation with GPVI selective agonist, 
CRP. (A-B) Aggregation responses of murine washed platelets for wild-type (+/+) and Cc2
–/–
 mice were 
determined following stimulation with the following agonists: (a-b) Thrombin (0.5-1 U/mL), (c-d) PAR-4 
agonist peptide (250-500 µM) and (e-f) CRP (5-10 µg/mL). Cc2
–/–
 platelets are hyper-responsive to 
stimulation by GPVI-selective agonist, CRP. These data are representative of at least four independent 
experiments performed (*P<0.05; n=4). 
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3.2.5 Cc2–/– platelets display enhanced GPVI-mediated alpha and dense granule 
secretion 
As Cc2
–/–
 platelets exhibited hyper-responsive GPVI-mediated platelet aggregation 
responses, we investigated whether the absence of CEACAM2 affects the platelet-release 
reaction stimulated by GPVI-specific agonist, CRP (0.5-2 µg/mL), thrombin (0.1-0.2 U/mL) 
and PAR-4 agonist peptide (100-300 µM). The ability of wild-type and Cc2
–/–
 platelets to 
secrete alpha (P-selectin) and dense granules (Quinacrine) upon GPVI and GPCRs 
stimulation was determined. As seen in Figures 3-8A and 3-9A, the release of alpha and 
dense granule contents from Cc2
–/–
 platelets upon stimulation by GPCRs agonists including 
thrombin and PAR-4 agonist peptide was similar to wild-type platelets. Furthermore, the 
release of alpha granule contents from Cc2
–/–
 platelets was similar to that from Cc1
–/–
 
platelets after CRP stimulation (Figure 3-8B). However, Cc2
–/–
 platelets released more alpha 
and dense granules at all doses of CRP compared with wild-type platelets but not when 
treated with thrombin and PAR-4 agonist peptide at any dose (*P<0.05; **P<0.01; 
***P<0.001; n=4; Figures 3-8B and 3-9B). These results support the hypothesis that 
CEACAM2 acts as a negative regulator specifically of GPVI-mediated platelet granule 
release. 
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Figure ‎3-8: Cc2–/– platelets display enhanced alpha granule release following stimulation with GPVI-
selective agonist, CRP. (A-B) Surface expression of P-selectin as a marker of alpha granule release was 
determined for washed platelets stimulated by thrombin (0.1-0.2 U/mL), PAR-4 agonist peptide (100-300 µM) 
and CRP (0.5-2.0 µg/mL) and then stained with either a buffer control and FITC-conjugated P-selectin mAb 
for both wild-type and Cc2
–/–
 platelets (A) and Cc1
–/–
 platelets (B). FITC-labelled samples were analysed on a 
FACS Canto II flow cytometer. Results are representative of three independent experiments (*P<0.05 and 
**P<0.01; n=3). 
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Figure ‎3-9: Cc2–/– platelets show enhanced dense granule release following GPVI-selective agonist, CRP 
stimulation. (A-B) Platelet dense granule exocytosis measured by release of fluorescent quinacrine by flow 
cytometry. Washed platelets (100x10
9
/L) derived from both wild-type and Cc2
–/–
 mice were stimulated with 
either no agonist, thrombin (0.12-1.0 U/mL), PAR-4 agonist peptide (100-300 µM) or CRP (0.25-4.0 µg/mL). 
Samples were analysed on a FACS Canto II flow cytometer. Data are reported as percentage quinacrine 
release and are representative of four independent experiments (*P<0.05 and ***P<0.001; n=4). 
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3.2.6 Cc2–/– platelets displayed enhanced static adhesion to immobilised type I 
fibrillar collagen 
We examined whether CEACAM2 modulates collagen–GPVI–mediated platelet 
responses in a manner similar to other platelet Ig-ITIM immunoreceptors such as PECAM-1 
and CEACAM1. Static platelet adhesion on type I fibrillar collagen was performed to 
determine the binding characteristics of platelets derived from wild-type and Cc2
–/–
 mice 
over time. Ceacam2-null platelets bound more to immobilised type I fibrillar collagen but 
not to the negative control (RCD buffer, pH 7.4) compared to wild-type platelets at all time 
points (Figure 3-10). These data show that upon static adhesion to immobilised type I 
collagen, Cc2
–/–
 platelets showed hyper-responsive platelet adhesion compared to wild-type 
platelets. 
 
 
Figure ‎3-10: Cc2–/– platelets display enhanced static adhesion on immobilised type I collagen. Time 
course of wild-type (+/+) and Cc2
–/–
 platelet adhesion to either buffer control or type I collagen (50 µg/mL) in 
the absence of magnesium for 15, 30, 45 and 60 minutes at 37
o
C. Non-adherent platelets were removed and 
adherent platelets were measured as described in Materials and Methods. Data represents four independent 
experiments. Note that Cc2
–/–
 platelets show a higher level of number of adherent platelets in high-power field 
(HPF) to type I fibrillar collagen than wild-type platelets (+/+) at all time points (*P<0.05, **P<0.01, 
***P<0.001; n=4). 
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3.2.7 Normal phosphatidylserine exposure in Cc2–/– platelets 
A number of flow studies examining mouse and human blood suggest that GPVI, a 
signal receptor, is solely responsible for regulating any procoagulant activity of platelets 
induced by collagen, providing a bridge between the processes governing platelet activation 
and coagulation [228, 246, 247]. A long and powerful rise in cytosolic [Ca
2+
]i regulates this 
procoagulant activity by changing the membrane location of the procoagulant 
phosphatidylserine (PS), a key coagulation regulator, on the outer surface of platelets [248]. 
As an example, membrane surfaces with high levels of exposed PS will significantly raise 
thrombin and factor Xa formation rates [249]. In order to determine the functional role of 
CEACAM2 in the regulation of the procoagulant activity of platelets, the effect on agonist-
induced phosphatidylserine exposure (Annexin V) in wild-type, Cc1
–/– 
and Cc2
–/– 
platelets 
was determined. Washed platelets (100x10
9
/L) were stimulated with G-protein coupled 
agonists, thrombin (0.12-0.5 U/ml) and PAR-4 agonist peptide (100-300 μM) and along 
with tyrosine kinase dependent GPVI-selective agonist, CRP (1-4 μg/ml). Cc2–/– platelets 
display a similar response of Annexin V-FITC binding in all GPCRs and GPVI agonists at 
all doses compared to wild-type platelets (Figure 3-11A). Moreover, Cc1
–/– 
platelets showed 
a typical response of Annexin V-FITC binding with all agonists doses tested compared to 
Cc2
–/– 
and wild-type platelets (Figure 3-11B). 
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Figure  3-11: Cc2–/– platelets display normal phosphatidylserine exposure. (A-B) The influence of 
CEACAM1 And CEACAM2 on phosphatidylserine exposure (Annexin V) of murine washed platelets was 
examined following stimulation with thrombin (0.12-0.5 U/ml) and PAR-4 agonist peptide (100-300 μM) and 
the GPVI-selective agonist, CRP (1-4 μg/ml). (A) The MFI of Annexin V-FITC binding in wild-type versus 
Cc2
–/– 
platelets was not significantly different to that in wild-type platelets. (B) MFI of PS exposure in wild-
type versus Cc1
–/– 
platelets was not significantly different to that in wild-type platelets. Data are reported as 
average of MFI Annexin V-FITC binding and are representative of six independent experiments (P>0.05; 
n=6). 
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3.2.8 Enhanced tyrosine phosphorylation in Cc2–/– platelets after GPVI- stimulation 
To determine whether CEACAM2 plays a negative regulatory role in ITAM 
signalling pathways in platelets, wild-type and Cc2
–/–
 platelets were stimulated using 10 
µg/mL of CRP over a 3 minute-period. Global tyrosine phosphorylation of proteins in 
platelet lysates derived from CRP-stimulated Cc2
–/– 
and wild-type mice was measured. 
Several tyrosine hyper-phosphorylated proteins of 54, 56, 65, 71, 74, 83 and 93kDa 
apparent molecular mass were detected in Cc2
–/–
 in response to CRP stimulation for 15 
seconds - 3 minutes by comparison to wild-type platelets (Figure 3-12A). Furthermore, 
PLCγ2, Src and Syk tyrosine phosphorylation was measured after CRP and Rhod-
stimulation for 0-90 seconds by immunoprecipitation and Western blot analysis with anti-
phosphotyrosine antibodies. As shown in Figure 3-12B, CRP-stimulated Cc2
–/–
 platelets 
showed a 5-fold increase in PLCγ2 tyrosine phosphorylation (0.5230±0.014 vs 
0.1340±0.004; ***P<0.001; n=3; Figure 3-12B.a), a 3-fold increase in Src tyrosine 
phosphorylation (0.4573±0.051 vs 0.2710±0.027; *P<0.05; n=3; Figure 3-12B.b), and a 3.5-
fold increase in Syk tyrosine phosphorylation (0.5437±0.011 vs 0.1167±0.008; ***P<0.001; 
n=3; Figure 3-12B.c) compared to wild-type platelets. The equivalence of protein loading 
was determined by stripping and reprobing the blot with antibodies to the relevant protein 
(bottom panel). These data are consistent with the notion that CEACAM2 plays a role in 
attenuating platelet collagen GPVI/FcR γ-chain ITAM signalling pathways. 
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Figure  3-12: Cc2–/– platelets show hyper-tyrosine phosphorylated proteins after GPVI selective agonist, 
CRP stimulation over time. (A)  Platelets (300x10
9
/L) from wild-type and Cc2
–/–
 mice were stimulated with 
10 µg/mL of CRP at 37 °C for 3 minutes. Platelet lysate of 30 µg was then loaded onto a 10% (w/v) SDS-
PAGE gel. Then Western blotting was performed to measure tyrosine phosphorylation, using 1/5000 of a 
HRP-conjugated anti-phosphotyrosine RC20 antibody. A protein loading control (bottom panel) blot was 
stripped and re-probed using anti-Erk-1/2 Ab for detection of Erk-1 and Erk-2 antigens. The data shown are a 
representative blot of similar results for 3 independent experiments. (B) Tyrosine phosphorylation of PLCγ2, 
Src and Syk was detected from platelet lysate after stimulation with 10 µg/mL of CRP versus resting at time 0 
and 90 seconds. Immunoprecipitation of PLCγ2, Src and Syk from platelet lysates was performed followed by 
immunoblotting to detect a. p-PLCγ2, using 1/5000 of a HRP-conjugated anti-phosphotyrosine RC20 
antibody. b. p-Src, using 1/2000 of anti-phospho Src and 1/20,000 of anti-rabbit. c. p-Syk, using 1/20,000 of a 
HRP-conjugated anti-phosphotyrosine 4G10 antibody. PLCγ2, Src and Syk antigens (bottom panel; a-c), 
loading control were confirmed by re-probing with polyclonal anti-PLCγ2, anti-Src and anti-Syk antibodies, 
respectively. The relative intensity of tyrosine phosphorelated PLCγ2, Src and Syk was quantified by ImageJ 
software Version 1.46r. The data shown are a representative blot of similar results for 3 independent 
experiments. 
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3.3 Discussion 
Maintaining platelet quiescence requires a balance between activation and inhibition 
signalling events mediated by ITAM and regulated by ITIM-bearing receptor signalling. 
Healthy arterial endothelium is able to provide powerful inhibitory signalling to platelets via 
release of bioactive NO and PGI2. However, upon endothelial damage or disease, where 
bioactive NO and PGI2 concentrations are low, collectively platelet ITIM-bearing receptors 
play an important role as negative regulators [74]. In addition, similar to the immune system 
a homeostatic balance is required between activation and inhibition and this is provided in 
platelets through ITAM and ITIM bearing receptor pathways [74]. This stimulates the 
activation mechanisms to produce pathological thrombus formation. Under these 
circumstances, it is thought that platelets provide the inhibitory signalling mediated via cell 
contact events. Platelets contain at least five ITIM-bearing receptors, PECAM-1, 
CEACAM1, G6B, SIRPα and TREM-like transcript 1 [179, 182, 185, 187, 219, 233]. While 
individually, these exert moderate inhibition of collagen and thrombin signalling in 
platelets, collectively they are important to regulate the cell contact signalling events 
involved in the initiation of platelet-collagen interactions.  
The key findings in this study is that CEACAM2 is expressed as the CC2-2L form in 
platelets (Figure 3-3BC), similar to other cell types such as ventromedial hypothalamus 
[188] and spermatids [242]. Moreover, CEACAM2 is expressed on the surface and in 
intracellular pools of resting murine platelets (Figure 3-3A). The current chapter suggests 
that under resting conditions, surface expression of CEACAM2 in murine platelets is low 
(Figure 3-3A), but undergoes a marked induction upon agonist stimulation with thrombin, 
PAR-4 agonist peptide, and CRP (Figure 3-3C). In vitro data show that CEACAM2 can 
negatively regulate the collagen GPVI ITAM-signalling pathway in platelets. Collectively, 
these findings of the initial characterisation of CEACAM2 in murine platelets and its ability 
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to negatively regulate platelet-collagen interactions in vitro are reminiscent of functions of 
the other related ITIM-bearing receptor, CEACAM1. These two receptors share similarities 
in structure and function in many biological systems, particularly in their ability to act as 
inhibitory co-receptors to modulate ITAM associated signalling pathways. 
CEACAM2 restricts platelet-collagen GPVI interactions by disrupting the signalling 
processes that modulate the adhesion between platelets and collagen. In turn, this restricts 
pathological thrombus formation when vascular walls are damaged by atherosclerotic 
plaques, exposing the type-I collagen matrix. Other receptors in the Ig-ITIM superfamily, 
CEACAM1 and PECAM-1, also inhibit platelet-collagen GPVI interactions and thrombus 
formation. Under normal physiological conditions, NO and PGI2 are produced in the 
vascular endothelium, negatively modulating the process, but their release is restricted when 
disease or injury occurs [74]. Rather than disrupting the interaction of platelets with the 
exposed collagen matrix, these mediators disrupt platelet aggregation via an auto-regulatory 
process. As a result, the normal negative mechanisms inhibiting platelet adhesion at the 
molecular level must include CEACAM2, CEACAM1 and PECAM-1 [74]. 
Based upon comparative studies of Cc1
–/–
 [187] versus Cc2
–/–
 platelets they appear to 
have similar functions in regulating GPVI dependent alpha and dense granule release 
(Figure 3-8B and 3-9B) and procoagulant activity of platelets via phosphatidylserine 
exposure (Figure 3-11A). It is possible that the dominant form of CEACAM1 in human 
platelets is the CC1-2L/2S [250], which is likely to be the “ortholog” of CEACAM2 in 
humans. In most tissues, the most dominant form of CEACAM2 is CC2-2S (even in spleen, 
kidney and testis where CEACAM2 is most highly expressed) [188, 241], except for the 
hypothalamus, where CC2-2L was cloned. In this case, CC2-4L/4S (with 4 Ig-Domain 
loops) was not found which is the most dominant form of CEACAM1. In addition, the same 
scenario in platelets would be expected, where it is likely that CEACAM2 is represented by 
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CC1-2L in human platelets, and that together with CCl-4L in humans, it exerts a broader 
range of control of vascular function by increasing the range of ligand binding to CEACAM 
proteins. Hence, CEACAM proteins may play a critical role in maintaining this function (as 
compared to PECAM-1 and other cell adhesion molecules in platelets the expression of 
which remains normal in either Ceacam1 or Ceacam2 null mice). 
GPVI acts as a major platelet-collagen activating receptor and directly interacts with 
collagen fibrils, following a triplicate GPO sequence using glycine, proline, and 
hydroxyproline [136]. Integrin-α2β1 interaction with collagen follows a GFOFER process, 
utilising glycine, phenylalanine, hydroxyproline, glutamic acid and arginine. Thus, in vitro 
studies used CRP as the GPVI-selective agonist because it contains 10 repeat GPO 
sequences, activates GPVI-mediated signalling and does not react with integrin-α2β1 [160, 
228, 251]. These attributes make it easier to differentiate between GPVI-mediated and 
integrin α2β1-mediated platelet responses. 
In common with members of the Ig-ITIM superfamily, GPVI/FcRγ-chain ITAM-
dependent pathway signalling may reach a dynamic equilibrium in the presence of proteins 
with ITIM motifs. Because previous research suggested that mouse platelets lack low-
affinity FcγRIIa, but contain the GPVI/FcRγ-chain ITAM-dependent pathway, we explored 
the possibility that CEACAM2 is an important inhibitory co-receptor that negatively 
regulates collagen-GPVI–mediated platelet responses. Essentially, Cc1–/– and Cc2–/– have 
similar phenotypes in platelet GPVI-collagen interactions. Moreover, CEACAM2 deletion 
was associated with CRP-stimulated platelets producing hyper-tyrosine phosphorylation of 
PLC-gamma2, Src and Syk, all components upstream and downstream of GPVI ITAM-
associated signalling pathways (Figure 3-12B). This would be consistent with CEACAM2 
acting as an ITIM-bearing receptor in platelets to down-modulate ITAM-associated 
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signalling, similar to CEACAM1 the ITIM-containing tail of which is almost identical to 
that of CEACAM2. 
To compare any potential differences between responses in the wild-type and 
Ceacam2-deficient platelets, we administered a broad range of agonists, including collagen 
and CRP, across a dose-dependent range. To test the specificity of platelet responses, 
different agonists stimulated a number of receptor signalling pathways, including G-
protein–coupled receptors, using PAR-4 agonist peptide and ADP; calcium ion channels, 
using CI; and collagen-coupled receptors, using acid soluble collagen and CRP. In the 
presence of PAR-4 agonist peptide, ADP, and CI, platelets displayed a normal, dose-
dependent response. In contrast, Cc2
–/–
 platelets displayed higher aggregation responses 
over the entire dose range tested with collagen and CRP as agonists (Figure 3-6). This 
hyper-responsiveness was particularly notable at sub-threshold concentrations, supporting 
the notion that CEACAM2 negatively regulates collagen-GPVI–mediated ITAM platelet 
responses. This contrasts with the responses in the presence of PAR-4 agonist peptide, ADP, 
and CI and further suggests that the Cc2
–/–
 platelet defect is restricted to GPVI-mediated 
platelet-collagen interactions. 
Many previous studies dispute this idea and argue that the GPVI-regulated platelet 
response merely assists coagulation and that, in vivo, a number of alternative platelet 
responses significantly influence the process [252, 253]. As a result, although there is a 
consensus that platelets play a major role in the production of thrombin and coagulation in 
plasma and whole blood, platelets derived from Cc2
–/–
 and Cc1
–/–
 mice display normal 
procoagulant PS exposure (Figure 3-11). More studies are needed to define the mechanisms 
and interaction between the different platelet coagulation responses.  
The hyper-responsiveness of Cc2
–/–
 platelets also fits the observed phenotypes of 
PECAM-1
–/– 
and Cc1
–/– 
[187, 219, 233]. The peak manifestation of the Cc1
–/–
 phenotype 
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occurred at lower and higher concentrations of collagen (1.5-4.0 µg/mL; respectively). A 
similar low dose hyper-responsiveness occurred when CRP was the GPVI-selective agonist. 
At sub-threshold collagen and CRP concentrations, of 1.5 and 0.625 µg/mL respectively, 
Cc1
–/–
 generated a platelet aggregation response of approximately 60%, unlike the low 
response of wild-type platelets [187]. At higher concentrations of CRP, 5-10 µg/mL, both 
wild-type and PECAM-1
–/– 
platelets responded at an equivalent level [219, 233]. 
Platelets derived from Cc2
–/–
 mice displayed enhanced, hyper-responsive adhesion to 
type I fibrillar collagen. The hyper-response was evident at all time points, and the Cc2
–/–
 
platelets, when stimulated with GPVI-selective ligands CRP (Figure 3-8B and 3-9B), 
displayed a lower threshold for alpha and dense granule release than wild-type platelets. 
This response did not occur if platelets were stimulated with the GPCR agonists, thrombin, 
and PAR-4 agonist peptide (Figure 3-8A and 3-9A). The results suggest the notion that, 
without these inhibitory co-receptors, collagen agonists stimulate higher levels of response, 
especially for collagen-GPVI receptor–mediated signalling. Thus, CEACAM2 negatively 
regulates interactions between platelets and collagen. 
In conclusion, this study demonstrates the presence of a new ITIM-bearing receptor, 
CEACAM2 (predominantly CC2-2L), in murine platelets that negatively regulates collagen 
GPVI signalling in vitro. Moreover, it shows the importance of CEACAM2 as an inhibitory 
co-receptor in murine platelets when expressed on the cell surface and within intracellular 
pools. CEACAM2 is a negative regulator of platelet-collagen interactions, because Cc2
–/–
 
platelets induced
 
sub-threshold hyper-responses during collagen- and CRP-mediated platelet 
aggregation; increased adhesion to type I collagen, enhanced alpha and dense granule 
release and hyper-tyrosine phosphorylation of PLCγ2, Src and Syk by stimulation with 
GPVI-selective ligand, CRP. 
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4 Chapter Four: In vitro studies of CEACAM2 regulation of 
CLEC-2 signalling pathway in platelets 
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4.1 Introduction 
Structural determination of CLEC-2 has shown that it is a 32-kDa C-type lectin-like 
receptor. In platelets, it acts as a receptor for rhodocytin, a venom extracted from the 
Malayan Pit Viper (Calloselasma rhodostoma), and podoplanin (PDPN, also known as gp38 
and T1α), a specific marker for lymphatic endothelium [142, 254]. The CLEC-2 signalling 
process involves the activation of the Src and Syk tyrosine kinases in sequence, which, in 
turn, activate PLCγ2. This progression is almost identical to the sequential process used by 
GPVI that is coupled with FcR γ-chain signalling pathway in human platelets [142]. 
However, there is one notable difference between the two processes: CLEC-2’s regulating 
function for PLCγ2 uses only its single YxxL sequences and does not fully rely upon the 
adaptor, SLP-76, while GPVI uses both of its YxxL sequences with partial reliance on SLP-
76 [142, 156]. 
It has long been understood that platelet activation follows a signalling pathway 
involving CLEC-2. This pathway emulates the processes used by collagen receptor GPVI, 
an ITAM, despite the fact that the CLEC-2 receptor contains only a single YxxL sequence 
in its cytosolic tail [142, 156]. When point mutations are engineered in the ITAM of the 
CLEC-2 receptor or one of the pair of Syk SH2 domains, their ability to bind with 
phosphotyrosine residues is compromised, disrupting CLEC-2 signalling [156]. In addition, 
research suggests that the specific fusion protein responsible for encoding the tandem 
Syk SH2 domains is the only one with the ability to cause the precipitation of cellular 
CLEC-2 from platelet lysates stimulated with rhodocytin [142, 156]. These processes 
suggest that the CLEC-2 YxxL sequence and tandem SH2 domains are an essential 
component of the CLEC-2 signalling process. 
In murine platelets, there are two hemi ITAM associated signalling pathways 
including collagen GPVI/FcR -chain and CLEC-2. The snake venom protein rhodocytin is 
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a CLEC-2 ligand, which plays a crucial role in CLEC-2 clustering and platelet activation 
[255]. CLEC-2 receptor induces activation-dependent signalling through a process similar to 
the GPVI-FcR  chain pathway. However, CLEC-2 signalling relies more on Syk rather 
than Src tyrosine kinases and PLCγ2-dependent mechanism of platelet activation [142, 255]. 
Previous studies have highlighted that homophilic binding in trans of Ig-ITIM 
superfamily members, PECAM-1 and CEACAM1 negatively regulates platelet-collagen 
interactions and modulates thrombus growth and stability in vivo [178, 187]. However, it is 
unknown if the Ig-ITIM superfamily member, CEACAM2 modulates CLEC-2-mediated 
platelet activation in a similar manner to collagen GPVI. Other mechanisms have been 
proposed where ligands are secreted (Gas6) or shed (Semaphorin 4D) from platelets during 
activation to act as bioactive molecules in the platelet gap [256]. Studies
 
of the interaction of 
the platelet receptor CD72, with its ligand, Semaphorin 4D show that this receptor does not 
negatively regulate GPVI-dependent platelet responses [210]. While CD72 constitutively 
associates with SHP-1, this phosphatase dissociates from the receptor upon platelet 
activation to negatively regulate GPVI-dependent platelet responses [210]. This is in 
contrast to PECAM-1 where SHP-2 recruitment occurs upon induction of tyrosine 
phosphorylation of PECAM-1 that requires platelet activation and/or aggregation events 
followed by dephosphorylation of ITAM-signalling elements [215]. In immunological 
systems, SHP-1 PTP is classified as a negative regulator, while in collagen GPVI platelet 
responses it has been proposed to act as a positive regulator but this is controversial [245]. 
Given this controversy, it will be informative to test the role of CEACAM2 that 
preferentially recruits SHP-1 in murine platelets using a novel mouse model of CEACAM2 
knockout platelets. In addition, unlike CEACAM1, CEACAM2 is a heterophilic binding 
receptor that may have differing roles in regulating platelet activation. Furthermore, as 
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CEACAM2 is expressed as the CC2-2L isoform in platelets and CEACAM1 is 
predominantly CC1-4L isoform, they may have different vascular functions. 
The key issue to be addressed is: 1) Does CEACAM2 positively or negatively 
attenuate CLEC-2-mediated platelet responses?. 
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4.2 Results 
4.2.1 Cc2–/– platelets are hyper-responsive to the CLEC-2 selective agonist, rhodocytin 
In order to test that CEACAM2 normally functions to attenuate CLEC-2-mediated 
platelet activation, a comparison of the ability of platelets derived from wild-type and Cc2
–/– 
mice in platelet aggregation responses over a dose-dependent range of the snake venom 
protein, rhodocytin (0.12-0.48 µg/mL) was undertaken. This was compared with the 
aggregation responses to the GPVI selective agonist, collagen-related peptide, CRP (0.625-
2.5 μg/mL); the G-protein coupled agonists, PAR-4 agonist peptide (125-500 μM) and ADP 
(2.5-10 μM); and calcium ionophore (1.25-5 μg/mL). Platelet aggregation was determined 
using PRP at 100x10
9
/L containing 1 mM CaCl2 and 100 µg/mL fibrinogen. PRP was 
stimulated using the CLEC-2 selective agonist, rhodocytin at 0.12-0.48 µg/mL (Figure 
4.1A-B). As described previously in Chapter 3, comparable platelet aggregation were 
observed in both wild-type versus Cc2
–/– 
platelets upon GPCRs agonists thrombin, PAR-4 
agonist peptide, ADP and calcium ion channel agonist, CI-A23187 (Figure 3-3A-B). 
However, platelet aggregation profiles were increased in Cc2
–/– 
platelets upon stimulation 
with the CLEC-2 selective agonist, rhodocytin compared to wild-type platelets. This data is 
similar that was obtained with GPVI agonists, type I collagen and CRP (Figure 3-4A-B). 
Therefore, this data suggests that absence of CEACAM2 leads to hyper-responsive GPVI-
and CLEC-2-mediated platelet aggregation. 
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Figure  4-1: Cc2–/– platelets show hyper-responsive aggregation to stimulation with the CLEC-2 selective 
agonist, rhodocytin (Rhod). (A-B) Platelet aggregation responses (PRP; 100x10
9
/L) for wild-type (+/+) and 
Cc2
–/– 
mice were determined. PRP was stimulated with rhodocytin (Rhod; 0.12-0.48 µg/mL). Cc2
–/–
 platelets 
are hyper-responsive to stimulation with CLEC-2-selective agonist, rhodocytin compared to wild-type 
platelets. These data are representative of at least four independent experiments performed (*P<0.05 and 
**P<0.01; n=4). 
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4.2.2  Cc2–/– platelets are hyper-responsive in alpha and dense granule secretion 
following rhodocytin stimulation 
As hyper-responsive CLEC-2-mediated platelet aggregation responses were observed 
in Cc2
–/– 
platelets, the second phase is to examine whether the presence or absence of 
CEACAM2 affected platelet granule release. In order to examine the influence on alpha and 
dense granule platelet release reaction of wild-type versus Cc2
–/– 
platelets, washed platelets 
(100x10
9
/L) were stimulated with rhodocytin (0.4-1.2 µg/mL) and the secretion of alpha and 
dense granules was determined. Cc2
–/– 
platelets displayed a significant increase in both P-
selectin exposure (alpha granules) and dense granule release (quinacrine) compared to wild-
type platelets (Figure 4-2 and 4-3). We have previously examined the influence of Cc2
–/– 
 on 
alpha and dense granule platelet release reaction using the G-protein coupled agonists, 
thrombin (0.1-0.2 U/mL) and PAR-4 agonist peptide (100-300 μM) along with the tyrosine 
kinase-dependent GPVI-selective agonist, CRP (0.5-2.5 μg/mL) as shown in chapter 3 
(Figure 3-6 and 3-7). Therefore, Cc2
–/– 
platelets release comparable alpha and dense 
granules upon GPCR agonist stimulation, but an increase in response to the tyrosine kinase 
dependent GPVI and CLEC-2 receptor stimulation. Therefore, these studies support the 
hypothesis that CEACAM2 negatively attenuates hemi (ITAM associated) CLEC-2-
mediated responses in murine platelets. 
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Figure  4-2: Cc2–/– platelets showed increased alpha granule release upon CLEC-2 selective agonist, 
rhodocytin stimulation. P-selectin exposure of wild-type and Cc2
–/–
 washed platelets (100x10
9
/L) was 
determined following stimulation with CLEC-2 selective agonist, rhodocytin (0.6-1.2 µg/mL). Platelets were 
stained with either control or FITC-conjugated CD62P mAb for both wild-type and Cc2
–/–
 platelets. Samples 
were analysed on a FACS Canto II flow cytometer. Data are representative of four independent experiments 
(**P<0.01 n=4). 
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Figure  4-3: Cc2–/– platelets display more dense granule release upon CLEC-2 selective agonist, 
rhodocytin stimulation. Quinacrine as dense granule release fluorescent marker was measured by flow 
cytometry. Wild-type and Cc2
–/–
 washed platelets (100x10
9
/L) were stimulated with rhodocytin at 0.4-1.2 
µg/mL. Samples were analysed on a FACS Canto II flow cytometer. Data are representative of four 
independent experiments (**P<0.01 and ***P<0.001; n=4). 
  
132 
 
4.2.3 Cc1–/– platelets are hyper-responsive in alpha and dense granule secretion 
following rhodocytin stimulation   
Next, to determine if CEACAM1 similarly to CEACAM2 can attenuate hemi (ITAM 
associated) CLEC-2-mediated responses in murine platelets, alpha and dense granules 
platelet secretion was examined. Furthermore, to examine the cross-talk between 
CEACAM1 and rhodocytin and compare it with CEACAM2 data, washed platelets were 
derived from wild-type and Cc1
–/– 
mice (100x10
9
/L) followed by CLEC-2-selective agonist, 
rhodocytin stimulation (0.4-1.2 µg/mL). The alpha and dense granule release upon 
rhodocytin stimulation was determined for both wild-type and Cc1
–/– 
platelets. Cc1
–/– 
platelets exhibited higher levels of alpha (P-selectin) and dense granule (Quinacrine) release 
at all doses compared to wild-type platelets (Figure 4-4 and 4-5). These results are 
comparable with Cc2
–/– 
platelets upon stimulation with rhodocytin and support the idea that 
CEACAM2 could negatively regulate hemi (ITAM-mediated) CLEC-2 signalling pathways 
in platelets. 
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Figure  4-4: Cc1–/– platelets show increased alpha granule release upon CLEC-2 selective agonist, 
rhodocytin stimulation. P-selectin exposure of wild-type and Cc1
–/–
 washed platelets (100x10
9
/L) was 
determined following stimulation with CLEC-2 selective agonist, rhodocytin (0.6-1.2 µg/mL). Platelets were 
stained with either control or FITC-conjugated CD62P mAb for both wild-type and Cc1
–/–
 platelets. Samples 
were analysed on a FACS Canto II flow cytometer. Data are representative of four independent experiments 
(*P<0.05 and **P<0.01; n=4). 
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Figure  4-5: Cc1–/– platelets display enhanced dense granule release upon CLEC-2 selective agonist, 
rhodocytin stimulation. Quinacrine as fluorescent marker of dense granule release was measured by flow 
cytometry. Wild-type and Cc1
–/–
 washed platelets (100x10
9
/L) were stimulated with rhodocytin at 0.4 and 1.2 
µg/mL. Samples were analysed on a FACS Canto II flow cytometer. Data are representative of four 
independent experiments (**P<0.01 and ***P<0.001; n=4). 
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4.2.4 Tyrosine phosphorylation in Cc2–/– platelets upon CLEC-2 selective agonist, 
rhodocytin stimulation  
As CEACAM2 has an identical ITIM to CEACAM1, we would predict similar 
features including SHP-1 recruitment [244]. To examine the influence on tyrosine 
phosphorylation and key substrates in ITAM-coupled signalling pathways, platelets derived 
from wild-type and Cc2
–/–
 mice were stimulated with rhodocytin (1.2 µg/mL) at T=0 and at 
T=90 seconds. The tyrosine phosphorylation profiles of immunoprecipitated ITAM-coupled 
signalling elements, PLC2, Syk and Src of wild-type and Cc2–/– platelets were determined 
using anti-phosphotyrosine antibody. As shown in Figure 4-6, rhodocytin-stimulated, Cc2
–/–
 
platelets showed a 3.5-fold increase in PLCγ2 tyrosine phosphorylation (0.4063±0.014 vs 
0.1093±0.034; **P<0.01; n=3; Figure 4-6), in the presence of equivalent PLCγ2 antigen 
(bottom panel) compared to wild-type platelets. Moreover, Cc2
–/–
 platelets displayed a 3-
fold increase in Syk tyrosine phosphorylation upon rhodocytin activation (0.4050±0.060 vs 
0.1508±0.029; **P<0.01; n=3; Figure 4-7), in the presence of equivalent Syk antigen 
compared to wild-type platelets. However, Cc2
–/–
 platelets showed similar Src tyrosine 
phosphorylation compared to wild-type platelets, in the presence of equivalent Src antigen 
(0.276±0.087 vs 0.258±0.077; P>0.05 n=3; Figure 4-8). These data suggest that platelet 
CEACAM2 plays a role in attenuating tyrosine phosphorylation of key elements, PLCγ2 
and Syk, but not Src in CLEC-2 ITAM-coupled signalling pathway. 
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Figure  4-6: Cc2–/– platelets display hyper tyrosine phosphorylation of PLCγ2 upon CLEC-2 selective 
agonist, rhodocytin stimulation. Washed platelets (300x10
9
/L) were isolated from wild-type and Cc2
–/–
 mice, 
and then immunoprecipitation of PLCγ2 was performed from platelet lysates at resting versus activation with 
1.2 µg/mL of rhodocytin for 90 seconds at 37
o
C. Immunoblotting was performed to detect phospho-PLCγ2 
using 1/20,000 of a HRP-conjugated anti-phosphotyrosine 4G10 antibody. Equivalence of loading control 
(PLCγ2 antigen; bottom panel) was confirmed by re-probing with a polyclonal anti-PLCγ2 (1/5000), followed 
by HRP-anti-rabbit at 1/20,000 antibodies. The relative intensity of tyrosine phospho-PLCγ2 was determined 
using ImageJ software Version 1.46r. The data shown are a representative blot of similar results for 3 
independent experiments. 
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Figure  4-7: Cc2–/– platelets display hyper tyrosine phosphorylation of Syk upon CLEC-2 selective 
agonist, rhodocytin stimulation. Washed platelets (300x10
9
/L) were isolated from wild-type and Cc2
–/–
 mice, 
and then immunoprecipitation of Syk was performed from platelet lysates at resting versus activation with 1.2 
µg/mL of rhodocytin for 90 seconds at 37
o
C. Immunoblotting was performed to detect phospho-Syk using 
1/20,000 of a HRP-conjugated anti-phosphotyrosine 4G10 antibody. Syk antigen (bottom panel), equivalence 
of loading control was confirmed by re-probing with a polyclonal anti-Syk (1/2000) antibody, followed by 
HRP-anti-rabbit at 1/20,000 antibody. The relative intensity of tyrosine phospho-Syk was determined using 
ImageJ software Version 1.46r. The data shown are a representative blot of similar results for 3 independent 
experiments. 
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Figure  4-8: Cc2–/– platelets displays similar tyrosine phosphorylation of Src upon CLEC-2 selective 
agonist, rhodocytin stimulation. Washed platelets (300x10
9
/L) were isolated from wild-type and Cc2
–/– 
mice, 
and then immunoprecipitation of Src was performed from platelet lysates at resting versus activation with 1.2 
µg/mL of rhodocytin for 90 seconds at 37
o
C. Immunoblotting was performed to detect phospho-Src using 
1/2000 of anti-phospho Src followed by 1/20,000 of anti-rabbit antibodies. Equivalence of loading control (Src 
antigen; bottom panel) was confirmed by re-probing with a polyclonal anti-Src (1/2000) antibody, followed by 
HRP-anti-rabbit at 1/20,000 antibody. The relative intensity of tyrosine phospho-Src was determined using 
ImageJ software Version 1.46r. The data shown are a representative blot of similar results for 3 independent 
experiments. 
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4.3 Discussion 
This chapter aimed to investigate the main hypothesis that CEACAM2 could regulate 
CLEC-2-mediated signalling pathway in murine platelets. In the absence of CEACAM2, 
rhodocytin mediated platelet aggregation (Figure 4-1), together with alpha granule release 
and dense granule release (Figure 4-2 and 4-3; respectively) were enhanced suggesting that 
when present CEACAM2 negatively regulate CLEC-2 ITAM-mediated signalling pathway 
in murine platelets. This is also supported by examination of downstream CLEC-2 ITAM-
mediated signalling components in the absence of CEACAM2 where phospho-Syk and 
phospho-PLC-gamma 2 but not phospho-Src were hyper-tyrosine phosphorylated following 
rhodocytin stimulation compared to wild-type murine platelets (Figure 4-6, 4-7 and 4-8; 
respectively). Similarly, deletion of CEACAM1 resulted in enhanced rhodocytin-mediated 
alpha and dense granule release compared to wild-type (Figure 4-4 and 4-5; respectively). 
To my knowledge there is no report in the literature that indicates that Ig-ITIM 
superfamily members negatively regulate hemi-ITAM CLEC-2 mediated signalling 
pathway in murine platelets. This study provides the first report of CEACAM1 and 
CEACAM2 serving to negatively regulate hemi-ITAM associated CLEC-2 signalling 
pathway in murine platelets. This is also likely to be the case in human platelets. Further 
studies will be required to address this issue. 
Often found operating in tandem, with a separation of between 15 and 30 amino acid 
residues, ITIM contains the consensus sequence (L/I/V/S)xYxx(L/V). Upon tyrosine 
phosphorylated, ITIMs recruit SH2-domain containing protein-tyrosine phosphatases, 
including SHP-1 and SHP-2. This has the effect of inhibiting ITAM-receptor-mediated 
signalling components. ITIM bearing receptors containing an ITIMs and an ITSMs can 
create activation signals, and also restrict activation signals regulated by GPCR [257]. At 
least five ITIM-containing receptors of the immunoglobulin superfamily occur in platelets: 
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PECAM-1, CEACAM1, G6B-b, a triggering receptor expressed on myeloid cell (TREM)-
like transcript-1 and SIRPα [179, 187, 258, 259]. Previous studies have suggested that 
PECAM-1 and CEACAM1 negatively regulate GPVI signalling in murine platelets [178, 
187, 219, 235]. Likewise, cell line modelling using a nuclear factor of activated T-cells 
(NFAT) transcriptional reporter assay showed Syk and Src inhibition by G6B-b and this 
resulted in both GPVI-FcR gamma-chain and CLEC-2 signalling pathways inhibition [180].  
Previous studies by May et al. indicated that antibody-mediated depletion of CLEC-2 
from mouse platelets resulted in normal platelet adhesion under flow. However, in vitro and 
in vivo thrombus formation was severely impaired [260]. In contract, other workers did not 
confirm this finding [261] and suggested that the genetic background of the mice used may 
be a predetermining factor. The results of May et al. raised the possibility of CLEC-2 
playing an important role in thrombus formation and stabilisation. As the CLEC-2 knockout 
mouse was embryonically lethal, it would be difficult to create a double knockout of CLEC-
2 and CEACAM2 [262]. However, for future studies, it would be informative to study the 
synergy between CEACAM2 knockout compared to wild-type mice with and without anti-
CLEC-2 mediated depletion in thrombus formation and stabilisation. 
In conclusion, if CLEC-2 proves to be important in thrombus formation and 
stabilisation, its functional relationship with CEACAM2 could provide a novel target for 
antiplatelet drug therapies to impair pathological thrombus formation. 
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5 Chapter five: In vivo studies of CEACAM2 negative 
regulation of platelet-collagen interactions and thrombus 
formation 
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5.1 Introduction 
Platelet thrombus formation during normal physiological functioning occurs when the 
sub-endothelial matrix component of type I collagen is exposed, facilitating platelet 
adhesion. Matrix exposure can arise from physical trauma, cardiovascular disease, and 
atherosclerotic plaque formation. The ‘2-site, 2-step’ model framework describes the 
processes guiding the complex platelet-collagen interactions. This model assumes that the 
high affinity receptor, integrin-α2β1, controls the initial collagen engagement, and GPVI, a 
low-affinity collagen receptor, activates the interaction [263, 264]. The model proposes a 
secondary function for integrin-α2β1, of facilitating the process rather than acting as the 
primary adhesive collagen receptor. 
There are several mechanisms associated with regulation of platelet thrombus growth 
and stability in vivo. These include the role of thrombin, fibrin and Ig ITIM superfamily 
members linked to Src-domain containing protein tyrosine phosphatases such as SHP-2. 
Thrombin and fibrin exert their effects in the potentiation of the coagulation cascade and 
platelet activation. In contrast, Ig ITIM bearing receptors exert their effect through 
regulation of the initial adhesion and signalling events where their presence would limit the 
surface coverage of platelets to reduce thrombus formation in vivo. 
Platelet- and coagulation-activating factors can induce the formation of thrombi. For 
platelets, collagen found in the extracellular matrix and vascular layers is a major factor, and 
exposure through injury initiates platelet activation and provides a surface for vWF 
mediated adhesion [137]. The main factor prompting coagulation is the tissue factor 
exposed by damage to vascular walls [252]. The arterial and venous systems display 
different modes of thrombosis: arterial thrombus formation is largely induced by platelet 
aggregation through collagen and vWF adhesion, while venous thrombosis is mainly 
initiated by tissue factor instigated coagulation.  
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An important Ig-ITIM immunoreceptor, GPVI, clusters with the FcRγ-chain on the 
platelet membrane to form the GPVI/FcRγ complex. FcRγ also has the ability to interact 
with other receptors expressed on the surface, such as GPIb [3]. Ligation in the presence of 
collagen or related ligands activates this platelet-specific receptor and initiates a sequential 
process involving the tyrosine phosphorylation of a number of signalling molecules [230, 
265]. This process involves predominantly two protein tyrosine kinases belonging to the Src 
family, Fyn and Lyn, where the FcRγ-chain undergoes tyrosine phosphorylation. At the next 
stage of the immunoreceptor signalling pathway, the GPVI-FcRγ-chain-complex activates 
Syk, a tyrosine kinase, which activates a number of downstream signalling proteins, 
including the adaptor or ‘scaffolding’ proteins, LAT and SLP-76; and Vav, a guanine 
nucleotide exchange factor (GEF) regulation G-protein [266]. In the same way, 
phosphoinositide 3-kinase (Pi3K), a protein kinase, activates the Btk/Tec subfamily, which 
stimulates a downstream target, PLCγ2, a phospholipase enzyme. Other downstream protein 
kinases activated as part of the GPVI-activated signalling chain include protein kinase C 
(PKC), Erk-1/2, and focal adhesion kinase (FAK). This signalling event chain induces 
integrin activation in platelets, prompting a number of changes that facilitate a response to 
vascular injury. Integrin activation causes an increase in intracellular free Ca
2+
 levels, 
stimulating increased platelet aggregation, cytoskeletal reorganisation, and granular 
secretion, ultimately leading to coagulation. In conclusion, GPVI is the main activating 
agent for the eventual procoagulant activity of platelets exposed to collagen, both in vitro 
and in vivo [69], but the exact nature and role of the downstream signalling molecules are 
not fully understood. 
A number of in vivo studies on mice support the hypothesis that GPVI may be the 
central receptor during platelet aggregation and thrombus formation in the arterial system. 
Evidence includes recent in vivo studies with mice, where platelet aggregation was assayed 
following the exposure of vascular collagen through arterial ligation [137, 267]. For FcR γ-
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chain deficient mice with no GPVI, or where JAQ1 antibody treatment down-regulated 
GPVI, in vivo platelet aggregation process was restricted. Previous in vitro studies have 
suggested that GPVI is a powerful procoagulant agent that is a central receptor for thrombus 
formation in vivo. 
Previous research suggests that the interaction between collagen and GPVI occurs at 
two separate sites [268]. Platelet activation by GPO-rich peptide CRP is severely inhibited 
by JAQ1, thus it is possible to propose that the antibody binds to the CRP site on the 
receptor, and that this is the main site for collagen binding. As JAQ1 inhibition is reduced at 
higher concentrations of collagen, there may also be a secondary site for interaction between 
GPVI and collagen. By cross-relating this finding with the observation that platelets 
deficient in FcRγ do not interact with collagen, due to absence of GPVI from the platelet 
surface. Previous in vivo studies found that platelets lacking GPVI following JAQ1 
treatment do not respond to collagen. It is possible that there may be binding to an alternate 
GPVI site [267]. It is also possible that there is only a single collagen binding site on GPVI, 
with JAQ1’s inhibiting action moderated by an allosteric effect that lowers GPVI’s affinity 
for collagen and CRP. This would produce exactly the same effect as reducing the number 
of GPVI receptors expressed on the surface of platelets, an effect noted to be greater for 
CRP/GPVI interactions than collagen/GPVI interactions [269]. 
A multi-faceted approach revealed a previously unknown function of CEACAM2, as 
an inhibitory co-receptor found on the surface and in intracellular pools of murine platelets. 
CEACAM2 is a novel platelet immunoreceptor that shown negatively regulates collagen-
GPVI-mediated platelet responses, and regulates type I collagen-mediated platelet in vitro 
(Chapter 3). Therefore, the potential involvement of CEACAM2 in regulating platelet-
collagen interactions and platelet thrombus formation and growth under in vitro flow 
conditions and in vivo is unknown. The aim of this chapter was therefore to examine the 
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contribution of CEACAM2 role in contact-dependent platelet adhesion under in vitro flow 
conditions and in vivo platelet thrombus formation. 
5.2 Results 
5.2.1 CEACAM2 regulation of platelet thrombus formation is dependent on platelet–
collagen interactions under arterial flow in vitro 
As Cc2
–/–
 platelets displayed strong adhesion on immobilised type I collagen (Figure 2-8), 
in vitro flow studies were performed to determine the functional role of CEACAM2 in 
modulating platelet thrombus formation. Rhodamine-labelled whole blood from both wild-
type and Cc2
–/–
 mice was perfused onto immobilised type I fibrillar collagen at arterial 
shear rate of 1800 seconds
-1
. Six minutes of blood perfusion was monitored, thrombi 
images were recorded in real-time for wild-type and Cc2
–/–
 platelets (Figure 5-1A). Z-
stacks were deconvolved and thrombus parameters of thrombus area, height and volume 
were determined. Cc2
–/–
 platelets exhibited a significant increase in thrombus area 
compared to wild-type platelets (2303±470.6 vs 907.2±87.26 µm
2
; ***P<0.001; n=10; 
Figure 5-1B; at 4 minutes). Similarly, Cc2
–/–
 platelets showed increased kinetics of 
thrombus volume over time compared to wild-type platelets (30480±3822 vs 12480±588.2 
µm
3
; ***P<0.001; n=10; at 4 minutes; Figure 5-1C). As Cc2
–/–
 females are obese and 
insulin resistant [188] and Cc2
–/–
 males are lean and insulin sensitive [241] and platelet 
activation is associated with diabetes, we sex-stratified the in vitro thrombus formation to 
investigate a potential sexual dimorphic effect. Based upon sex stratified data, Cc2
–/–
 
platelets showed increased thrombus volume to a similar extent in both male and female 
mice compared to wild-type platelets (*P<0.05; Figure 5-1D). Collectively, platelet 
adhesion onto immobilised type I collagen under arterial flow demonstrated that 
CEACAM2 is important in regulating platelet thrombus formation in vitro under flow on 
type I collagen. 
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Figure  5-1: Cc2–/– platelets display greater adhesion and thrombus formation under arterial flow on immobilised type I collagen. (A-D) Rhodamine-labelled whole 
blood of wild-type and Cc2
–/–
 mice was perfused over 500 µg/mL type I fibrillar collagen-coated µ-slide III
0.1
 at a shear wall flow rate of 1800 seconds
-1
. Z-stack images 
were recorded over 6 minutes with a Zeiss Axiovert microscope captured with Axiocam MRm camera and analysed using Zeiss Axiovision Rel4.6 software. Thrombi 
formed were analysed by deconvolution and 3D reconstructions. (A)  Images of in vitro thrombus formation under arterial flow on immobilised type I fibrillar collagen for 
both wild-type and Cc2
–/–
 platelets over 6 minutes. (B) Thrombus area (µm
2
) over time was calculated based on surface area measurement of thrombi. (C) Kinetics of 
thrombus volume (µm
3
) over time was derived by multiplying thrombus area (µm
2
) with thrombus height (µm) for both wild-type and Cc2
–/–
 (■) platelets (30480±3822 vs 
12480±588.2 µm
3
; ***P<0.001; at 4 minutes; n=10). (D) Thrombus volume (µm
3
) data from panel C was stratified according to sex, male and female for both wild-type 
and Cc2
–/–
 platelets at the 4 minutes time point (*P<0.05; n=5/group). These data are representative of at least ten independent experiments performed and results represent 
mean ± SEM.  
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5.2.2 CEACAM2 role in FeCl3–induced vascular injury of mesenteric arterioles 
Next, to determine whether CEACAM2 plays a similar role to PECAM-1 or 
CEACAM1 in platelet thrombus formation in vivo, the FeCl3-induced vascular injury model 
of mesenteric arterioles was utilised for wild-type and Cc2
–/–
 mice. This method used to 
induce vascular injuries and encourage thrombus formation is exposure to FeCl3 solution 
[270]. This compound physically damages blood vessels by ablating the endothelium to 
reveal the subendothelial matrix proteins [207]. To explore the effects of FeCl3-induced 
injury on in vivo mouse arterioles, a 7.5% (w/v) FeCl3 solution was administered to the 
mesentery adventitial surface for a four minute period, causing an injury. Thrombus growth 
characteristics were observed by measuring the fluorescently labelled platelets bound at 
injury sites. In anaesthetised mice, the appropriate size of mesenteric arterioles (80-100 µm) 
was identified and the animal was infused with rhodamine 6G dye. Thrombus formation 
was monitored in real time in wild-type and Cc2
–/–
 murine arterioles over 10 minutes period. 
Z-stack images were deconvolved and analysed using the Zeiss Axiovert microscope and 
Axiovision Rel4.6 software. The thrombus formation parameters of thrombus area, height 
and volume, percentage of vessel occlusion and stability score were determined. 
Representative images of Cc2
–/–
 arterioles display an increase in thrombus formation 
particularly at 2-4 and 4-6 minutes compared to wild-type arterioles (Figure 5-2A). The 
kinetics of thrombus area, height and volume were increased gradually in Cc2
–/–
 arterioles 
compared to wild-type arterioles (Figure 5-2B-D). 
Thrombus formation parameters were quantified at all time points (0-2, 2-4, 4-6, 6-8 
and 8-10 minutes) using Z-stack deconvolved images. Following Z-stack analysis at 4-6 
minutes of thrombus formation, Cc2
–/–
 arterioles showed increased thrombus growth and 
stability over ten-minutes, and they had a larger surface coverage of platelets (thrombus 
area) than wild-type arterioles (6145±125.6 vs 5627±117.7 µm
2
; **P<0.001; n=30/group; 
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Figure 5-3A). Moreover, thrombus height in Cc2
–/–
 arterioles was greater compared to wild-
type arterioles (27.33±0.926 vs 19.95±0.406 µm; ***P<0.0001; n=30/group; Figure 5-3B). 
Furthermore, thrombus volume in Cc2
–/–
 arterioles was significantly larger (166900±7601 
vs 120500±2390 µm
3
; ***P<0.0001; n=30/group; Figure 5-3C), and the percentage of 
vessel occlusion was larger compared to wild-type arterioles (67.77±1.363 vs 29.79±1.239; 
***P<0.0001; n=30/group; Figure 5-3D). The stability score of thrombi formed in Cc2
–/–
 
arterioles was higher than in wild-type arterioles (7.267±0.143 vs 3.493±0.136; 
***P<0.0001; n=30/group; Figure 5-3E). Cc2
–/–
 arterioles showed no difference in the time 
to first thrombus larger than 20 µm
2
, and time to vessel occlusion (P > 0.05; n=30), when 
compared to wild-type arterioles. These differences suggest that GPVI, for FeCl3-induced 
arteriole injuries, plays a significant role in encouraging platelet aggregation. 
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Figure  5-2: Cc2–/– mice display larger and more stable thrombi in vivo. (A) Z-stack thrombus formation images of FeCl3-induced vascular injury were monitored in 
arterioles of wild-type versus Cc2
–/–
 mice over 0-2, 2-4, 4-6, 6-8 and 8-10 minutes. The different lengths of time after FeCl3 application are specified. Note that thrombi are 
larger in Cc2
–/–
 arterioles over time compared to wild-type control arterioles (n=30 per group). (B-D) Quantitative analysis of arterial thrombogenesis of wild-type (●) 
versus Cc2
–/–
 (■) arterioles. (B) The kinetics of thrombus area (surface area of thrombi) in µm2 and height in µm were measured (**P<0.001 and ***P<0.0001; n=30). (C) 
The kinetics of thrombus height was also calculated. Cc2
–/–
 arterioles displayed a significantly larger thrombus height at 2-4, 4-6, 6-8 and 8-10 minutes  compared to wild-
type arterioles (***P<0.0001; n=30 per group). (D) The kinetics of thrombus volume of wild-type versus Cc2
–/–
 arterioles over time was reliably measured. Cc2
–/–
 arterioles 
was significantly increased at 4-6 minutes compared to wild-type arterioles (166900±7601 vs 120500±2390 µm
3
; ***P<0.0001; n=30 per group). These data are 
representative of at least 30 independent experiments performed and results represent mean ± SEM. Each symbol represents one arteriole of three examined per mouse. 
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Figure ‎5-3: Cc2–/– mice display larger and more stable thrombi in vivo. (A-E) Thrombus formation images of FeCl3-induced vascular injury were monitored in arterioles 
of wild-type versus Cc2
–/–
 mice over 10 minutes. Quantitative analysis of arterial thrombogenesis of wild-type (●) versus Cc2–/– (■) arterioles at time 4-6 minutes were 
calculated. Note that thrombi are larger in Cc2
–/–
 arterioles over time compared to wild-type control arterioles (n=30 per group). (A) Thrombus area in µm
2
, (B) thrombus 
height in µm, (C) thrombus volume in µm
3
, (D) Average percentage (%) of vessel occlusion  and (E) The thrombus stability was scored from 1 to 10, with 1 being 0% to 
10% occupancy and 10 being 91% to 100% occupancy (i.e. complete vessel occlusion) visualised over time. Cc2
–/–
 arterioles showed greater stability in thrombi formed 
(7.267±0.143 vs 3.493±0.136; ***P<0.0001; n=30 per group). Cc2
–/–
 arterioles displayed a significantly larger thrombus area, height, volume and % vessel occlusion at 4-6 
minutes compared to wild-type arterioles (***P<0.0001; n=30 per group). These data are representative of at least 30 independent experiments performed and results 
represent mean ± SEM. Each symbol represents one arteriole of three examined per mouse. 
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5.2.3 CEACAM2 role in Laser-induced vascular injury of cremaster arterioles 
The Ig-ITIM superfamily members, PECAM-1 and CEACAM1, negatively regulates 
platelet GPVI-collagen interactions and thrombus growth, in vitro and in vivo [187, 219]. 
Thus, we tested whether CEACAM2 plays a similar role in platelet thrombus formation in 
vivo. The FeCl3-induced vascular injury model of mesenteric arterioles and laser-induced 
vascular injury of cremaster arterioles were utilised for wild-type and Cc2
–/–
 mice. 
Thrombus growth characteristics were observed by measuring the fluorescently labelled 
platelets bound at injury sites. 
It has long been established that platelet aggregation is the main precursor of arterial 
thrombosis, making it important to understand the processes behind platelet activation and 
thrombus formation. To study the stability of thrombi in vivo, a direct visualisation 
technique was used, which allowed a detailed examination of the kinetics of Cc2-deficient 
platelets during thrombus formation. This temporal, three-dimensional observation uses 
confocal microscopy, with high-resolution imaging providing detailed representations of 
how individual platelets behave in mesenteric arterioles [271, 272]. The laser technique 
utilises precise thermal injury with lasers to generate highly reactive oxygen molecules and 
free radicals that physically damage the arteriole endothelium. A number of studies have 
examined in vivo thrombus formation after laser-induced exposure of the arteriole 
subendothelial matrix in the cremaster muscle microcirculatory system of mice [206, 273, 
274]. Building upon these findings, this research suggested that Ceacam2-null mice 
displayed a higher accumulation of platelets than the wild type control group (Figure 5-4).  
Thrombus formation parameters were analysed at 2-4 minutes using Z-stack 
deconvolved images. Following laser-induced vascular injury of cremaster arterioles, Cc2
–/–
 
and Cc1
–/– 
arterioles had greater thrombus volume compared to wild-type arterioles 
(37355±702.6 vs 31956±785.1 vs 15578±543.7, respectively; ***P<0.0001; n=30/group; at 
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2-4 minutes; Figure 5-4D). Furthermore, the stability score of thrombi formed in Cc2
–/–
 
arterioles was more stable than Cc1
–/–
 and wild-type arterioles (5.733±0.143 vs 4.80±0.010 
vs 2.967±0.0894, respectively; ***P<0.0001; n=30/group; Figure 5-4F). Likewise, Cc2
–/–
 
platelets showed increased the kinetics of thrombus area, height, volume, vessel occlusion 
and stability over time compared to wild-type platelets (Figure 5-5). The visualisation 
showed that over time more Cc2-deficient platelets aggregated at the injury site and form 
more stable thrombi than wild-type platelets (Figure 5-4 and 5-5). This significant 
difference suggests that CEACAM2 plays a major role in stabilising thrombus formation at 
sites of laser-induced vascular injury of cremaster arterioles. Overall, the results suggest 
that, for vascular wall injuries caused by laser, Cc2-deficient cremaster arterioles develop 
larger thrombi that are more stable over time. 
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Figure  5-4: In vivo imaging of thrombus formation after laser-induced injury of cremaster muscle arterioles. (A-F) Platelet thrombus formation in response to laser 
induced injury in wild-type (●), Cc1–/– (■) and Cc2–/– (▲) arterioles. Thrombus volume in Cc2–/– and Cc1–/– arterioles was significantly greater than wild-type arterioles 
(37355±702.6 vs 31956±785.1 vs 15578±543.7, respectively; ***P<0.0001; n=30 per group) and displayed greater stability in thrombi formed (5.733±0.143 vs 4.80±0.010 
vs 2.967±0.0894, respectively; ***P<0.0001; n=30 per group). These data are representative of at least 30 independent experiments performed and results represent mean ± 
SEM. Each symbol represents one arteriole of three examined per mouse. 
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Figure  5-5: In vivo kinetics of thrombus formation after laser-induced injury of cremaster muscle arterioles. (A-E) Kinetic of platelet thrombus formation in response 
to laser induced injury in wild-type (●), Cc1–/– (■) and Cc2–/– (▲) arterioles. Thrombus area, height, volume, % of vessel occlusion and stability score in Cc2–/– and Cc1–/– 
arterioles was significantly greater than wild-type arterioles. These data are representative of at least 30 independent experiments performed and results represent mean ± 
SEM. Each symbol represents one arteriole of three examined per mouse. 
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5.2.4 The role of CEACAM2 in GPVI-depleted platelets in thrombus formation in 
vivo 
As GPVI collagen receptors interact directly with type I collagen during thrombus 
formation, GPVI was depleted in vivo for five days prior to FeCl3 injury treatment with the 
GPVI neutralising antibody, JAQ1 (100 µg/mouse) [137]. GPVI depletion was confirmed 
using Western blotting of wild-type and Cc2
–/–
 platelet lysate (not shown). Different cohorts 
of wild-type and Cc2
–/–
 mice were treated with negative isotype control IgG (100 
µg/mouse). Compared to wild-type isotype control treated or untreated wild-type arterioles, 
JAQ1-treated Cc2
–/–
 arterioles displayed significant differences for a two-fold reduction in 
thrombus volume and stability score (***P<0.001; n=10/group; Figure 5-6C). Importantly, 
upon JAQ1 treatment, Cc2
–/–
 arterioles displayed reversal of the increased thrombus 
stability and growth phenotype compared to wild-type arterioles (4.80±0.359 vs 3.30±0.213; 
***P<0.001; n=10/group; Figure 5-6E). In general, these results suggest that CEACAM2, in 
tandem with GPVI, contributes to the more stable thrombus phenotype. 
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Figure ‎5-6: Reversal of more stable thrombus growth phenotype in Cc2–/– arterioles following GPVI depletion. (A-E) Thrombus formation in response to FeCl3 after 
inhibition of mouse GPVI with specific monoclonal antibody (mAb) JAQ1 administration to wild-type and Cc2
–/–
  mice compared with control IgG-treated wild-type and 
Cc2
–/–
 or untreated wild-type and Cc2
–/–
 mice. Thrombus parameters including (A) thrombus area, (B) thrombus height, (C) thrombus volume, (D) % of vessel occlusion 
and (E) stability score were calculated at 10 minutes of thrombus formation. Compared with untreated Cc2
–/–
 or control IgG-treated Cc2
–/–
 arterioles, JAQ1-treated Cc2
–/–
 
arterioles displayed around 2-fold smaller thrombus volume at 10 minutes (154300±4741 vs 144600±6613 vs 70050±5077 µm
3
, respectively; ***P<0.0001; n=10 arterioles 
from 3 mice/group) and (E) around 2-fold lower stability score at 10 minutes (7.500±0.166 vs 7.400±0.371 vs 4.800±0.359, respectively; ***P<0.0001; n=10 arterioles 
from 3 mice/group). In contrast, compared with untreated wild-type or control IgG-treated wild-type arterioles, JAQ1-treated wild-type arterioles displayed around 3-fold 
smaller thrombus volume at 10 minutes (118700±5102 vs 109800±4497 vs 55080±5269 µm
3
, respectively; ***P<0.0001; n=10 arterioles from 3 mice/group) and a 
moderately lower stability score at 10 minutes (4.100±0.100 vs 4.600±0.163 vs 3.300±0.213, respectively; **P<0.01; n=10 arterioles from 3 mice/group). These data are 
representative of at least ten independent experiments performed and results represent mean ± SEM. Each symbol represents one arteriole of three examined per mouse. 
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5.3 Discussion 
It is known that atherosclerotic plaque rupture exposes high levels of type I collagen 
which induces localised thrombus formation via the adhesion of platelets to exposed 
subendothelial matrix components in vascular walls. This initiates a cascade process that 
leads to coagulation. To examine how CEACAM2 contributes to platelet aggregation and 
pathological thrombus formation, two methods for inducing arterial injury were used, for 
wild type and Cc2-deficient mice, and for two types of vascular beds. FeCl3 was added, to 
induce injury and expose the subendothelial matrix in mesenteric arterioles and laser was 
utilised to induce injury in cremaster arterioles. The resulting formation of thrombi was 
examined over a 10 minute time period, using in vivo intravital microscopy and Z-stack 
images to provide a spatial context.  
Unlike CEACAM1, the physiologic role of platelet CEACAM2 in thrombus 
formation in vivo had not been determined. These two receptors share some structural 
similarities, but differ in the number of extracellular Ig-Domains and in the ligand binding 
properties of their distal variable N-terminal Ig-Domain. The fact that CEACAM2 has 
different ligand properties than CEACAM1 would suggest unique biological roles as the 
avidity of ligand interactions (activation versus clustering) appears fundamental to drive cell 
signalling responses. In recent studies, CEACAM2 appears to function in a similar way as 
CEACAM1, at least in the context of insulin metabolism [188].
 
A more recent study has 
demonstrated that a closely related Ig-ITIM superfamily member, CEACAM1 serves as a 
negative regulator of platelet collagen GPVI-FcR -chain mediated signalling [187]. Using 
intravital microscopy to FeCl3-injured mesenteric arterioles, we have shown that thrombi in 
Cc2
–/–
 mice are larger and are more stable over time than wild-type mice providing evidence 
that CEACAM2 negatively regulates platelet-collagen interactions and thrombus growth in 
vivo. Collectively, this study has highlighted that these cell surface receptors interact with 
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their ligands and have the ability to negatively modulate downstream signalling events and 
thrombus formation. 
This chapter describes real time observation via intravital microscopy to reveal how 
CEACAM2 influences thrombus formation in vitro and in vivo, and highlights the 
importance of CEACAM2 in regulating thrombus formation on immobilised collagen under 
arterial flow conditions produced in vitro. Under in vitro conditions of physiological arterial 
shear flow, absence of CEACAM2 results in increased surface coverage of platelets on 
immobilised type I collagen (Figure 5-1). There was no evidence of sexual dimorphism in 
this enhanced thrombus growth phenotype of Cc2
–/–
 platelets. Moreover, to observe the 
processes under different conditions, we included vascular injury of mesenteric arterioles 
induced by FeCl3 and laser-induced vascular injury of cremaster arterioles. FeCl3-induced 
injury exposed a number of sub-endothelial collagen types, allowing collagen-GPVI 
platelets to interact with the exposed type I collagen. Thus, FeCl3-induced injury led to 
larger thrombi, in terms of area and volume, among mice lacking CEACAM2 than in wild-
type mice (Figure 5-2). Importantly, these differences were consistent over time, and the 
thrombi in Cc2
–/–
 null mice were more stable than in the wild-type control group (Figure 5-
3). The in vivo thrombus stability phenotype observed in Cc2
–/–
 mice required platelets with 
GPVI receptor sites (Figure 5-6). Using the laser-induced vascular injury model, Cc2
–/–
 
cremaster muscular arterioles displayed an increase in thrombus volume and thrombi that 
were more stable compared to wild-type arterioles (Figure 5-4D, F). Therefore, using 
several models of microvascular thrombosis in vivo, we have shown that CEACAM2 
deletion results in larger and more stable thrombi than wild-type mice and that this is at least 
partly depends on the presence of GPVI (Figure 5-6). This suggests that CEACAM2 
negatively regulates thrombus growth, in vivo, in both mesenteric and cremaster muscle 
arterioles. Future studies could compare the relative importance of platelet-expressed 
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CEACAM2 with the endothelial type in regulating the in vivo growth of thrombi. 
CEACAM2 is a third example of the Ig-ITIM superfamily that negatively regulates the 
stationary adhesive signalling of platelet-collagen interactions and thrombus growth in vivo. 
Previous research into arteriole thrombus formation in PECAM-1 and CEACAM1–
deficient mice, using the FeCl3 vascular injury model, revealed slight differences in the time 
taken to reach the 75% vessel occlusion level [178, 187]. Overall, the mean rate of vessel 
occlusion in PECAM-1
–/–
 and Cc1
–/– 
mice was slightly shorter than for the control group. By 
contrast, the laser-induced injury model, which does not expose type I collagen but 
promotes tissue factor generated platelet/fibrin thrombi, produced a larger response [178]. 
This suggests that PECAM-1, CEACAM1 and CEACAM2 all contribute to negative 
regulation during in vivo platelet-collagen interactions and thrombus formation. 
Whether CEACAM2 regulates thrombin signalling in platelets remains unknown. In 
response to thrombin (at 0.25-1.0 U/mL), Cc2
–/–
 platelets had comparable amplitude and 
slope of thrombin-mediated aggregation responses compared to wild-type platelets (Figure 
3-5). In addition, GPCR platelet aggregation mediated by ADP, thrombin and PAR-4 
agonist peptide were comparable in Cc2
–/–
 and wild-type platelets (Figure 3-3). Moreover, 
Cc2
–/–
 platelets had similar alpha and dense granules release upon thrombin and PAR-4 
agonist peptide stimulation compared to wild-type platelets (Figure 3-6A and 3-7A). While 
these results would argue against CEACAM2 regulating thrombin signalling, more studies 
using thrombin at subthreshold concentrations are needed to fully address this question.  
Moreover, the laser injury model used in this study is mediated by thrombin:tissue factor 
inflammatory process and the Cc2
–/–
 arterioles had increased thrombi that were more stable 
under these conditions (Figure 5-5). Thus, more studies are needed to investigate whether 
CEACAM2 affects thrombin signalling pathway. 
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Unlike human platelets, murine platelets lack the low-affinity IgG receptor, 
FcgammaRIIa, but contain two ITAM-bearing receptors, GPVI/FcR gamma chain and 
CLEC-2. Based on our in vivo mouse thrombus models, we show that Cc2
–/–
 arterioles have 
larger thrombi that are more stable in response to type I collagen exposure (i.e: FeCl3-
induced vascular injury of mesenteric arterioles; Figure 5-2) and thrombin-driven processes 
without type I collagen exposure (i.e: laser induced injury of cremaster muscle arterioles 
[224, 275]; Figure 5-5). This was also the case for Cc1
–/–
 (in this Chapter) and PECAM-1
–/–
 
arterioles [178]. While GPVI depletion resulted in the reversal of thrombus growth, 
thrombus stability was less affected indicating the involvement of other potential 
mechanisms regulating thrombus stability (Figure 5-3E). 
Like CEACAM1, CEACAM2 plays a role in limiting thrombi formed under 
conditions of type I collagen exposure such as in the pathological process of atherosclerotic 
plaque rupture. Further studies are required to decipher its role in other mechanisms in 
platelet function, thrombus stabilisation and wound healing. 
In conclusion, the chapter has defined the importance of CEACAM2 as an inhibitory 
co-receptor in murine platelets in platelet-collagen interactions in vivo. CEACAM2 is a 
negative regulator of platelet-collagen interactions and platelet thrombus formation and 
growth in vivo. CEACAM2 restricts arteriolar thrombus growth and postpones the 
development of thrombosis linked to type I collagen. Ultimately, this could be beneficial as 
it could lower the rate of thrombus formation in vessels with disease or with ruptured 
atherosclerotic plaques that expose the type I collagen matrix. 
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6 Chapter Six: In vitro studies of CEACAM2 positive 
regulation of integrin αIIbβ3-mediated platelet functions 
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6.1 Introduction 
The process of platelet aggregation at sites of vascular injury is complex and the exact 
roles of CEACAM2 and integrin αIIb3 are not known. During normal haemostasis and 
thrombogenesis, platelets aggregate and adhere to damaged vascular surfaces, creating a 
haemostatic plug [276]. By contrast, under diseased conditions such as those created by 
atherosclerotic lesions, vascular rupture leads to exposure of type I collagen resulting in 
platelet aggregation and formation of pathological thrombi [277]. In vivo, platelets rarely 
react with inactivated endothelial surfaces, but become more active in the presence of 
stimulated or injured vascular surfaces, and will undergo rolling, adherence, translocation or 
detachment processes [276, 278-280].  
The processes governing platelet adhesion and aggregation at sites of vascular injury 
are complex and involve a number of stages and substrates, including vWF and collagen. 
Under different flow conditions, numerous receptors are involved, including integrin αIIbβ3, 
integrin α2β1, collagen GPVI and GPIb/IX/V complex. Under conditions of high flow and 
shear stress, the initial platelet tethering requires vWF to interact with the amino-terminal 
domain of the GPIbα subunit [276, 278]. In turn, this leads to integrin αIIbβ3 activation, a 
precursor for the mediation of (i) irreversible stable adhesion, (ii) cytoskeletal 
reorganisation, (iii) platelet spreading, (iv) platelet aggregation, and (v) stable thrombus 
formation and growth [277]. To promote cytoskeletal reorganisation, fibrinogen and 
integrin αIIbβ3 bind and stimulate platelet adhesion and activation, creating intracellular 
signals that nucleate the reorganisation process. Finally, integrin-agitating receptors undergo 
conformational changes when integrin αIIbβ3 is stimulated by agonist-induced activation. 
During this process, the receptor converts from a resting, low-affinity state to an active, 
high-affinity state, where it binds its soluble ligand, fibrinogen. 
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To facilitate bidirectional signalling, integrin αIIbβ3 uses two types of signalling event, 
an ‘inside-out’ process, usually under conditions of agonist induced stimulation, and an 
‘outside-in’ process, which incorporates fibrinogen-occupied integrin αIIbβ3 post-ligand 
integrin αIIbβ3 binding. These signalling events are responsible for stimulating irreversible 
stable platelet adhesion and thrombus growth, by influencing processes such as cytoskeleton 
reorganisation, the retraction of clots, platelet aggregation and microvesicle formation. A 
genetic abnormality in integrin αIIb3 leads to defects in ligand binding, prolonged bleeding 
time and platelet aggregation in Glanzmann’s Thrombasthaenia patients [281]. 
Prototypic platelet ITIM-bearing receptors, PECAM-1 and CEACAM1, have 
previously been shown to be negative regulators of platelet-collagen-GPVI interactions and 
positive regulators of integrin αIIbβ3-mediated platelet functional responses [187, 219]. As 
earlier discussed in chapters 3 and 5, CEACAM2 has also been confirmed as a negative 
regulator of platelet collagen GPVI interactions in vitro and in vivo. Importantly, 
CEACAM2 and CEACAM1 share some similarity in structure, but differ in their number of 
extracellular Ig-Domains and in the ligand binding properties of their distal variable N-
terminal Ig-Domain. CEACAM2 contains 2 Ig-Domains while CEACAM1 contains 4 
extracellular Ig-Domains. Furthermore, CEACAM2 N-terminal variable Ig-Domain 1 does 
not allow homophilic binding, while CEACAM1 N-terminal variable Ig-Domain 1 mediates 
homophilic binding [186]. At this stage the only ligand identified for CEACAM2 is the 
murine coronavirus mouse hepatitis virus spike glycoprotein (s). Both CEACAM2 and 
CEACAM1 contain transmembrane receptors and contain identical ITIMs in their 
cytoplasmic domains. The role of CEACAM2 genes in platelet function is not clearly 
defined but it is important to study CEACAM2 in murine platelets in terms of integrin αIIbβ3 
responses because it will help understand the function of human CEACAM1 in platelets as 
it represents the sum of mouse CEACAM2 and CEACAM1. 
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As CEACAM1 has been reported to have a physiological relationship with β3 integrin, 
it raises the possibility that CEACAM2 might also have a relationship with integrin αIIbβ3 in 
murine platelets. This chapter aimed to assess if CEACAM2 has any functional association 
with integrin αIIb3, the major glycoprotein present in platelets. Therefore, this chapter 
aimed to investigate the functional properties of Cc2
–/–
 platelets during integrin αIIb3-
dependent events; and differences in the roles of platelet CEACAM2 during the adhesive 
and signalling events connected to haemostasis and thrombosis.  
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6.2 Results 
6.2.1 In vivo tail bleeding analysis  
Murine platelets and other cell types, including intestinal tissue crypt epithelia, kidney 
cells and testis, express CEACAM2, so a series of in vivo tail bleeding assays allowed a 
thorough examination of the mice for abnormal vascular or platelet-mediated haemostasis. 
In order to test if CEACAM2 plays a role in primary haemostasis in vivo, tail bleeding times 
and volume of blood lost were tested for Cc2
–/–
 mice compared to wild-type mice. As shown 
in Figure 6-1A, a significant difference in the mean tail bleeding times between the wild-
type and Cc2
–/–
 groups was observed. In addition, the data-spread further revealed longer 
bleeding times for CEACAM2-deficient mice (***P<0.001, n=20). Overall, the Cc2
–/–
 mice 
lost double the mean volume of blood during tail bleeding (*P<0.05, n=20; Figure 6-1B). 
 
 
Figure ‎6-1: Cc2–/– mice displayed prolonged tail bleeding times and increased volume of blood lost. Tail 
bleeding measurement of wild-type and Cc2
–/– 
mice was assessed using 6-8 week old age and sex-matched 
mice (A) Tail bleeding time was recorded from the time of initial tail cessation (***P<0.001, n=20/group). 
(B)  The volume of blood lost during tail bleeding time was measured in both mice (***P<0.001, 
n=20/group). Both tail bleeding time and blood lost are greater in Cc2
–/– 
mice compared to wild-type mice. 
Data are representative of at least of 20 independent experiments per group and presented as mean ± SEM.  
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6.2.2 Cc2–/– platelets display delayed kinetics of clot retraction in vitro 
The main scope of this chapter involved detecting any significant differences in the 
clot retraction processes and dynamics of Cc2
–/–
 and wild-type platelets, preceding a multi-
stage investigation of the potential reasons behind any dissimilarity. To operationalise the 
experiment and reduce the impact of potential confounding variables, it was important to 
highlight any physiological differences between the two mice genotypes from the outset. An 
initial examination showed that the CEACAM2-deficient mice were otherwise healthy and 
had normal Mendelian inheritance characteristics [188, 241]. In addition, haematological 
parameters were examined in Cc2
–/–
 mice and revealed a normal range, including platelet 
production (Chapter 3). In vitro evidence suggested that modulation of integrin αIIbβ3–
mediated functions was influenced by engagement of PECAM-1 and CEACAM1 receptors, 
so the next stage involved testing if a fundamental integrin αIIbβ3 platelet abnormality 
existed in the CEACAM2 deficient platelets. Integrin αIIbβ3 is crucial for normal platelet 
aggregation, platelet spreading and clot retraction functionality, so the research involved 
examining any significant differences in the kinetic properties of the clot retraction process 
in Cc2
–/–
 compared to wild-type platelets. 
To initiate clotting, 2.5U/mL thrombin was added to the wild-type and Cc2
–/–
 
normalised platelet count (PRP; 100x10
9
/L) groups, at a temperature of 37°C. For the first 
hour, clots were observed at ten minute intervals, with further observation over a 24-hour 
period. To display the clotting process in detail, digital camera technology was used and 
imaged were captured at various time points (0-24 hours). The Cc2
–/– 
platelets revealed a 
significant delay in the kinetics of clot retraction when compared to wild-type platelets 
(Figure 6-2A). After 30 minutes, Cc2
–/– 
platelets showed no clot retraction (data not shown), 
with partial retraction after four hours, and nearly complete retraction after 10-24 hours. In 
contrast, wild-type platelets showed faster clot retraction, with partial retraction after 30 
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minutes and complete retraction after 4 hours. To further investigate this observation, the 
remaining volume of serum, after the removal of the fibrin clots, was measured as described 
in the methodology section. The Cc2
–/– 
platelets revealed a 2-fold reduction in serum volume 
compared to the wild-type group after 4-10 hours (P<0.05, n=4; Figure 6-2B) To exclude 
the possibility that the expression level of integrin αIIbβ3 could affect the clot retraction 
process, surface expression of integrin αIIbβ3 was measured on the Cc2
–/– 
platelets by flow 
cytometry and displayed normal expression. This suggested that the defect in the clot process 
was not related to the reduced expression of integrin αIIbβ3 on the surface of the Cc2
–/– 
platelets (Figure 6-2C). This data was further supported by the normal expression of CD9 
and CD44 on Cc2
–/– 
platelets, making it possible to conclude that CEACAM2 is essential for 
optimal ‘outside-in’ integrin αIIbβ3–mediated signalling events in murine platelets. 
  
 
1
6
8
 
 
Figure  6-2: Cc2–/– platelets display delayed kinetics of clot retraction compared to wild-type platelets. Normalised PRP from wild-type and Cc2–/– mice was stimulated 
with 2.5 U/mL of thrombin over time points. (A) Digital photographs display in vitro kinetics of clot retraction over a 10-hour time period. Each photograph is 
representative of at least 4 independent experiments. (B) Following a 2.5 U thrombin stimulation, serum volume was also recorded from wild-type and Cc2
–/– 
platelets after 
clot retraction at 1, 2, 4 , 8  and 24 hours. (C) Surface expression of several glycoproteins was measured on platelet surface including integrin αIIbβ3, CD9 and CD44. Data 
shown are representative of at least 4 independent experiments and presented as mean ± SEM. 
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6.2.3 Cc2–/– platelets display normal static platelet adhesion to integrin αIIbβ3-mediated 
matrices 
Clot retraction is an integrin αIIbβ3-mediated function involving cytoskeletal 
reorganisation as part of the process. Therefore, in order to investigate the role of CEACAM2 
in cytoskeletal reorganisation, the spreading of Cc2
–/– 
platelets on immobilised fibrinogen was 
compared to that of wild-type platelets. The next stage determined if CEACAM2 deficiency 
modulates integrin αIIbβ3–mediated adhesive events, by evaluating the static platelet adhesion 
responses of wild-type and Cc2
–/– 
platelets in the presence of immobilised fibrinogen (100 
µg/mL), as an ECM protein, over a 0-60 minute period. A negative control was performed 
using adhesion to RCD buffer, pH 7.4. After the washing steps, the number of platelets 
adhering to fibrinogen was quantified using DIC microscopy (x63 oil lens). Under static 
conditions, Cc2
–/– 
platelets displayed decreased kinetics of platelet adhesion to fibrinogen when 
measured at 30, 45 and 60 minute intervals compared to wild-type platelets (**P<0.01; n=4; 
Figure 6-3). However, as shown in chapter 3, Cc2
–/– 
platelets demonstrated increased platelet 
adhesion to type I fibrillar collagen when measured at intervals of 15, 30, 45 and 60 minutes 
(Chapter 3; Figure 3-8). Further emphasising this variation, without agonist stimulation, Cc2
–/– 
platelets displayed reduced spreading surface area on both fibrinogen and type
 
I collagen in 
comparison to the wild-type group (***P<0.001 and **P<0.01; n=100 platelets). As shown in 
Figures 6-4A-C, the delay in spreading was corrected when the platelets underwent agonist 
stimulation at concentrations of 20 µM ADP, 0.5 mM PAR-4 agonist peptide, or 100 nM PMA. 
In conclusion, the differing static platelet adhesion responses suggest that absence of 
CEACAM2 had no noticeable effect on platelet adhesive properties where inactive integrin 
αIIbβ3 binds to an immobilised ligand, fibrinogen. In addition, when platelets are undergoing 
adhesion to immobilised fibrinogen and type I collagen, Cc2
–/– 
platelets displayed reduced 
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cytoskeletal reorganisation capability compared to wild-type platelets. This lends credence to 
the idea that Cc2
–/– 
platelets have a moderately defective integrin αIIb3-mediated functionality. 
 
 
 
Figure  6-3: Cc2–/– platelets demonstrate a reduction in platelet adhesion on fibrinogen. Time course of wild-
type and Cc2
–/–
 platelet adhesion to either buffer control or fibrinogen (100 µg/mL) for 15, 30, 45 and 60 minutes 
at 37
o
C. Non-adherent platelets were removed and adherent platelets were measured as described in methods and 
materials. A mild reduction in platelet adhesion on fibrinogen was observed in Cc2–/– platelets compared to wild-
type platelets (**P˂ 0.01; n=4). Each data were performed in duplicate and represents mean ± SEM of four 
independent experiments. 
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Figure  6-4: Cc2–/– platelets showed a reduction in platelet spreading on fibrinogen and type I collagen. 
Platelet spreading on fibrinogen (100 µg/mL) was assessed for wild-type, and Cc2
–/–
 platelets at 60 minutes at 
37°C under certain conditions. Spread surface area of adhered platelets was measured in µm
2
 without agonist, with 
PAR-4 (0.5 mM), ADP (20 µM), and PMA (100 nM). (A) Representative images of platelet spreading on 
fibrinogen under resting conditions or upon activation with agonists. (B) A reduction in platelet spreading on 
fibrinogen was observed in Cc2–/– platelets but not wild-type platelets (***P˂0.001; n=3). Each bar represents at 
least 100 platelets analysed. Data represent mean ± SEM of three independent experiments. (C) Platelet
 
show a 
delay in platelet spreading on Type I fibrillar collagen (**P˂0.01; n=3). Each bar represents at least 100 platelets 
analysed. Data represent mean ± SEM of three independent experiments. 
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6.2.4 Restricted cytoskeletal reorganisation of Cc2–/– platelets 
The next phase of this chapter focused upon physical changes in the shape and spreading 
properties of platelets, testing if CEACAM2 inhibited post-ligand occupancy and the formation 
of filopodia in Cc2
–/– 
platelets and whether this could be responsible for the defect in clotting 
properties. When platelets adhere to fibrinogen, they undergo reorganisation of the 
cytoskeleton, which alters their shape and spreading action. This occurrence, known as post-
ligand occupancy, occurs when integrin αIIbβ3 complex clusters upon the membrane of the 
platelets, where it initiates a downstream process of ‘outside-in’ integrin αIIbβ3–mediated 
signalling events. To determine if CEACAM2 deficiency altered this process, high resolution 
SEM was used to look for platelet filopodia formation and spreading properties over 60 minutes 
at 37°C. Cc2
–/– 
platelets showed a reduction in their adhesion to fibrinogen compared to wild-
type platelets (Figure 6-5A-B). In addition, unstimulated Cc2
–/– 
platelets had limited 
cytoskeletal reorganisation and ability to extend filopodia compared to wild-type platelets. Cc2
–
/– 
platelets extended fewer filopodia, with a small quantity having only 1-3 filopodia and fewer 
still with more than 3 filopodia (***P<0.001, n=4; Figure 6-5C). This data suggests that, 
when adhering to immobilised fibrinogen, Cc2
–/– 
platelets have a defective ability to reorganise 
the cytoskeleton. 
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Figure  6-5: Cc2–/– platelets show restricted cytoskeleton reorganisation upon spreading on fibrinogen. Wild-
type and Cc2
–/–
 washed platelets (100x10
9
/L) were allowed to adhere to fibrinogen (100 µg/mL) for 60 minutes at 
37°C, then fixed and examined using SEM. (A-B) Representative images of platelet spreading on immobilised 
fibrinogen for wild-type versus Cc2
–/–
 platelets. (C) Filopodia per platelet were analysed on SEM images from 
random fields involving 100 platelets counted. The number of filopodia demonstrating each category was 
expressed as a percentage of the total adherent platelets counted. Platelet filopodia were classified into 3 
independent groups including 0, 1-3, and >3 filopodia (***P<0.001; n=4). Images were captured using a JCM-
6000 scanning electron microscope (10 kV). Data shown are representative of at least of 4 independent 
experiments and presented as mean ± SEM. 
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6.2.5 Cc2–/– platelets display normal ‘inside-out’ integrin αIIbβ3-mediated signalling 
properties 
Cc2
–/– 
platelets display a number of defects during post-ligand occupancy processes, so 
the next phase involved establishing if their ‘inside-out’ integrin αIIbβ3–mediated signalling 
properties were normal. Testing integrin αIIbβ3 activation on Cc2
–/– 
platelets involved 
comparing the ability of the wild-type versus Cc2
–/– 
platelets to bind to soluble FITC-
fibrinogen and JON/A-PE mAb. Flow cytometry was used to assess the binding ability of 
soluble FITC-fibrinogen and JON/A-PE binding under resting conditions, using a range of 
platelet agonists: thrombin (0.12-1 U/mL); PAR-4 agonist peptide (100-300 µM); ADP (10 
µM); ADP (10 µM) plus epinephrine (20 µM); and PMA (20 µM) stimulation (Figure 6-6A-D). 
When subjected to agonist stimulation, the wild-type and Cc2
–/– 
platelets displayed equivalency 
in their ability to bind soluble FITC-fibrinogen. In addition, they showed a similar ability to 
bind with JON/A mAb, which detects the active conformation of integrin αIIbβ3 complex on 
murine platelets. In summary, the above results show that Cc2
–/– 
platelets possess normal 
‘inside-out’ integrin αIIbβ3 signalling properties. 
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Figure  6-6: Cc2–/– platelets show normal soluble FITC-fibrinogen and JON/A mAb binding. (A-B) Flow 
cytometric analysis on a FACS Canto II analyser of FITC-conjugated fibrinogen binding to washed wild-type and 
Cc2
–/– 
platelets stimulated by varying agonists including thrombin (0.12, 0.25, 0.5, 1 U/mL), PAR-4 agonist 
peptide (100, 150, 300 µM), 10 µM ADP, 10 µM ADP + 20 µM Epinephrine, 20 µM PMA or CRP (0.25, 0.5, 1, 2, 
4, 8 µg/mL). Unstimulated platelets were used as control (resting). The assay samples were run in triplicates, and 
the data shown are representative of at least 4 independent experiments, and presented as MFI ± SEM. (C-D) 
JON/A-PE mAb binding in the absence or presence of agonists on wild-type and Cc2
–/–
 platelets was also 
determined as described in panel A-B (With the only exception that thrombin was used at 0.12-0.5 U/mL). The 
assay samples were run in triplicate, and the data shown are representative of at least 4 independent experiments, 
and presented as MFI ± SEM. 
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6.3 Discussion 
Previous studies have demonstrated a possible functional relationship between PECAM-1 
or CEACAM1 with β3 integrins in platelets or even other cell types [174, 282-284]. However, 
there is no direct evidence to support CEACAM2 roles in modulation of integrin functions in 
any cell type including platelets. Therefore, this chapter looked for evidence of any 
physiological relationship between CEACAM2 and integrin αIIbβ3 in platelets. This chapter has 
examined the functional properties of Cc2
–/–
 platelets during a number of processes dependent 
on integrin αIIbβ3, and examined Cc2
–/–
 platelets during the adhesion and signalling phases of 
haemostasis. The results suggested that CEACAM2 works in a comparable way to PECAM-1 
and CEACAM1. This chapter shows that CEACAM2 can positively regulate platelet functions 
that incorporate integrin αIIbβ3-mediated processes. In addition, Cc2
–/–
 mice had significantly 
longer tail bleed times and a higher volume of blood loss, indicating an underlying vascular or 
platelet defect compared to wild-type mice (Figure 6-1A-B). Finally, this chapter demonstrates 
that CEACAM2 is essential for optimal integrin αIIbβ3-mediated functioning in platelets (Figure 
6-4). In conclusion, it is possible to propose that CEACAM2 appears to play an important role 
during thrombosis and haemostasis, by mediating adhesion and signalling events. 
Platelets derived from Cc2
–/–
 mice were used for identifying and defining the regulating 
function of CEACAM2 during integrin αIIbβ3-mediated processes. The data showed that Cc2
–/–
 
platelets contributed to a number of defects in the post-ligand occupancy events of integrin 
αIIbβ3. These included delays in kinetics of clot retraction and impeded cytoskeletal 
reorganisation associated with platelet spreading on immobilised fibrinogen matrix (Figures 6-3 
and 6-4). However, as described in chapter 3, Cc2
–/–
 platelets showed increased binding to type 
I collagen (Figure 3-8). Further analysis showed that these spreading defects were largely 
negated during stimulation by agonists such as PAR-4 agonist peptide, ADP and PMA (Figure 
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6-4C-D). In contrast, the equivalent binding of soluble FITC-fibrinogen and JON/A monoclonal 
antibody showed that ‘inside-out’ integrin αIIbβ3-mediated signalling processes were normal in 
Cc2
–/–
 platelets (Figure 6-6). These results further support the notion that CEACAM2 expressed 
on platelets influences optimal integrin αIIbβ3-mediated functions during haemostasis and 
thrombosis. Overall, it is possible to suggest that CEACAM2 regulates lateral integrin 
clustering (avidity) events during the cell adhesion process, rather than moderating the 
conformation during integrin activation (affinity). 
Previous studies have demonstrated that PECAM-1 or CEACAM1 (unpublished data) 
modulates integrin functions, and the exact mechanism behind this regulation is known [8]. 
However, because no previous studies used Ceacam2–deficient mice to search for 
abnormalities in the integrin αIIbβ3 function or activation processes, this chapter could provide a 
unique and detailed insight into how deletion of CEACAM2 affects integrin αIIbβ3 function 
properties in murine platelets. To separate ‘outside-in’, integrin αIIbβ3 clustering mechanisms 
from ‘inside-out’, integrin αIIbβ3 conformation changes, and eliminate the confounding effects 
of nuclear signalling, this study used terminally differentiated anucleate platelets. Contrary to 
the initial premise, CEACAM2–deficient platelets displayed no integrin activation defects. 
‘Outside-in’ integrin αIIbβ3 function events were affected, and the Ceacam2–deficient platelet 
defects caused restricted filopodia extension and spreading on integrin αIIbβ3–dependent 
matrix, fibrinogen (Figure 6-5). In addition, Ceacam2–deficient platelets displayed inhibited 
clot retraction (Figure 6-2), a process that uses retractile forces to bind the active integrin αIIbβ3 
complex to actin-myosin cytoskeletal proteins.  
Previous studies showed that PECAM-1 or CEACAM1, a related member of the Ig-ITIM 
superfamily, negatively regulate collagen GPVI-FcR -chain signalling pathways [187, 219]. 
 178 
 
Under in vitro flow physiological condition, when blood perfused across a type I collagen 
matrix, PECAM-1
–/–
 platelets formed a larger thrombus over time than wild-type platelets 
[219]. The PECAM-1 and CEACAM1–deficient mice also developed larger thrombi in vivo, 
when subjected to laser-induced vascular injury [178, 187, 219, 233, 234, 285, 286]. In 
contrast, PECAM-1 plays a positive modulation role during platelet integrin αIIbβ3-mediated 
functions [8]. These studies suggested the presence of at least two PECAM-1 and CEACAM1 
regulation mechanisms in platelets. The first mechanism involves negative modulation for 
ITAM-coupled signalling pathways that involve the collagen GPVI-FcR -chain and low-
affinity IgG receptor, FcRIIa. The second mechanism is positive modulation of integrin αIIbβ3-
mediated processes. However, it is unclear if these mechanisms are general Ig-ITIM receptor 
signalling processes in platelets. This chapter revealed an alternative Ig-ITIM bearing receptor 
in platelets, CEACAM2, which positively modulates integrin αIIbβ3-mediated functions. The 
results also implied a functional connection between Ig-ITIM bearing receptors and integrin 
αIIbβ3 in platelets, although the exact nature of the molecular interactions between CEACAM2 
and integrin αIIbβ3 in platelets remains unclear. In addition, it is possible to propose that, 
because CEACAM2-2L is a heterophilic adhesion molecule while CEACAM1-4L is both 
homophilic and heterophilic, it may have a function in mediating platelet interactions.  
These research results suggest an interesting anomaly. The previous study implied that 
CEACAM2 negatively modulates interactions between platelets and collagen/GPVI-FcR -
chain interaction (Chapter 3) [287]. This is in distinct contrast to this research, which found that 
CEACAM2 is a positive regulator during integrin αIIbβ3-mediated processes. However, it is 
important to note that CEACAM-2 has very similar ITIM properties to PECAM-1 and 
CEACAM1, related Ig-ITIM superfamily members. For example, PECAM-1
–/–
 mice also 
displayed prolonged bleeding times due to the deficiency in endothelial PECAM-1 [288]. 
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Likewise, platelet PECAM-1 acted as a positive regulator of integrin αIIbβ3-mediated functions 
in vitro [8]. Moreover, Cc1
–/–
 mice have prolonged bleeding time due to the deficiency in 
platelet Ceacam1. CEACAM1 acts as a positive regulator of integrin αIIbβ3-mediated functions 
(Unpublished data). As a result, the active functions of PECAM-1, CEACAM1 or CEACAM2, 
three members of the Ig-ITIM superfamily, may be moderated by homophilic or heterophilic 
ligand interactions, higher rates of expression, or modifications to the process of cellular 
distribution to areas of cellular contact in platelets. These changes could modulate the adhesion 
and signalling events in platelets that affect in vivo thrombogenesis. 
The mechanism is not known as to why Cc2
–/– 
platelets show a delay in the kinetics of 
‘outside-in’ integrin αIIbβ3 signalling event. The possible reasons for that could be related to 
ligand clustering interactions or receptor engagement being compromised in some way or 
signalling strength being reduced that downregulated integrin αIIbβ3-dependent events. 
Previous studies did not reveal any integrin abnormality in Ceacam2-deficient mice, so it 
was important to establish if CEACAM2 played a significant role in regulating platelet integrin 
αIIbβ3. This would involve assessing how CEACAM2 deletion affects the modulation, 
conformation and clustering properties of integrin αIIbβ3 in murine platelets. This research 
revealed a new role for CEACAM2, as a positive modulator of integrin αIIbβ3-mediated 
function, and confirmed that platelet CEACAM2 plays a crucial role throughout the adhesion 
and signalling events that affect haemostasis and thrombosis. 
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7 Chapter Seven: General discussion and future directions 
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7.1 General discussion 
In this thesis, evidence is provided for a unique platelet function regulator model for 
CEACAM2 which was defined as a novel platelet immunoreceptor that negatively regulates 
GPVI platelet-collagen interactions and thrombus formation both in vitro and in vivo. In 
addition, CEACAM2 was also defined as a negative regulator of the rhodocytin-CLEC-2-
mediated signalling pathway in platelets. Furthermore, CEACAM2 promotes as a positive 
regulator of integrin αIIbβ3-mediated platelet functions.  
As described in Chapter 3, CEACAM2 shares some similarities with CEACAM1 in 
structure, but differs in the number of extracellular Ig-Domains (CEACAM1 contains 4 Ig-
Domains while CEACAM2 contains 2 Ig-Domains) and in the ligand binding properties of their 
distal variable N-terminal Ig-Domain. There are two CEACAM genes in mouse (CEACAM1 
and CEACAM2) but their role in humans appears to be carried by the CEACAM1 gene [185]. 
Both CEACAM2 and CEACAM1 are transmembrane receptors and contain identical ITIMs in 
their cytoplasmic domains. 
In this thesis, CEACAM2 was shown to be expressed on the surface and in intracellular 
pools as the CEACAM-2L (CC2-2L) isoform in murine platelets (Figure 3-1B). As CEACAM1 
and CEACAM2 genes are located within 50 centimorgan distal on the mouse chromosome 7, it 
was important that CEACAM1 expression was confirmed to be unaffected by deletion of 
CEACAM2 (Figure 3-2A), including upregulation of CEACAM1 surface expression following 
agonist stimulation using thrombin, PAR-4 agonist peptide and CRP (Figure 3-2D).  
In this thesis, it has been shown that deletion of CEACAM2 resulted in GPVI/FcRγ-chain 
signalling pathway enhancement by enhanced collagen- and CRP-mediated platelet aggregation 
but not GPCR agonist signalling pathways (Figure 3-3, Figure 3-4 and Figure 3-5). 
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Furthermore, deletion of CEACAM2 also enhanced CRP-mediated alpha and dense granule 
release but not thrombin or PAR-4 agonist peptide alpha or dense granule release (Figure 3-6 
and Figure 3-7). However, the procoagulant potential of platelet exposure of phosphatidyl 
serine was unaffected as shown by Annexin V-FITC binding (Figure 3-9). Likewise, 
CEACAM2 deficiency enhanced static adhesion of platelets to immobilised type I collagen 
(Figure 3-8). Finally, as shown in Figure 3-10B, deletion of CEACAM2 demonstrated hyper-
tyrosine phosphorylation of collagen GPVI/FcRγ-chain signalling pathway components 
downstream including p-PLCγ2, p-Src (Tyr416) and p-Syk (Tyr352). 
Based upon the results of this study, there does not appear to be evidence of redundancy 
as deletion of CEACAM2 from murine platelets resulted in a clear phenotype of enhanced 
collagen GPVI/FcRγ-chain signalling pathway. The phenotype observed could not be explained 
by alteration in any other platelet glycoproteins or alteration in expression of other Ig-ITIM 
inhibitory molecules in platelets, such as CEACAM1 and PECAM-1. Therefore, the global 
CEACAM2 knockout showed no compensatory mechanisms to account for the phenotype. 
In a physiological setting, the presence of CEACAM2 will limit platelet-collagen 
adhesion signalling events to reduce the formation of thrombi on type I collagen. In the clinical 
setting of atherosclerotic plaque rupture where type I collagen is exposed, CEACAM2 along 
with other Ig-ITIM inhibitory receptors, CEACAM1 and PECAM-1 will limit the development 
of pathological thrombi. The vascular endothelium releases negative regulators, NO and PGI2 
but if injury or disease occurs the bioactive mediators NO and PGI2 are reduced [74]. These 
compounds inhibit platelet aggregation through auto-regulation, but influence the subsequent 
platelet-platelet binding rather than the initial interaction with exposed collagen. Therefore, the 
natural negative inhibitory mechanisms of adhesion are provided in platelets molecules by 
CEACAM2, CEACAM1 and PECAM-1 [74]. On the other hand, in the absence of CEACAM2 
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at the site of injury, excessive thrombus formation will be formed faster, larger and even more 
stable (Figure 7-1). As a result, this thesis is one of the few projects that identifies a potential 
natural inhibitor of platelet activation in the presence of collagen. Because collagen is a 
powerful instigator of platelet adhesion and thrombus growth, this research could be used to 
develop a CEACAM2 based approach to clinically mitigate thrombotic complications 
associated with CVD. 
 
Figure  7-1: Haemostatic thrombus formation. Thrombus formation is initiated by platelet-collagen interactions 
at the site of endothelium injury or trauma. In the presence of Ig-ITIM receptors such as CEACAM2 or 
CEACAM1, thrombus formation is reduced while in the absence of CEACAM2 or CEACAM1, thrombus growth 
and stability is enhanced. CEACAM2 negatively regulate platelet-collagen interaction and thrombus growth in 
vitro and in vivo. Adapted from [289].  
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Chapter 4 of this thesis discusses the role of CEACAM2 in CLEC-2 contact-dependent 
platelet activation and signalling pathway in platelets. The results showed that in the absence of 
CEACAM2, hyper-responsiveness to the CLEC-2 selective agonist, rhodocytin which induced 
amplified platelet aggregation responses (Figure 4-1). Likewise, deletion of CEACAM2 
enhanced rhodocytin induced alpha and dense granule release (Figure 4-2 and Figure 4-3; 
respectively). Similarly, deletion of CEACAM1 also enhanced rhodocytin induced alpha and 
dense granule release (Figure 4-4 and Figure 4-5; respectively). Furthermore, deletion of 
CEACAM2 enhanced tyrosine phosphorylation of CLEC-2 signalling pathway components 
including p-PLCγ2 and p-Syk (Tyr352) (Figure 4-6 and Figure 4-7; respectively) but not p-Src 
(Tyr416) (Figure 4-8). Thus, CEACAM2 and CEACAM1 negatively regulate the CLEC-2 
signalling pathway in murine platelets. Further studies would be required to show whether 
human CEACAM1 also regulates the CLEC-2 signalling pathway, although as CEACAM2 in 
mouse platelets is thought to be analogous to CEACAM1-2L in human platelets, this may well 
be the case. 
The results in Chapter 5 of this thesis discuss in great detail the role of CEACAM2 in 
contact-dependent platelet adhesion under in vitro and in vivo flow conditions. Previous 
research was unclear about which of these collagen receptors adopts the primary role during 
platelet activation, but studies using platelets lacking GPVI have proposed that GPVI is a potent 
agent for enhancing platelet activation and the growth of stable thrombi [290]. The idea that 
CEACAM2 can restrict thrombus growth was further supported by a series of in vitro studies 
assessing platelet adhesion. CEACAM2 deficiency enhanced in vitro thrombus formation 
growth over time on immobilised type I collagen under arterial flow conditions (Figure 5-1). By 
using FeCl3 induced vascular injury of mesenteric arterioles, deletion of CEACAM2 displayed 
enhanced thrombus growth and stability in vivo (Figure 5-2 and Figure 5-3). Similarly, deletion 
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of CEACAM2 showed enhanced thrombus growth and stability in vivo using laser induced 
vascular injury of cremaster muscle arterioles (Figure 5-4 and Figure 5-5). Antibody depletion 
of GPVI in conjunction with absence of CEACAM2 displayed a reversal in the thrombus 
stability phenotype (Figure 5-6E). 
In our study of microvascular thrombosis, FeCl3-induced vascular injury was used to 
expose type I collagen, so that platelet-collagen interactions could be studied in the absence of 
CEACAM2 in vivo. Therefore, deletion of CEACAM2 enhanced thrombus growth and stability 
indicating that it can negatively regulate platelet-collagen interactions in vivo and that it is 
partially dependent on the collagen GPVI/FcRγ-chain. In contrast, the laser induced injury 
model is an inflammatory thrombin: tissue factor model that does not expose type I collagen 
[223, 224, 275]. This issue was first highlighted by Rosen et al. during studies that used laser-
induced injury on blood vessels located in the mouse ear [291]. Therefore, based on the results 
of this study raises the possibility that CEACAM2 may also negatively regulate the thrombin 
signalling pathway. Conversely, as shown in Chapter 3, washed platelets showed equivalent 
thrombin aggregation, alpha and dense granule release at different concentrations in the 
presence or absence of CEACAM2 (Figure 3-5; 3-6 and 3-7). Further studies will be required to 
examine this possible mechanism in platelets. 
To highlight the main similarity and differences between Ig-ITIM receptors in literature, 
laser induced injury of cremaster muscle arterioles in the PECAM-1 knockout mice revealed 
larger thrombi that were more stable [178]. Likewise, Cicmil et al. demonstrated that PECAM-
1 could negatively regulate thrombin signalling pathway in human platelets [234]. This may 
highlight a role for CEACAM2 in regulating the thrombin signalling pathway. Previously, an in 
vitro flow studies on type I collagen under arterial flow was done by Jones et al. who found that 
in the absence of PECAM-1 there was increased kinetics thrombus formation over time [219]. 
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Similarly, in vitro flow studies by Wong et al. displayed larger thrombus volume on type I 
collagen in the absence of CEACAM1 than in control wild-type mice [187]. Therefore, the 
results for Cc2
–/–
 mice correlate with the previous studies on PECAM-1
–/–
 and Cc1
–/–
 mice. 
Thus, these studies highlight the importance of Ig-ITIM receptors in relation to negative 
regulation of platelet-collagen interactions and thrombus formation in vitro and in vivo. Apart 
from platelet CEACAM2 regulating collagen interactions involving collagen GPVI, thrombus 
growth and stabilisation, it also appears to negatively regulate the CLEC-2 signalling pathway. 
Further studies with antibody depletion of platelet CLEC-2 to examine thrombus formation and 
stabilisation will be required. 
The results in Chapter 6 presented some interesting findings about the role of CEACAM2 
in ‘outside-in’ integrin αIIbβ3-mediated signalling pathways. The major findings in the absence 
of CEACAM2 were that Cc2
–/–
 mice had increased in vivo tail bleeding times, and volume of 
blood lost (Figure 6-1), delayed kinetics of clot retraction (Figure 6-2A-B) and delayed static 
adhesion on immobilised fibrinogen over time (Figure 6-3). Furthermore, lack of CEACAM2 
restricted cytoskeletal reorganisation that delayed platelet spreading on fibrinogen without 
agonist stimulation (Figure 6-4). In fact, this spreading defect was corrected by agonist 
stimulation with PAR-4 agonist peptide, ADP and PMA (Figure 6-4). Therefore, CEACAM2 
deficiency leads to an ‘outside-in’ integrin αIIbβ3-mediated functional defect but not ‘inside-out’ 
integrin αIIbβ3-mediated functional defect. Thus, this suggests that when CEACAM2 is 
normally present it acts as a positive regulator to optimise ‘outside-in’ integrin αIIbβ3-mediated 
functions in platelets. Similar findings have been observed with Cc1
–/–
 mice (Unpublished 
data). Furthermore, a study by Wee et al. demonstrated that PECAM-1 act as a positive 
regulator to optimise ‘outside-in’ integrin αIIbβ3-mediated functions in platelets [8]. 
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This defect may suggest that the clustering of integrin αIIbβ3 (fibrinogen ligand occupied 
state) is compromised to a certain extent by the absence of CEACAM2, CEACAM1 or 
PECAM-1. The exact mechanism is not clearly understood at this stage and warrants further 
investigation. 
7.2 Conclusion 
In this thesis, several studies have demonstrated the presence of a novel and new ITIM-
bearing receptor, CEACAM2 in murine platelets. It has been shown that using an innovative 
tool of a Ceacam2-deficiency mouse model has revealed how CEACAM2 negatively regulates 
hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo. 
This may potentially have therapeutic ramifications for the treatment of CVD. The presence of 
CEACAM2 can restrict adhesive signalling events and thrombus formation to diminish the risk 
of atherosclerosis by reducing the thrombus volume, size of thrombi, delaying the rate of 
thrombus growth and promoting thrombus instability. The Ceacam2-deficient murine platelets 
also suggested that the Ig-ITIM member, CEACAM2 is a crucial component of platelet 
adhesion, activation and aggregation, influencing the ‘outside-in’ integrin αIIbβ3-mediated 
function events. Overall, the results highlight the crucial function of CEACAM2 in platelet-
collagen interactions, thrombus growth, CLEC-2 signalling, and integrin αIIbβ3-mediated 
platelet functions. Therefore, upregulating Ig-ITIM superfamily member expression in the 
context of atherosclerosis may offer an avenue for targeting treatments and lowering the risk of 
CVD problems.  
7.3 Future directions  
The studies carried out in this thesis demonstrate that CEACAM2 negatively regulates 
CLEC-2 signalling pathway in murine platelets. As in human platelets the role of CEACAM2 is 
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carried by CEACAM1 gene, therefore, further studies will be required to examine the role of 
CEACAM1 via the CLEC-2 mediated signalling pathway in murine and human platelets. 
Moreover, further studies will be required involving depletion of platelet CLEC-2 using 
specific anti-CLEC-2 antibody INUI (200 µg) to examine the role of CEACAM2 or 
CEACAM1 in thrombus formation and stabilisation under in vitro flow and in vivo in the 
presence of control wild-type mice. 
Based upon the results of this thesis, the deletion of CEACAM2 showed normal platelet 
aggregation responses, alpha and dense granule secretion following thrombin stimulation 
compared to control wild-type mice. Interestingly and conversely, the deletion of CEACAM2 
enhanced thrombus growth compared to wild-type arterioles. Based on the fact that laser 
induced injury is involves the inflammatory thrombin: tissue factor pathway, more work is 
required to understand the role of CEACAM2 regulation of thrombin signalling pathways in 
Cc1
–/–
 and Cc2
–/–
 mice platelets. In addition, further work at cellular level will be required 
involving measurement of global tyrosine phosphorylation over time or PLCγ2, Src and Syk 
tyrosine phosphorylation upon thrombin-stimulation for 0-90 seconds by immunoprecipitation 
and Western blot analysis with anti-phosphotyrosine antibodies. 
Future work on how CEACAM2 and the integrin αIIbβ3 tyrosine phosphorylation 
signalling mechanism influence ‘outside-in’ integrin αIIbβ3-mediated signalling events will be 
warranted. The integrin β3 cytoplasmic domain undergoes tyrosine phosphorylation which, in 
turn, prompts the activation of cytosolic proteins myosin and adaptor protein Src homology 
collagen (Shc), together with linkage with actin which are necessary for clot retraction and 
platelet stimulation respectively. However, exactly how 
125
FAK undergoes tyrosine 
phosphorylation after the integrin αIIbβ3 clustering prompted by platelet aggregation is unclear. 
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This crucial stage of the process occurs early during integrin β3 tyrosine phosphorylation and 
the recruitment of Src family kinase members, particularly c-Src and Syk. Intensive studies 
need to be performed to examine the role of CEACAM during ‘outside-in’ integrin αIIbβ3-
mediated signalling pathways upon activation or adhered on immobilised fibrinogen (100 
µg/mL). Measurement of PLCγ2, Src and Syk tyrosine phosphorylation are the hardest 
experiments because when integrin αIIbβ3 bind to fibrinogen leads to ligand clustering 
interactions or receptor engagement being compromised or the strength of signalling being 
reduced in some way. Furthermore, a number of potential physical associations and functions: 
the physical interaction of CEACAM2 and integrin αIIb3 in murine platelets is subject to 
further studies. 
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